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PART I
GENERAL 
INTRODUCTION
Chapter 1
Prostate cancer
Chapter 2
Screening for prostate cancer: the European Randomized Study of 
Screening for Prostate Cancer (ERSPC)
Chapter 3
Scope of the thesis

General introduction
Th is thesis describes research on screening for prostate cancer. To improve understanding of 
the thesis, some background information will be provided in this introduction. First, a short 
description of the prostate and of prostate cancer will be given in Chapter 1, followed by more 
detailed background information on screening for prostate cancer in Chapter 2. Th e fi nal part 
of this introduction, Chapter 3, will outline the scope of this thesis.

Prostate cancer 
CHAPTER 1
12 Chapter 1
1.1 | Th e prostate
Th e prostate is a gland which is located beneath the urine bladder, surrounding the proximal 
urethra in men. It produces a fl uid which constitutes part of the semen and prolongs the lifespan 
of sperm.
1.2 | Prostate cancer
1.2.1 | Diagnosis
Th ere are several ways to examine the prostate for the presence of prostate cancer: a 
serum prostate specifi c antigen (PSA) test, a digital rectal examination (DRE), transrectal 
ultrasonography (TRUS) and prostate biopsy. 
 PSA is a protein produced by prostate cells, which may leak into the blood stream. An 
increased serum PSA level indicates an increased prostate cancer risk. However, an increase 
in the serum PSA level may also be caused by other causes: 1) an increase in normal prostate 
glands like in benign prostate hyperplasia (BPH) or 2) an increased leakage of PSA into the 
bloodstream due to infectious processes or obstruction. An increased PSA level thus is not 
specifi c for prostate cancer. Moreover, a low PSA level does not exclude prostate cancer: even in 
very low PSA ranges, a considerable prostate cancer detection rate has been described.1 Despite 
the important limitations of lack of specifi city and lack of what might be considered a “normal” 
level of PSA, the discovery of PSA has drastically changed prostate cancer care. In general, PSA 
levels increase prior to the occurrence symptoms of metastasis, while prostate cancer mostly 
manifests itself clinically only at the time of (bone) metastasis. Th is shift s the diagnosis to an 
earlier and possibly curable stage of prostate cancer. Furthermore, PSA plays an important role 
in the follow-up of prostate cancer patients.
 A DRE entails the palpation of the prostate through the rectal wall (Figure 1). Th e size of 
the prostate can be evaluated as well as the presence of nodules or indurations suspicious for 
prostate cancer. TRUS produces an image of the prostate, which may show signs of prostate 
cancer and can provide an accurate measure of prostate volume. TRUS is oft en used for guiding 
prostate biopsies.
 PSA, DRE and TRUS all give an indication about the risk of prostate cancer, but the defi nite 
diagnosis can only be made with histological prostate tissue examination. During a prostate 
biopsy, generally under ultrasound guidance, tissue cores are taken from the prostate with a 
needle. Th ese tissue samples are examined by a pathologist and may confi rm the diagnosis of 
prostate cancer. 
 More diagnostic tests are available, for example PSA derivates2, and prostate cancer antigen 
3 (PCA3)4 have been described amongst others to show promising results. However, those tests 
have not yet been incorporated in standard clinical care.
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  Figure 1 | Digital rectal
  examination, adapted from3
1.2.2 | Staging
Th e extent of the disease is classifi ed according the Tumour/Node/Metastasis (TNM) 
classifi cation (Table 1). Th e stage of the disease is predictive for the prognosis and is useful in 
selecting treatment. Th e local stage of the tumour is determined by DRE and TRUS, known as 
clinical tumour stage. Th e defi nite stage, or pathological tumour stage, can only be obtained 
aft er radical prostatectomy.
1.2.3 | Grading
Th e grade of the tumour expresses the degree of abnormality of the tissue and thus the 
aggressiveness of the tumour. Prostate cancer is graded using the Gleason grading system.4 Th e 
growth pattern is scored 1 (well diff erentiated) to 5 (poorly diff erentiated tumour) (see fi gure 
2). Th e most common and second most common growth pattern observed by the pathologist 
are summed to give a Gleason score, ranging from 2 to 10. A Gleason score is assigned to biopsy 
tissue and prostatectomy specimens and both are highly prognostic for patient outcome.
14 Chapter 1
Table 1 | TNM classifi cation, 2002
T-primary tumour Tx Primary tumour cannot be assessed
T0 No evidence of primary tumour
T1 Clinically unapparent tumour 
neither palpable nor visible by 
imaging
T1a Tumour incidental histological fi nding 
in 5% or less of tissue resected
T1b Tumour incidental histological fi nding 
in more then 5% of tissue resected
T1c Tumour identifi ed by needle biopsy 
(e.g. because of elevated PSA)
T2 Tumour confi ned within the 
prostate
T2a Tumour involves one-half of one lobe 
or less
T2b Tumour involves more than one-half 
of one lobe, but not both lobes
T2c Tumour involves both lobes
T3 Tumour extends through the 
prostatic capsule
T3a Extracapsular extension in 
periprostatic tissue
T3b Invasion of seminal vesicle(s)
T4 Tumour is fi xed or invaded adjacent 
structures other than the seminal 
vesicles: bladder neck, external 
sphincter, rectum, levator muscles, 
or pelvic wall
N- regional 
lymph nodes
Nx Regional lymph nodes cannot be 
assessed
N0 No regional lymph node metastasis
N1 Metastasis in regional lymph nodes
M- distant 
metastasis
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis M1a Non-regional lymph nodes
M1b Bone(s)
M1c Other sites
1.2.4 | Treatment
Treatment of prostate cancer depends on patient and tumour characteristics. Overall, treatment 
can be divided into 4 main modalities: surgical treatment, radiation therapy, hormonal 
treatment and monitoring, i.e. active surveillance or watchful waiting. 
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 Figure 2 | Gleason grading system, adapted from6
1.3 | Prostate cancer as a major health problem
In Western countries, prostate cancer is the most common non-skin cancer type diagnosed 
amongst men.7 Based on rates of 2004-2006, a man in the US has a life-time risk of being 
diagnosed with prostate cancer of almost 16%.8 Th is indicates that 1 in 6 men will develop 
prostate cancer. Th e incidence of prostate cancer has been rising since the early nineties (Figure 
4). Several factors may have induced this increase, amongst which aging of the population, 
increased awareness of prostate cancer, and the possibility of early detection through PSA. 
Prostate cancer is the second leading cause of death from malignancy.7 When one compares the 
incidence and mortality rates a striking diff erence between those rates is observed (Figure 4). 
Th is implies that more men die with prostate cancer than from prostate cancer. Especially in 
the last decades, incidence and mortality rates have diverged (Figure 4). In addition to the rise 
in prostate cancer detection, a more recent decline in mortality has occurred. Explanations for 
this decrease may be found in improved prostate cancer treatment, wide-spread use of statins 
and possibly for a part in screening for prostate cancer.9,10
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Figure 3 | Age-standardised rates (European Standardised Rate) for incidence and mortality of prostate 
cancer in the Netherlands 1970-2006 (incidence rates 1970-1988: data Comprehensive Cancer Centre 
South; incidence rates 1989-2006: data Netherlands Cancer Registry - no diff erences between CCCS and 
NCR data in period 1989-2006 -; mortality rates 1970-2006: Netherlands Cancer Registry)
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2.1 | Introduction
Th e European Randomized Study of Screening for Prostate Cancer (ERSPC) is a large 
randomized study which aims to show or exclude a reduction in prostate cancer specifi c mortality 
due to screening. In addition, the feasibility of such a program for population-wide use, the 
cost-eff ectiveness and quality of life are studied. Recently, aft er the third interim analysis, the 
fi rst selected data end-points of the ERSPC have been published: PSA-based screening reduced 
prostate cancer specifi c mortality by 20%.1 In this chapter, an attempt is made to describe the 
ongoing ERSPC.
2.2 | Background
2.2.1 | Th e start of the ERSPC
With emerging insights about the use of PSA as a screening test2, an idea of conducting a 
randomized controlled study of screening for prostate cancer originated in Belgium and the 
Netherlands during 1990-1991.3,4 No evidence of the eff ectiveness of screening for prostate 
cancer existed at that time and the only way of obtaining such evidence seemed to be by 
conducting a prospective randomized controlled trial (RTC). Several uncertainties existed 
related to randomization, acceptance and value of screening tests, follow-up and others. 
Th erefore, between 1991 and 1994 a series of pilot studies were carried out in Belgium and 
in the Netherlands. Summaries of the results of these pilots were published in 1995.5,6 Th e 
main conclusion was that a European RCT of screening for prostate cancer seemed feasible. 
Yet, the expense of such a trial made international co-operation a prerequisite, as no single 
country could aff ord such a study. Th e ERSPC formally started on July 1 1994 in Belgium and 
the Netherlands. Aft er successfully conducting pilot studies7, Finland became the third partner 
in the ERSPC during 1995. Furthermore, Sweden, Spain, Italy, Switzerland and France joined 
the ERSPC.
 A publication of Adami et al8 in 1994 gave rise to a public discussion about the ethical 
justifi cation of such a RTC. Some felt that prerequisites for performing screening studies, 
for example knowing the natural history and eff ectiveness of treatment, were not met. Th is 
controversy has been subject of an extensive discussion.9,10,11 However, in all participating 
countries, ethical approval was obtained and the ERSPC started in 1994.
2.2.2 | Purpose and structure of the study
Th e main goal of the ERSPC is to show or exclude a prostate cancer mortality reduction through 
screening and early treatment. In this large randomized controlled trial screening is off ered 
to the intervention group and the control group is managed according to regional health care 
policies. Th e trial aims at showing or excluding a 20% diff erence in prostate cancer mortality 
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with a power of 90%. Th is was decided at a consensus workshop held in 1994 on the basic 
elements of screening in a RCT.12 
 Other important decisions were made at the consensus workshop, like the determination of 
4.0 ng/ml as a PSA threshold for recommending a biopsy and initially including Digital Rectal 
Examination (DRE) and Transrectal Ultrasound (TRUS) as screening tests. An age range of 
55-70 years was determined as being the core age range on which power is calculated. Inclusion 
of higher or lower age ranges could be chosen by the individual centers. Initial sample size 
calculations were made without consideration of possible contamination in the control arm by 
opportunistic PSA-based screening and it was calculated that 65,000 men per arm and a follow-
up of 10 years would be needed. Re-calculations considering this contamination showed that a 
sample size of 85,000 men per arm would be needed.13
 Furthermore, basic requirements for participation in the ERSPC and the content of the 
future database were discussed during this workshop. Th is resulted in the establishment of 
the following committees which run and control the ERSPC: an Epidemiology Committee, a 
Pathology Committee, a PSA Committee, a Quality Control Committee, a Causes of Death 
Committee, an independent Data Monitoring Committee (DMC) and the supervisory body 
of the study as a whole, the Scientifi c Committee (SC). All important decisions are made by 
the voting members of the SC, which consists of two representatives of each center. Every 
participating center has accepted the authority of the controlling committees (i.e. the Quality 
Control Committee and Data Monitoring Committee) and signed the set of basic requirements 
as a cooperative contract. Because of the relative autonomy of the participating centers, the 
ERSPC is conducted in a decentralized fashion. Centralized data collection is in the hands of an 
independent center located in the UK (the Central Database).
2.3 | Randomization
Due to diff erences in legal requirements for running a RTC in the participating countries, two 
diff erent randomization schemes are used. In Belgium, Spain, Switzerland and the Netherlands, 
informed consent is required before randomization (Figure 1). In the other countries, informed 
consent is only required for those men who are randomized to the screen arm.
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  Figure 1
2.4 | Screening tests
2.4.1 | PSA, DRE and TRUS
At the time the ERSPC started, PSA, DRE and TRUS were potential screening tests. Other 
screening methods, such as the use of PSA derivatives (e.g. PSA velocity, PSA density, PSA 
doubling time) and biomarkers are possibly proper screening tests as well, which were to be 
evaluated in a later phase. 
 Between ERSPC centers next to the diff erences in randomization schemes, slightly diff erent 
screening protocols are used. Except one center all use a four-year screening interval (Sweden 
uses two years). A PSA cut-off  value of 3.0 ng/ml is applied aft er the prevalence screen and 
was suggested to all centers as of 1997. Th e core age group is 55-69 and all centers use sextant 
biopsies, at least initially.
 Up to May 1997, a PSA >= 4.0 ng/ml and/or abnormal fi ndings on DRE and/or TRUS was 
an indication for prostate biopsy in the Rotterdam center of the ERSPC.
  For a proper screening algorithm, it is very important to fi nd a delicate balance between 
sensitivity and specifi city of the screening tests, as lead-time and over-diagnosis are inevitable 
in prostate cancer screening. Th erefore, evaluation of screening procedures was and is an 
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essential part of the ERSPC, and prior to the initiation of the study, it was agreed that screening 
procedures would be adjusted one time if necessary. 
 Th e fi rst contribution to this evaluation came from the Italian group14, and was followed by 
major investments made by other centers as well to clarify the role of the diff erent screening tests. 
Improvements of test characteristics, potential reduction of proportions of men to be biopsied, 
the loss of otherwise diagnosed cancers and the numbers of biopsies needed per prostate cancer 
were investigated and simulated by Bangma et al.15,16 Th ese studies indicated the future direction 
of test evaluation: main goal was to improve specifi city (avoidance of unnecessary testing and 
biopsies) and still maintain the detection rate of the fi rst round (4-5%). Th e search for methods 
for improvement of specifi city was continued and led to many suggestions.17,18 However, great 
reluctance existed to change the protocol with the acceptance of the loss of a proportion of 
prostate cancers, whose fi nal outcomes could not be judged. Nevertheless, a major change in 
the screening protocol was implemented as a result of the evaluation outcomes. From February 
1996, men with a PSA value of 0-0.9 ng/ml were not further screened but advised to be re-
screened four years later. Th is change was based on the observation that in 1451 men, 174 
biopsies detected 4 cancers, resulting in a positive predictive value of 2% and a cancer detection 
rate of 0.3%.17 All centers adopted this change in protocol, saving a screening visit for 35% of the 
whole screening population and leading to an obvious reduction in costs of the study.
 A second major change was omitting DRE and TRUS as screening tests and lowering the 
biopsy threshold to a PSA value of 3.0 ng/ml. Th is decision was based on a study from the 
Rotterdam center, where the value of DRE was investigated. Ideally, sensitivity and specifi city of 
a screening test are calculated. However, the prevalence of the disease is unknown in the case of 
prostate cancer. Th erefore, an estimate of the prevalence is set as the “gold standard” and used 
to calculate a relative sensitivity and specifi city.19 Relative sensitivity and specifi city of DRE was 
assessed in 10,523 consecutive men randomized to the screening arm of the Rotterdam section 
of the ERSPC, based on estimates of the predictive index (the number of cancers that would 
have been detected if all men had been biopsied, the “gold standard”). Of these men, 7055 were 
found to have PSA values < 4.0 ng/ml. In the PSA-ranges 0-0.9, 1-1.9, 2-2.9 and 3-3.9 ng/ml, 
positive predictive value (PPV) of a positive DRE was 4%, 10%, 11% and 33% respectively. In 
these PSA ranges, relative sensitivity and specifi city levels were 21%, 24%, 14%, 39% and 94%, 
92%, 91% and 98%. Overall PPV of DRE in the PSA-range =< 3.0 ng/ml was 8.8%. Omitting 
DRE as a screening test in men with a PSA <3.0 ng/ml, would have missed 57 of 473 cancers 
actually detected (12.1%) and saved 533 biopsies (23.5%). Biopsying every men with a PSA of 
3-3.9 ng/ml, would have added 43 cancers and decreased the false-negative biopsy indication 
drastically. Furthermore, cancers detected in the PSA range < 4.0 ng/ml were classifi ed as 
minimal, moderate and advanced in 42%, 42% and 16% in men screened during the fi rst round 
in Rotterdam.20,21
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 Th e new screening protocol, with only a PSA higher than or equal to 3.0 ng/ml as a biopsy 
indication, was implemented from February 1997 and a validation of this protocol was carried 
out on 7943 men consecutively randomized to the screening arm of the ERSPC Rotterdam.22 It 
was shown that the detection rate remained almost the same (5.0% vs. 4.7% in the new protocol) 
and the PPV of a PSA of 3.0 ng/ml or higher, predicted to be 12.3%, was actually 18.0%. Th e 
proportion of men with a biopsy indication decreased from 28.2% to 19.5%. Furthermore, the 
overall tumour characteristics found in the new protocol diff ered very little from those detected 
in the old regimen, based on PSA, DRE and TRUS. Th erefore, the new protocol contributes to 
reaching a delicate balance between sensitivity and specifi city. However, the search for an even 
better balance is continuing. More research on the evaluation of screening tests is still being 
performed and defi nite judgments on the validity of test regimens will only be possible aft er the 
fi nal conclusions of the trial have been reached. 
2.4.2 | Biopsy 
Similar to the screening regimen policy, the biopsy regimen depends on the choice of the 
individual screening centers. At the time the ERSPC started, a systematic sextant needle biopsy 
was the general accepted biopsy regimen among urologists. In Rotterdam, a lateralized sextant 
biopsy scheme was chosen as the prostate cancer detection rate increases when the lateral 
peripheral zone is sampled.23,24 Nowadays, the trend is to obtain more than six biopsy cores, as 
this increases the detection rate of prostate cancer.25 Some centers adopted this more extensive 
biopsy regimen to assure comparability with the control group. Others, including Rotterdam, 
continue performing sextant biopsies, aiming for maximum of data consistency during the 
study.
2.5 | Screening interval
2.5.1 | Lead-time
All centres, except for Sweden, have adopted a screening interval of four years. Th is was based 
on estimations of lead-time available at the beginning of the ERSPC. Lead-time was estimated 
to be 6-10 years, based on serum banks used for PSA-determinations and the subsequent 
diagnosis of clinical prostate cancer.26,27 Of course, data that could confi rm the correctness of 
this relatively long interval were highly desirable. 
 A fi rst evaluation of lead-time came from Finland.28 Auvinen et al defi ned lead-time as the 
duration of follow-up needed to accrue the same expected number of incident prostate cancer 
cases in the absence of screening as detected in the initial screening round. Expected numbers 
were calculated using an age-cohort model. Based on fi ndings among 10,000 men screened 
in 1996-1997 with 292 screen-detected cancers, lead-time was estimated as approximately 5-7 
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years. With the assumption that the cancers are detected on average at the midpoint of the 
detectable preclinical phase, this detectable preclinical phase was estimated to be 10-14 years.
 In the Netherlands, a micro simulation model (MISCAN) was used to estimate lead-time.29 
Simulation models are based on results of the Rotterdam section, which enrolled 42,376 men 
and in which 1,498 cases of prostate cancer were identifi ed, and on baseline prostate cancer 
incidence and stage distribution data. Th e models were used to predict mean lead times, over-
detection rates, and ranges. Mean lead times and rates of over-detection depended on a man’s 
age at screening. For a single screening test, the estimated mean lead-time was 12.3 years at age 
55 and six years at age 75. For a screening program with a 4-year screening interval from age 
55 to 67, the estimated mean lead-time was 11.2 years (range 10.8-12.1 years), and the over-
detection rate was 48% (range 44%-55%). Th is screening program increased the lifetime risk of 
a prostate cancer diagnosis from 6.4% to 10.6%.
 Th ese studies seem to confi rm the appropriateness of an inter-screening interval of at least 
4 years.
2.5.2 | Distribution of prognostic factors at re-screening
For a screening interval to be appropriate, characteristics of tumours found at re-screen should 
be favourable for curative treatment.
 Th e incidence of potentially advanced malignancies in the second screening round of the 
Rotterdam section was evaluated by Postma et al.30 Potentially advanced malignancy was defi ned 
as a biopsy Gleason score of 7 or higher. During the second screening round, 503 prostate 
cancers were detected, of which 30 (6.0%) with features of potentially advanced malignancy, 
in 11,210 screened men. Curative treatment was off ered to 26 men, 12 men were treated with 
radical prostatectomy. Of those 12 RP specimens, 11 showed organ-confi ned disease. Th is study 
showed that potentially advanced disease is a rare fi nding in the second screening round, and 
that prostate cancer was still potentially curable in most men.
 In addition, other studies demonstrated a shift  toward more favourable tumour characteristics 
in the second screening round, compared to the initial round.31,32 In Sweden, where screening 
is performed with a two-year interval, stage distribution showed a trend toward a lower stage at 
the second screening (an increase in T1 lesions from 60% to 74% in the second round) as well 
as lower PSA in men diagnosed with cancer.31
 First and second round fi ndings from the Rotterdam section were evaluated as well.32 In the 
second screening round, the mean prostate-specifi c antigen value was lower (5.6 versus 11.1 ng/
mL), advanced clinical stage T3-T4 was 7.1-fold less common, and 76.4% versus 61.5% of the 
biopsy Gleason scores were less than 7. In the fi rst screening round, 13 regional and 9 distant 
metastases were detected. In the second round, 2 cases with distant metastasis were found. 
Overall, a shift  toward more favourable tumour characteristics was seen for the second round 
of screening. Th ese results support the screening methods used and the inter-screening interval 
of 4 years.
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2.5.3 | Interval cancers
An interval cancer is a cancer detected during the interval between 2 screening visits. Th e rate 
of interval cancers is an important parameter in determining the sensitivity of the screening 
procedure and screening interval. In the Swedish centre, 5,854 men participated in the fi rst 
screening round and 145 prostate carcinomas were detected. During the second screening 
round, two years later, 5,267 men participated and 111 cancers were found. Nine interval 
carcinomas were diagnosed (10.6% of the control group prevalence).31 Of these, three men had 
metastatic disease, the others seemed confi ned to the prostate gland and were detected through 
opportunistic screening or because of urinary symptoms. 
 In the Rotterdam section, interval carcinomas were studied in a cohort of 17,226 men (8350 
in the screening arm, 8876 in the control arm), enrolled consecutively to the ERSPC.33 During 
the fi rst screening round, 412 prostate cancers were detected. During the following four-year 
interval, 135 cancers were found in the control group, and 25 interval cancers were diagnosed in 
the screened arm (18.5% of the control group prevalence). Of these 25, seven men had refused 
a recommended biopsy in the initial screening round. Th e remaining 18 prostate cancers were 
all classifi ed as T1 or T2A and none were poorly diff erentiated or metastatic. Th ese data, which 
show a low interval carcinoma rate, suggest that the 4-year screening interval is reasonable.
 Th is was supported by a comparative study of the Swedish and Dutch ERSPC study centres, 
comparing rates of overall interval cancers and high-grade interval cancers.34 Th e cumulative 
incidence rates of interval cancers was 0.43% in Rotterdam with a 4-year interval versus 0.74% 
in Sweden with a 2-year interval (p=0.51). Th e cumulative incidence rates of high-grade interval 
cancer was 0.11% versus 0.12% (p=0.72).
2.6 | First end-point related results
2.6.1 | Recruitment and cancer detection
A total of 182,160 men aged 50-74 participated in the ERSPC, and part of this cohort is still 
participating in the ongoing study. Of those, 162,387 men were in the core age range group, 
i.e. 55-69 years old, of which 72,890 were randomized to the screening arm and 89,353 to the 
control arm (see fi gure 2 NEJM). Randomization is unequal because Finland did not randomize 
in a 1:1 ratio. Of the men randomized to the screening arm, 82.2% were actually screened at 
least once. A total of 5,990 PC cases were detected in the screening arm and 4,307 in the control 
arm, leading to cumulative incidence rates of 8.2% and 4.8%.1
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 Figure 2 | Adapted from1
2.6.2 | Distribution of prognostic features
For screening to be eff ective, a stage shift  into the direction of a more favorable distribution of 
prognostic factors with respect to local tumour extent, grading (Gleason score) and presence 
of metastases is a prerequisite. An early report on this issue is given by Rietbergen et al35 on 
the Rotterdam section of the ERSPC. Th e TNM classifi cation of 459 screen-detected prostate 
cancers was compared to the TNM classifi cation of a cohort of 4,708 men from the Amsterdam 
Cancer Registry. A stage-shift  towards more favorable features was seen for the screen-detected 
cancers. Furthermore, the incidence of metastases was 24% in the cancer registry cohort, 
compared to 1.7% in the screen-detected series.
 Another report on the issue of metastatic disease comes from the Swedish section.36 
Metastatic prostate cancer incidence at diagnosis in a screened cohort was compared with a 
control cohort, both 10,000 men. For the control group, diagnosis of metastatic prostate cancer 
was monitored by using the Swedish Cancer Registry. During a time period of 10 years, the 
risk of being diagnosed with prostate cancer with metastasis at the time of diagnosis diff ered 
by 48.9%, decreasing from 47 cases in the control group to 24 cases in the group randomized 
to PSA-based screening. However, the PC incidence in the screened cohort was 1.8-fold higher 
than in the control group.
 A comparison of all cancers found in the screening and the control arm of the Rotterdam 
section was performed in 2003.37 By January 1, 2003, 1,269 cancers were detected in the 
screening arm and 336 were detected in the control arm. A shift  to more favourable clinical 
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stage was seen in the screening arm of the trial. T1C and T2 cancers were 5.8 and 6.2 times more 
oft en diagnosed, respectively, in the screening arm than in the control arm of the trial. 
A grading shift  towards lower Gleason scores in screen-detected PC was reported by Postma 
et al.38 In radical prostatectomy specimens of the screening arm, 34.6% of the cancers had a 
Gleason score equal to or higher than 7, a signifi cantly lower proportion as compared to the 
53.5% of cancers in the control arm. Furthermore, the median tumour volume was signifi cantly 
smaller in the screened population (1.0 ml versus 3.9ml). 
 Th ese studies suggested that the prerequisite for eff ective screening, i.e. the shift  towards 
more favourable prognostic features, is met in the ERSPC.
2.6.3 | Prostate cancer specifi c mortality
Aft er a third interim analysis, a signifi cant reduction of prostate cancer mortality was found 
in the screening arm compared to the control arm.1 Aft er a median follow-up of 9 years, there 
were 214 prostate cancer deaths in the screening arm and 326 in the control arm (fi gure 3). Th is 
resulted in an adjusted rate ratio of 0.80 (95% CI 0.65-0.98, p=0.04). Prostate cancer screening, 
based on PSA testing, thus reduced prostate cancer specifi c mortality by 20% in the intention-
to-screen analysis.
  Figure 3 | Adapted from1
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2.7 | Contamination
2.7.1 | Contamination and eff ective contamination
PSA contamination, i.e. the opportunistic PSA based screening in the control arm of the study, 
can jeopardize the power of the ERSPC. With increasing contamination during the early years 
of the study, the power decreases, necessitating higher numbers of participants in both the 
screening and control arm. Th erefore, the extent of contamination has been carefully studied in 
several participating centres.39-42
 However, it is important to realize that “eff ective” contamination cannot be determined by 
assessing the number of PSA tests only. It is necessary to evaluate the number of men who were 
PSA tested and who subsequently had a biopsy if indicated by the PSA level. 
 Such an analysis of “eff ective contamination” in the Rotterdam area was reported by Otto et 
al.42 During a period of 2.9 years, 2895 of 14,349 men (20.2%) in the control arm were PSA tested 
and 1981 of 14,052 men (14.1%) in the screening arm were PSA-tested outside the screening 
protocol. Th e proportion of men in the control arm with a PSA >= 3.0 ng/ml followed by a 
biopsy and a prostate cancer diagnosis was 7-8% and 3% respectively (3% and 0.4-0.6% in the 
screening arm). Th erefore, although the PSA testing rate in the control arm was high, this was 
not followed by a substantial increase in prostate biopsies and, more importantly, in detection 
of prostate cancer. Th e eff ective PSA contamination was relatively small and may not jeopardize 
the power of the trial. Furthermore, the rate of eff ective contamination was in line with the 
predicted contamination rate of 20% used in adjusting the initial sample size of the ERSPC.13
2.7.2 | Adjustment for contamination and non-compliance
Next to contamination, another process that may dilute the eff ects of the ERSPC is non-
compliance. Non-compliers are participants randomized to the screening arm, who are not 
screened or do not participate in the whole screening protocol. When an adjustment is made for 
contamination and non-compliance during the fi nal analysis of the ERSPC, the unbiased eff ect 
of screening can be determined for those who are willing to participate in a screening program. 
A method for this adjustment has been described by Cuzick et al.43
 Roemeling et al reported on a feasibility study and impact simulation of a secondary analysis, 
according to Cuzick et al, on the results of the Rotterdam center.44 Endpoints in this analysis 
were simulated prostate cancer mortality reductions and contamination was defi ned as a PSA 
test only. Th is study concluded that the adjustment for contamination and non-compliance was 
feasible. A second analysis according to Cuzick was described by Kerkhof et al.45 In this analysis 
data on the presence of metastasis at diagnosis, as a proxy for mortality, in both study arms from 
the Rotterdam section were evaluated. A non-compliance rate of 26% and a contamination 
rate of 12% were observed. Prostate cancer screening signifi cantly reduced the occurrence of 
metastasis in the intention-to-screen analysis (risk ratio 0.75, 95% CI 0.59-0.95, p=0.02). Aft er 
adjustment for both contamination and non-compliance, the risk was further reduced: RR 0.68, 
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95% CI 049-0.94, p=0.02. Th e authors concluded that the screening eff ect on those who are 
actually screened is approximately 28% greater than the overall eff ect seen without adjustment 
for contamination and non-compliance.
 Finally, a secondary analysis on the fi nal results of the ERSPC was carried out to provide 
accurate information for those men actually screened. Roobol et al46 reported a relative risk 
reduction of 0.69 (95% CI 0.51-0.92) to 0.71 (95% CI 0.55-0.93) for men actually screened 
aft er adjustment for contamination and non-compliance using 2 diff erent estimates for 
contamination. Th us, PSA screening reduces the risk of dying from prostate cancer by up to 
31% in men who are actually screened. 
2.8 | Overdiagnosis and indolent disease
2.8.1 | Overdiagnosis
Overdiagnosis is the detection of prostate cancer that would never have been diagnosed without 
screening. Th ose cases of prostate cancer would not have led to symptoms or death during life 
and therefore would not have been diagnosed clinically. Th is may relate to a relatively harmless 
tumour behaviour or to competing causes of death. However, if such a carcinoma is found 
through screening, adverse psychological and physical eff ects may arise. Especially, invasive 
treatment for prostate cancer, which would not have been clinically relevant, with possible side 
eff ects, may be harmful. 
 Using the micro simulation (MISCAN) model, the extent of overdiagnosis in the Rotterdam 
section of the ERSPC was estimated.29 A 100% attendance rate for each screening program was 
assumed. Obviously, overdiagnosis leads to a rise in prostate cancer incidence. Th e fi rst-round 
detection rate in the screened arm was almost 17 times as high as the prostate cancer detection 
rate in the control arm (54 versus 3.18 cases per 1000 man-years). 
 Screening men aged 55 to 67 years with a 4-year screening interval detects 41 irrelevant 
cancers in 1000 men. Th is corresponds with an overdiagnosis rate of 48% (range 44%-55%). 
Furthermore, the lifetime prostate cancer risk increases from 64 to 106 per 1000, a relative 
increase of 65%. 
 Th is amount of overdiagnosis may be unacceptable in population-based screening, for both 
health care providers and policy makers. Reduction of overdiagnosis by increasing specifi city, 
i.e. through individualizing screening programs and fi nding new markers, will be of great 
importance during the years to come.47
2.8.2 | Indolent prostate cancer
However, as long as screening can not been made more selective for aggressive or clinically 
signifi cant prostate cancer, another approach was taken with the identifi cation of potentially 
indolent cancers. Indolent prostate cancer is cancer that will not cause any symptoms or 
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mortality during life due to a relatively benign behaviour. If such a tumour is diagnosed and 
treated radically, side eff ects may occur, possibly reducing the quality of life. To avoid this 
unnecessary treatment or overtreatment, many attempts are made to identify indolent prostate 
cancer. For the screening situation, a nomogram was described by Steyerberg et al based on 
data from the ERSPC.48 Th is nomogram can be used to identify 20-30% of screen-detected PC 
as “potentially indolent” depending on the probability level chosen (70-80%).
 Instead of radical treatment, those cases of indolent cancer may be off ered active surveillance, 
a strategy of closely monitoring the patient and off ering radical treatment with curative intent 
if signs of progression occur. Th e safety and feasibility of such a treatment strategy is subject 
of investigation of the project Prostate Cancer Research International: Active Surveillance 
(PRIAS).49 Th is international website-based study has been launched at the end of 2006 and has 
included around 850 prostate cancer patients up to June 2009. First reports of this study show 
favourable results on quality of life and feasibility. Furthermore, no adverse eff ects of active 
surveillance were shown in a retrospective study.50 However, the safety of active surveillance 
remains to be proven.
2.9 | Quality of life and costs of screening
2.9.1 | Quality of life
Th e evaluation of quality of life in relation to screening and treatment aspects of prostate 
cancer has been considered essential from the start of the ERSPC. Th erefore, next to mortality 
reduction, quality adjusted life years (QALYs) will be calculated. Unfortunately, only in one 
of the centers (Rotterdam) a truly systematic study of quality of life has been conducted and 
is still ongoing. So far, only short-term eff ects could be analyzed and fi nal conclusions about 
the impact of prostate cancer screening on quality of life will only become clear aft er the fi nal 
analysis of the ERSPC. 
 Up to now, it has been shown that prostate cancer screening induced no important short-
term health status eff ects, with some exceptions of high levels of anxiety in subgroups.51 Health-
related quality of life (HRQoL) was related to tumour stage and the detection method (screen 
vs. clinically detected PC).52 Furthermore, the type of post-treatment HRQoL impairments 
was dependent on treatment modality (prostatectomy or radiotherapy). Patients with screen-
detected or clinically diagnosed PC reported similar post-treatment HRQoL.53 
Prostate cancer diagnosis was shown to worsen mental and self-rated overall health immediately 
aft er diagnosis in screened patients. However, six months later, health status scores improved 
and no longer diff ered signifi cantly from pre-diagnosis scores.54 
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2.9.2 | Costs of screening
Due to screening, some cases will be prevented from reaching the advanced stage. In order 
to evaluate a screening program thoroughly, it is important to quantify course, care, and 
accompanying costs of advanced disease. Data on these factors are reported in.55 Together 
with the eff ects of advanced prostate cancer on quality of life, these data will be used for the 
evaluation of prostate cancer screening. A report on the costs of screening is in progress.
2.10 | Future prospects
In the ERSPC, a prostate cancer specifi c mortality reduction has been shown due to PSA based 
screening. However, 1410 men need to be screened and 48 cases needed to be treated in addition 
to the control arm to avoid one prostate cancer death aft er 9 years of observation.1 Th ese 
numbers needed to screen and needed to treat are very high and could be lowered by increasing 
the screening specifi city for aggressive disease and avoiding overdiagnosis and overtreatment. 
Th is is very important, as screening for prostate cancer is being performed on a growing 
scale by general practitioners and urologists, independently of the fi nal recommendations of 
the ERSPC. Th erefore, attention should be drawn to optimizing the screening regimen. For 
example, the use of individual characteristics of the screening participant, new biomarkers, and 
the use of nomograms may play a role in this search for optimal future screening programs. 
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Scope and outline of the thesis
CHAPTER 3
38 Chapter 3
3.1 | Scope
PSA based screening for prostate cancer reduces prostate cancer specifi c mortality.1 Due to 
screening the prostate cancer is diagnosed earlier in time and hopefully curable treatment can 
be off ered and disease specifi c mortality can be reduced. Diff erences in treatment distribution 
between the screening and the control arm of the study and possible treatment bias were 
assessed in the second part of the thesis.
 Although a mortality reduction has been shown due to screening, some important 
drawbacks prevent the introduction of a population based screening program at the moment. 
Th e fi rst reason is the lack of specifi city of PSA for prostate cancer in general, with a subsequent 
large number of unnecessary biopsies. Th e third part of this thesis contributes to improvement 
of the current screening protocol.
 Another essential limitation of screening is the substantial overdiagnosis and subsequent 
overtreatment. Th is is refl ected in a high number needed to treat (n=48, in excess to the control 
group). Th e overdiagnosis results from the lack of specifi city of the PSA based screening 
protocol for clinically signifi cant prostate cancer. However, as long as the protocol cannot be 
made more selective for aggressive disease, we will need to be able to diff erentiate indolent from 
aggressive prostate cancer and possibly prevent overtreatment. In the last part of the thesis an 
eff ort is made to improve this diff erentiation.
3.2 | Outline
A diff erent distribution of treatment for prostate cancer in the screening and control arm seems 
logical, with the observed stage and grade shift  between both study arms. However, if diff erences 
in age, stage and grade do not completely explain the discrepancy in treatment between both 
arms, the observed mortality reduction could be at least in part be due to diff erences in 
treatment. In Part II, chapter 4 describes a study which evaluates treatment in both arms and 
the possible infl uence of diff erences in treatment on prostate cancer mortality.
 In Part III, an attempt is made to improve the current screening protocol. First, the 
performance of PSA velocity, i.e. the rise in PSA per year, as a screening test was assessed in 
Chapter 5. Specifi cally, the detection of clinically signifi cant prostate cancer was described. 
In Chapter 6 it was investigated whether pathological characteristics of a biopsy could 
identify men with increased risk of prostate cancer diagnosis during a next screening visit. If 
such characteristics could be identifi ed, the screening protocol could be intensifi ed for men 
harbouring these high risk features or the protocol could be made less strict for men without 
these characteristics. Another study on prostate biopsies is described in Chapter 7. Th e number 
and characteristics of suspicious lesions and prostate cancer lesions are described that were 
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missed during the original pathological examination. Knowledge about these missed lesions 
could improve the diagnostic accuracy and prevent the delay of prostate cancer diagnosis.
In Part IV, Chapter 8 contains an evaluation of the independent prognostic value of tumour 
volume. Although tumour volume alone unequivocally has been reported to be predictive for 
patient outcome as a sole predictor, its value aft er correction in multivariable analysis for other 
prognosticators like tumour stage and grade has been disputed. In Chapter 9, we reassessed 
the 0.5 ml tumour volume threshold commonly used to identify indolent prostate cancer on 
a radical prostatectomy series from the Rotterdam section of the ERSPC. Additionally, the 
prognostic value of the tumour volume threshold for indolent disease was evaluated. Finally, 
a study which aims to improve the diff erentiation of clinically signifi cant and indolent cancer 
with the use of immunohistochemical staining on biopsy specimens is described in Chapter 10.
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Abstract
Prostate cancer (PC) mortality is the most valid end-point in screening trials, but could be 
infl uenced by the choice of initial treatment if treatment has an eff ect on mortality. In this study, 
PC treatment was compared between the screening and control arms in a screening trial.
 Data were collected from the European Randomized Study of Screening for Prostate Cancer 
(ERSPC). Characteristics and initial treatment of PC cases detected in the screening and the 
control arm were compared. Polytomous logistic regression analysis was used to assess the 
infl uence of study arm on treatment, adjusting for potential confounders and with statistical 
imputation of missing values.
 A total of 8,389 PC cases were detected, 5,422 in the screening arm and 3,145 in the control 
arm. Polytomous regression showed that trial arm was associated with treatment choice aft er 
correction for missing values, especially in men with high risk PC. A control subject with 
high-risk PC was more likely than a screen subject to receive radiotherapy (OR 1.43, 95% CI 
1.01-2.05, p=0.047), expectant management (OR 2.92, 95% CI 1.33-6.42, p=0.007) or hormonal 
treatment (OR 1.77, 95% CI 1.07-2.94, p=0.026) instead of radical prostatectomy. However, trial 
arm had only a minor role in treatment choice compared to other variables.
 Concluding, a small eff ect of trial arm on treatment choice was seen, particularly in men 
with high-risk PC. Th erefore, diff erences in treatment between arms are unlikely to play a major 
role in interpretation of the results of the ERSPC.
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4.1 | Introduction
With the introduction of the serum prostate-specifi c antigen (PSA) test, early detection of 
prostate cancer has become possible. PSA is nowadays widely used as a screening test for 
prostate cancer. Recently, the European Randomized Study of Screening for Prostate Cancer 
(ERSPC) has reported a disease-specifi c mortality reduction due to screening1. 
 Th e mortality reduction induced by screening for PC may be infl uenced by diff erences in 
treatment. Due to early detection, prostate cancer is diagnosed in an earlier stage and grade 
and may subsequently be more oft en suitable for radical treatment, like surgery. A diff erent 
treatment distribution is thus expected between the intervention and the control arm of the 
ERSPC. However, similar PC cases are preferably treated similarly in both arms. Otherwise, 
the mortality reduction may not only be due to early detection and early treatment, but could 
possibly also be caused by diff erent treatment choices for the same types of patients as treatment 
choice is intermediate between randomization to a study arm and mortality. Since study arm 
cannot be blinded, diff erent treatment among diagnosed cancers could have an impact on study 
arm diff erences, i.e. mortality. We analyze treatment choice as an embedded observational study 
within the parent clinical trial, i.e. the ERSPC.
 However, a complete separation between screening per se and treatment eff ect cannot be 
made since a screen detected tumour diff ers in various ways from a clinically detected tumour. 
Especially, correction may not be fully possible for the lead-time eff ect in screening.
 In the current study, we aim to describe and compare the treatment modalities in the 
intervention and control arm of the ERSPC, with correction for available patient and tumour 
characteristics as far as possible. 
4.2 | Methods
Th e main goal of the ERSPC trial was to show or exclude a 20% reduction in PC mortality due to 
screening. Th e trial started in 1993 in Belgium and the Netherlands, soon followed by Finland, 
Sweden, Spain, Italy, Switzerland and France.2 Th e recruitment has been completed with 162,243 
men randomized in the core age range of 55-69 years old, 72,890 in the intervention arm and 
89,353 in the control arm1. Informed consent was obtained from all subjects.
 Th e ERSPC has established a Central Database for data monitoring and joint analyses.3 
From this Central Database, numbers of cancers in the screening and control arm were 
obtained. Furthermore, age at diagnosis, PSA at diagnosis, Gleason score, TNM stage and initial 
treatment were retrieved. Data were complete up to December 31, 2006, with identical follow-
up in the two study groups.1
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 Patient and tumour characteristics, and the initial treatment were described for the whole 
cohort and compared between study arms. Treatment was classifi ed as radical prostatectomy 
(RP), radiotherapy (RT), active surveillance (AS) or hormonal therapy (HT). Th e treatment 
which was chosen as original treatment was scored. For example, when AS was chosen but HT 
was applied aft er a year in case of symptoms, treatment was scored as AS. Men who declined 
treatment were classifi ed in the AS group. To describe treatment per risk group, all PC cases 
were divided in three risk groups: low, intermediate and high risk PC, according to the criteria 
of d’Amico et al4. Low risk was defi ned as stage =< T2a and PSA=< 10 ng/ml and Gleason score 
= 6. High risk was defi ned as stage T2c or higher or a PSA-level >20 ng/ml or Gleason score 
>=8. Th e remaining cases (stage T2b or a Gleason score of 7 or a PSA level >10 ng/ml and <= 
20 ng/ml) were defi ned as intermediate risk, unless data on PSA, Gleason score or T-stage were 
missing. Cases with known positive lymph nodes or distant metastases were defi ned as high 
risk.
 Th e ERSPC was approved by the local institutional boards of all participating centers.
4.2.1 | Statistical analysis
Diff erences in treatment between trial arms, i.e. screening arm and control arm, were evaluated 
using polytomous multivariate logistic regression. In the multivariable analysis, adjustment 
was made for age (continuous), PSA (log transformation), Gleason score (3 categories: <7, =7, 
>7) and TNM stage. Statistical signifi cance was assessed with the likelihood ratio test, which 
follows a chi-square distribution. Chi-square values were also used to indicate the relative 
importance of the variables in the model. Th e higher the overall total Chi-square value, the 
better the performance of the predictive model. In addition, the higher the Chi-square value 
for a particular variable, the more important this variable is in predicting treatment choice. We 
report odds ratios (OR) for a screen subject compared to a control subject for the 4 treatment 
modalities based on the polytomous analysis with RP as a reference, using SPSS soft ware (v 15, 
SPSS Inc, Chicago, Ill). 
 Th is multivariable analysis was hampered by missing data for potential confounders. 
Th erefore, an imputation procedure was followed for missing data. Missing values were fi lled 
in by a statistical method that accounted for correlations between the variables. We used the 
fi rst imputation of a multiple imputation procedure with the Impute function in R soft ware (v 
2.7.2, R foundation for statistical computing), with inclusion of treatment, study arm, and all 
potential confounders as variables in the imputation model. A total of 3964 confounder values 
were missing, comprising 9.5% of all values. By fi lling in these values, the 3030 patients with any 
missing value (37.8% of all patients) could be included in the analysis. Apart from increasing 
sample size, imputation corrects for a possible selection bias due to selective missingness5,6. A 
p-value less than 0.05 was considered statistically signifi cant.
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4.3 | Results
4.3.1 | PC characteristics in the screening and the control arm
A total of 10,297 PC cases were detected, 5,990 in the screening arm and 4,307 in the control 
arm. For 8,389 (81.5%) cases data on initial treatment were available and those men were 
included in the analyses (87.5% of all PC cases detected in the screening arm and 73.0% of all 
PC cases detected in the control arm).
 Of 8,389 PC cases, 5,244 (62.5%) had been diagnosed in the screening arm and 3,145 
(37.5%) in the control arm. Men diagnosed with PC in the control arm were on average 1 year 
older than those in the intervention arm (mean age 66.5 vs. 65.2 years, p<0.001). Th e PSA level 
was much higher among PC cases in the control arm than in the screening arm (median 10.3 
vs. 5.5 ng/ml, p<0.001). Gleason scores and TNM stage were also signifi cantly worse among 
cases in the control group (table 1). In the screened arm, 2766 (52.7%) cases were classifi ed as 
low-risk PC, 1319 (25.2%) as intermediate risk PC and 1159 (22.1%) as high risk PC. For the 
control group, these numbers were 873 (27.8%), 976 (31.0%) and 1296 (41.2%) respectively.
Table 1 | General characteristics of the overall cohort and per study arm. All diff erences were signifi cant 
at the p<0.001 level.
Total group N=8389 Screen N=5244 Control N=3145
Age in years
Mean (median)
65.7 (66.0) 65.2 (66.0) 66.5 (67.0)
PSA in ng/ml
Mean (median)
33.3 (6.8) 17.6 (5.5) 64.2 (10.3)
Gleason 
 < 7
 = 7
 > 7
 unknown
4815 (57.4)
1695 (20.2)
 766 (9.1)
1113 (13.3)
3360 (64.1)
 946 (18.0)
 345 (6.6)
 593 (11.3)
1455 (46.3)
 749 (23.8)
 421 (13.4)
 520 (16.5)
T-stage 
 T1 a-c
 T2
 T3
 T4
 unknown
4581 (54.6)
2453 (29.2)
1985 (11.7)
 161 (1.9)
 209 (2.5)
3121 (59.5)
1521 (29.0)
 447 (8.5)
  55 (1.0)
 100 (1.9)
1460 (46.4)
 932 (29.6)
 538 (17.1)
 106 (3.4)
 109 (3.5)
N-stage 
 N0
 N+
 unknown
6627 (79.0)
 156 (1.9)
1606 (19.1)
4475 (85.3)
  66 (1.3)
 703 (13.4)
2152 (68.4)
  90 (2.9)
 903 (28.7)
M-stage 
 M0
 M+
 unknown
7353 (87.7)
 379 (4.5)
 657 (7.8)
4773 (91.0)
 132 (2.5)
 339 (6.5)
2580 (82.0)
 247 (7.9)
 318 (10.1)
48 Chapter 4
4.3.2 | Initial treatment and diff erences in treatment by trial arm
Th e proportions of the treatments were signifi cantly diff erent between the screen and control 
arms (p<0.001, table 2). In the screening arm, surgery (40.3% vs. 30.3%) and AS (21.3% vs. 
13.9%) were performed more oft en than in the control arm. Hormonal treatment (20.8% vs. 
7.8%) was used more frequently in the control arm. 
 We excluded 379 men with distant metastases of whom 353 received HT, to improve the 
statistical analyses. Th e model estimation was compromised with inclusions of these cases due 
to small numbers of men with metastases. No diff erence in treatment distribution was found 
between study arms in this subgroup of cases with metastasis. Th is left  a cohort of 8010 men 
for further analyses (see table 3). Th e treatment modalities in the screening arm and control 
arm were described stratifi ed per risk group as well. Th is risk stratifi cation showed that the 
diff erences in treatment between the study arms were largely caused by diff erences in the high-
risk group: RP in 34.2% and 19.6% of screen and control cases, HT in 14.7% and 29.5% (Chi 
square test, p<0.001).
Table 2 | Treatment modalities in the whole cohort and per study arm. Treatment distribution was 
signifi cantly diff erent between arms (Chi-square test, p<0.001).
Treatment Total group n=8389 
(%)
Screen n=5244 
(%)
Control n=3145 
(%)
Radical prostatectomy 3067 (36.6) 2113 (40.3)  954 (30.3)
Radiotherapy 2704 (32.2) 1604 (30.6) 1100 (35.0)
Active surveillance 1553 (18.5) 1116 (21.3)  437 (13.9)
Hormonal therapy 1065(12.7)  411 (7.8)  654 (20.8)
 Th e polytomous regression analysis showed that study arm was not a signifi cant factor in 
treatment choice in the original dataset (table 4). In the analysis with completed data, however, 
study arm was a signifi cant predictor in treatment choice, but with a very small impact compared 
to the other variables (chi-square 8 on a total chi-square of 2428, table 5). PSA and age were the 
most important factors for treatment choice, followed by T-stage.
 A control subject was more likely to receive HT (OR 1.28, 95% CI 1.05-1.57, p=0.016) or 
RT (OR 1.13, 95%CI 1.01-1.28, p=0.039) than a screen subject using RP as reference treatment. 
Additional analyses with AS as reference treatment, showed that a control subject was more 
likely to receive HT instead of AS than a screen subject (OR 1.27 95% CI 1.02-1.59, p=0.036). 
No diff erences were found between the other treatment modalities. 
The effect of study arm on prostate cancer treatment in a large screening trial (ERSPC) 49
C
ha
pt
er
 4
Ta
bl
e 3
 | T
re
at
m
en
t m
od
al
iti
es
 in
 th
e c
oh
or
t a
nd
 p
er
 st
ud
y 
ar
m
, e
xc
lu
di
ng
 m
en
 w
ith
 d
ist
an
t m
et
as
ta
se
s (
n=
37
9)
. A
dd
iti
on
al
ly,
 tr
ea
tm
en
t p
er
 ar
m
 is
 d
es
cr
ib
ed
 st
ra
tifi
 e
d 
by
 ri
sk
 g
ro
up
 a
cc
or
di
ng
 to
 th
e 
cr
ite
ri
a 
by
 d
’A
m
ic
o.
 D
iff 
er
en
ce
s i
n 
tr
ea
tm
en
t d
ist
ri
bu
tio
n 
w
er
e 
st
at
ist
ic
al
ly
 si
gn
ifi 
ca
nt
 in
 a
ll 
ri
sk
 g
ro
up
s a
t t
he
 p
<0
.0
5 
le
ve
l.
Tr
ea
tm
en
t
To
ta
l g
ro
up
 
(%
)
Sc
re
en
 (%
)
C
on
tr
ol
 (%
)
Lo
w 
ri
sk
 P
C
In
te
rm
ed
ia
te
 ri
sk
 P
C
H
ig
h 
ri
sk
 P
C
Sc
re
en
C
on
tr
ol
 
Sc
re
en
C
on
tr
ol
 
Sc
re
en
C
on
tr
ol
 
R
ad
ic
al
 
pr
os
ta
te
ct
om
y
30
64
 (3
8.
3)
21
13
 (4
1.
3)
 9
51
 (3
2.
8)
10
99
 (3
9.
7)
34
2 
(3
9.
2)
 6
63
 (5
0.
3)
40
3 
(4
1.
3)
 3
51
 (3
4.
2)
 2
06
 (1
9.
6)
R
ad
io
th
er
ap
y
26
89
 (3
3.
6)
15
97
 (3
1.
2)
10
92
 (3
7.
7)
 6
95
 (2
5.
1)
24
6 
(2
8.
2)
 4
19
 (3
1.
8)
36
5 
(3
7.
4)
 4
83
 (4
7.
0)
 4
81
 (4
5.
9)
A
ct
iv
e 
Su
rv
ei
lla
nc
e
15
45
 (1
9.
3)
11
11
 (2
1.
7)
 4
34
 (1
5.
0)
 9
16
 (3
3.
1)
25
1 
(2
8.
8)
 1
53
 (1
1.
6)
13
0 
(1
3.
3)
  
42
  (
4.
1)
  
53
 (5
.1
)
H
or
m
on
al
 th
er
ap
y
 7
12
 (8
.9
)
 2
91
 (5
.7
)
 4
21
 (1
4.
5)
 5
6 
(2
.0
)
 3
4 
(3
.9
)
  
84
 (6
.4
)
 7
8 
(8
.0
)
 1
51
 (1
4.
7)
 3
09
 (2
9.
5)
To
ta
l
80
10
51
12
28
98
27
66
87
3
13
19
97
6
10
27
10
49
50 Chapter 4
Ta
bl
e 
4 
| O
dd
s 
ra
tio
s 
(O
R)
 fo
r 
al
l i
nc
lu
de
d 
va
ri
ab
le
s 
w
ith
 r
ad
ic
al
 p
ro
st
at
ec
to
m
y 
as
 r
ef
er
en
ce
 tr
ea
tm
en
t, 
ba
se
d 
on
 p
ol
yt
om
ou
s 
lo
gi
st
ic
 r
eg
re
ss
io
n 
an
al
ys
es
 fo
r 
th
e 
or
ig
in
al
 d
at
a 
(n
=5
28
5)
 a
nd
 th
e 
co
m
pl
et
ed
 d
at
a 
(n
=8
01
0)
. *
 lo
ga
rit
hm
ic
 tr
an
sf
or
m
at
io
n 
of
 P
SA
 w
as
 u
se
d,
 e
ff e
ct
 p
er
 1
0-
fo
ld
 in
cr
ea
se
.
Tr
ea
tm
en
t
Ra
di
ot
he
ra
py
 
O
R 
(9
5%
 C
I)
 
or
ig
in
al
 d
at
a
Ra
di
ot
he
ra
py
 
O
R 
(9
5%
 C
I)
 co
m
pl
et
ed
 d
at
a 
Ac
tiv
e s
ur
ve
ill
an
ce
 
O
R 
(9
5%
 C
I)
 
or
ig
in
al
 d
at
a
Ac
tiv
e s
ur
ve
ill
an
ce
 
O
R 
(9
5%
 C
I)
 
co
m
pl
et
ed
 d
at
a 
H
or
m
on
al
 tr
ea
tm
en
t 
O
R 
(9
5%
 C
I)
 
or
ig
in
al
 d
at
a
H
or
m
on
al
 tr
ea
tm
en
t 
O
R 
(9
5%
 C
I)
 
co
m
pl
et
ed
 d
at
a 
ag
e
1.
13
 (1
.1
1-
1.
15
)
1.
12
 (1
.1
1-
1.
14
)
1.
20
 (1
.1
8-
1.
23
)
1.
19
 (1
.1
7-
1.
21
)
 1
.2
8 
(1
.2
3-
1.
32
)
 1
.2
7 
(1
.2
4-
1.
30
)
PS
A
*
1.
91
 (1
.5
0-
2.
42
)
2.
02
 (1
.6
7-
2.
43
)
0.
22
 (0
.1
6-
0.
30
)
0.
30
 (0
.2
3-
0.
39
)
16
.9
0 
(1
1.
23
-2
5.
33
)
16
.0
1 
(1
2.
07
-2
1.
24
)
Tu
m
ou
r s
ta
ge
 
 
T1
 
T2
 
T3
 
T4
1 0.
74
 (0
.6
4-
0.
86
)
3.
76
 (2
.6
5-
5.
32
)
6.
21
 (1
.2
7-
30
.3
4)
1 0.
79
 (0
.7
1-
0.
90
)
4.
46
 (3
.5
7-
5.
58
)
3.
26
 (1
.2
9-
8.
21
)
1 0.
26
 (0
.2
1-
0.
32
)
0.
26
 (0
.1
1-
0.
64
)
3.
27
 (0
.2
4-
43
.9
9)
1 0.
33
 (0
.2
8-
0.
39
)
0.
36
 (0
.2
1-
0.
61
)
2.
85
 (0
.6
8-
12
.0
1)
 1  0
.8
3 
(0
.6
1-
1.
12
)
 1
.8
8 
(1
.0
8-
3.
28
)
 2
.7
5 
(0
.4
3-
17
.4
7)
 1  1
.1
1 
(0
.8
9-
1.
39
)
 4
.3
8 
(3
.1
8-
6.
03
)
 5
.2
5 
(1
.9
3-
14
.2
9)
G
le
as
on
 sc
or
e
 
<=
6
 
=7
 
>=
8
1 0.
95
 (0
.8
1-
1.
12
)
1.
19
 (0
.9
1-
1.
56
)
1 1.
03
 (0
.9
0-
1.
17
)
1.
22
 (0
.9
9-
1.
50
)
1 0.
27
 (0
.2
1-
0.
35
)
0.
11
 (0
.0
6-
0.
23
)
1 0.
30
 (0
.2
5-
0.
37
)
0.
20
 (0
.1
3-
0.
32
)
 1  0
.9
9 
(0
.7
2-
1.
36
)
 1
.4
6 
(0
.9
3-
2.
27
)
 1  0
.9
5 
(0
.7
5-
1.
19
)
 1
.2
9 
(0
.9
6-
1.
75
)
Ly
m
ph
 n
od
e 
in
vo
lv
em
en
t
 
N
eg
at
iv
e
 
Po
sit
iv
e
1 0.
23
 (0
.0
8-
0.
56
)
1 0.
72
 (0
.4
3-
1.
21
)
1 5.
48
 (1
.9
0-
15
.7
8)
1 1.
75
 (0
.8
1-
3.
78
)
 1  5
.1
1 
(2
.4
2-
10
.7
9)
 1  6
.2
4 
(3
.7
9-
10
.2
7)
St
ud
y 
ar
m
 
Sc
re
en
 
C
on
tr
ol
1 1.
11
 (0
.9
5-
1.
30
)
1 1.
13
 (1
.0
1-
1.
28
)
1 1.
06
 (0
.8
4-
1.
23
)
1 1.
01
 (0
.8
7-
1.
17
)
 1  1
.2
1 
(0
.9
1-
1.
60
)
 1  1
.2
8 
(1
.0
5-
1.
57
)
The effect of study arm on prostate cancer treatment in a large screening trial (ERSPC) 51
C
ha
pt
er
 4
 Subgroup analyses were performed for the risk groups, since treatment distribution seemed 
especially diff erent between arms in the high risk group and less obvious in low and intermediate 
risk (table 3). Indeed, study arm remained a signifi cant predictive factor in treatment choice 
in high risk PC: overall p-value 0.018, with a Chi square of 10 on a total of 401) (model not 
shown). Compared to a screening subject, a control subject was more likely to receive RT (OR 
1.43, 95% CI 1.01-2.05, p=0.047), AS (OR 2.92, 95% CI 1.33-6.42, p=0.007) or HT (OR 1.77, 
95% CI 1.07-2.94, p=0.026) instead of RP. No diff erences between other treatments were found. 
In low and intermediate risk PC, no signifi cantly predictive value was observed for study arm 
(p=0.334 and p=0.701 respectively). Th ese results remained unchanged in the completed data.
Table 5 | Overall eff ect of patient and tumour characteristics on treatment for the original data and the 
completed data aft er imputation. Th e importance of a variable for the model is expressed in the Chi-square 
value relative to the total Chi-square.
Eff ect Original data Completed data
Chi-square p-value Chi-square p-value
Study arm    3   0.421    8   0.042
PSA  801 <0.001  647 <0.001
Age  574 <0.001  862 <0.001
Gleason score  197 <0.001  244 <0.001
T stage  293 <0.001  545 <0.001
N stage   78 <0.001  122 <0.001
Total Chi-square 1923 2428
4.4 | Discussion
Th is study shows a major stage and a grade shift  of prostate cancer between the screen and the 
control arm in the ERSPC, with more favorable characteristics in the screening arm. Th is is in 
line with earlier reports from individual centers of the ERSPC7-10, but has not previously been 
reported for the whole ERSPC. 
 Currently, there is a striking diff erence in the cumulative incidence of PC between the 
study arms: 5,990 (8.2%) PC cases were detected in the screening arm and 4,307 (4.8%) in the 
control arm1.. Th is markedly higher incidence in PSA-screened men has been reported by some 
individual centers, as well other large databases7-12.. Two main reasons should be mentioned. 
First, lead-time bias is inherent to screening: the disease is identifi ed earlier in a screening 
setting than in the clinical setting. For the ERSPC, this lead-time is calculated to be around 10 
years13,14. Th erefore, one would expect a higher detection rate in the screened arm and to detect 
more additional PC cases in the control arm in the future. Second, the high detection rate in the 
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screening arm is partly caused by the detection of indolent disease (overdiagnosis). Th ose PC 
cases would not have been diagnosed during a man’s lifetime in the absence of screening, due to 
a non-aggressive natural course and competing causes of death. Th erefore, screening currently 
leads to over-detection, which presents a challenge to optimize screening and treatment 
regimens in order to minimize the harms of screening.15
 Our results indicate a dissimilar distribution of initial treatments in the two arms of the 
ERSPC. Th is is not surprising as stage and grade are important determinants in treatment choice 
and these were signifi cantly lower in the screening arm. Th is is refl ected in the distribution 
of treatment: AS and RP were more oft en used in the screening arm, whilst especially HT 
was more frequently chosen in the control group. Th is observation is in line with a report of 
the Swedish ERSPC group.9 It is worth noting that all expectant management strategies were 
categorized in one group (AS), while the intent of treatment may diff er: curative, similar to 
active surveillance, or palliative as in watchful waiting.16 In the trial database, the intent was 
not recorded. Furthermore, all patients who received radiotherapy were categorized as a single 
group, including those receiving monotherapy and those who received RT in combination 
with HT. Th is approach was chosen because subdivision of the RT group resulted in too small 
numbers for reliable statistical modeling.
 Arm was not signifi cantly predictive for treatment in the total cohort (overall p-value<0.001) 
aft er correction for important factors in PC treatment choice, i.e. age, PSA and tumour 
characteristics. A bias could be introduced in the analysis due to cases with missing values 
(3,030 of 8,010, 37.8%). Nowadays, advanced statistical procedures are readily available to fi ll 
in missing data.17 Th is increases effi  ciency and limits any selection bias. Aft er correction for 
missing values using an imputation method some diff erences in treatment choice were found 
between both study arms: a control subject was more likely than a screen subject to receive 
HT or RT instead of RP, and was also more likely to receive HT instead of AS. Th is could be of 
importance if treatment aff ects the outcome within this group. Th is is especially true for men 
treated with HT, as those are oft en men with high-risk PC and thus more prone to die from their 
disease.
 We note that study arm had statistically signifi cant associations with treatment, but was 
far less important than age, PSA level, T-stage, or Gleason score. Th erefore, no systematic 
discrepancy in treatment selection between arms could be shown and a mortality reduction 
solely caused by a treatment eff ect is very unlikely. Inclusion of ERSPC center, or exclusion 
of non-attendees and interval cancers in the screening arm did not change results (models 
not shown). Th e discrepancy was mainly observed in 2076 men with high-risk PC without 
metastases. Obviously, these patients are more likely to die from their disease. A total of 490 
patients died from PC in the total cohort of men included in this report, and 187 (38.2%) 
of these were in the current selection of 2076 men . Th e remaining major part of PC deaths 
occurred in men with metastasis (207 or 42.2%) and in men with low or intermediate risk PC 
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(96 or 19.6%). In these groups, no treatment diff erence was observed. Th erefore, only a minor 
part of the PC mortality could be infl uenced by a treatment diff erence between arms.
 Although the role of study arm was small, it could have some infl uence on mortality if 
treatment indeed infl uences outcome in the high-risk PC group. A screen subject was more 
likely to receive RP than a control subject. Unfortunately, randomized studies comparing radical 
prostatectomy to a control group in high risk cases are not available. Available randomized 
studies in high-risk patients compare RT in combination with HT to RT alone18 or HT alone19 
and show a mortality diff erence in favor of combined therapy. Further exploration of the 
treatment data in the 2076 high-risk patients showed that in the screening arm, 29.2% received 
RT alone, 14.7% HT alone and 17.8% received a combination of RT with HT. For the control 
arm these rates were 15.8%, 29.5% and 30.0% respectively. Th us, the only treatment which has 
shown to be superior is a combination of RT with HT and this treatment was given more oft en 
in the control arm. If an eff ect of diff erent treatment on mortality would occur, this might be in 
favor f the control arm based on available randomized trials. Concluding, a very small overall 
eff ect on PC mortality, if any, is expected from the diff erent treatment in the high-risk PC cases.
 Th e most important reason for the uneven treatment distribution between arms in high 
risk disease, even when correction for patient and tumour characteristics is made, is that a 
screen-detected tumour per defi nition diff ers from a clinically detected tumour. Even aft er the 
correction for age, PSA, Gleason and TNM-stage, a screen-detected tumour is not similar to a 
clinically detected tumour due to a lead-time eff ect. For example a screen-detected T3 tumour 
most probably has a more favorable prognosis than a clinically detected T3 tumour. Clearly, 
this distinction plays a role in treatment selection. Th is should not be regarded as a bias, but a 
screening eff ect. However, no correction could be made for this factor and this could, at least 
partly, explain the fact that a control subject was more likely to receive HT. Moreover, men 
in the control arm were diagnosed clinically and at least some of them were thus presumably 
symptomatic, while the screen-detected cases were more likely to be non-symptomatic. Th e 
presence or absence of symptoms is important in choosing a particular treatment, but no data 
on symptoms were available.
 Some other limitations of the analysis of treatment distribution between arms should be 
taken into account. Firstly, HT is especially selected in men with high-risk PC or patient-bound 
factors that make radical therapy less suitable, for instance men with locally advanced PC or 
men with high age or extensive co-morbidity. In the analysis, correction was made for tumour 
characteristics, PSA and age. However, extent of co-morbidity was not included in our data. 
Co-morbidity plays an important role in treatment choice20 and its prevalence and degree 
may diff er between study arms. It is likely that absence of this variable may explain part of the 
treatment diff erence: it has been shown that trial participants tend to be healthier than their 
general population counterparts (“healthy attendee bias”21). Th erefore, the control subjects may 
have been less suitable for radical treatment.
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 Secondly, hospital of treatment was not included, although treatment choice is likely to diff er 
between clinics. Moreover, choice of hospital possibly diff ers between study arms. Screening for 
PC within the ERSPC mostly takes place in large (university) hospitals and subsequently the 
screen subject is more likely to be treated in this university hospital than a control subject who is 
diagnosed in any hospital. Although participants were treated in similar hospitals in one center, 
in another center a discrepancy in hospital of treatment was seen: 36.3% of screened men were 
treated in the screening university hospital versus 7.9% of all control subjects (data not shown). 
Hypothetically, this could result in diff erences in treatment choice. 
 Finally, treatment was not available for all cases initially selected for the analysis, especially 
in the control arm. Th ese cases were excluded from analysis. Explanations for the missing data 
include the eff ect of post randomization consent used in the Scandinavian countries and in 
Italy, which makes it more diffi  cult to retrieve clinical information from the control group. 
Although unlikely, this may infl uence the outcomes of the current analysis. If the data become 
more complete during the coming years a second analysis can be considered .
4.5 | Conclusions
In conclusion, 8389 cases of prostate cancer with known treatment have been found so far in 
the core age range cohort of the ERSPC, of which 5,244 in the screening arm and 3,145 in the 
control arm. A stage and a grade shift  were seen, with more favorable characteristics in the 
screening arm. 
 Study arm played a statistically signifi cant but minor role in treatment selection in patients 
with high-risk PC: a control subject was more likely to receive RT, AS or HT instead of RP 
than a screening subject, but no major diff erences in other treatment choices were seen. Th is 
indicates that an eff ect of diff erent treatment between arms on PC mortality may be possible but 
probably will be small. Some important factors could not be corrected for in the analyses, while 
they may diff er by study arm and could explain treatment choice. However, even in absence of 
these factors, study arm played only a minor role. Th erefore, these results show that a mortality 
reduction in the ERSPC based solely on unequal treatment in both arms is very unlikely.
The effect of study arm on prostate cancer treatment in a large screening trial (ERSPC) 55
C
ha
pt
er
 4
References
1. Schröder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized 
European study. NEJM 2009;360:1320-8
2. Schröder FH, Denis LJ, Roobol MJ and all participants of the ERSPC. Th e story of the European Randomized 
Study of Screening for Prostate Cancer. BJU I 2003;92 suppl 2:1-13
3. Smith P.H. Th e data monitoring committee-bridging the gap between urology and public health epidemiology. 
BJUI 2003;92 suppl 2:55-56
4. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw 
AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome aft er radical prostatectomy, external beam radiation 
therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974
5. Little RJA, Rubin DB. Statistical analysis with missing data. John Wiley, New York. 2002
6. Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. 
Springer, New York. 2008
7. Postma R, Van Leenders GJLH, Roobol MJ, Schröder FH and Van der Kwast TH. Tumour features in the 
control and screening arm of a randomized trial of prostate cancer. Eur Urol 2006;50:70-75
8. Aus G, Bergdahl S, Lodding P, Lilja H and Hugosson J. Prostate cancer screening decreases the absolute risk of 
being diagnosed with advanced prostate-cancer – results from a prospective, population-based randomized 
controlled trial. Eur Urol 2007;51:659-664
9. Van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, De Koning HJ, Van der Kwast TH and 
Schröder FH. Comparison of screen detected and clinically diagnosed prostate cancer in the European study 
of screening for prostate cancer, section Rotterdam. J Urol 2005;174:121-5
10. Mäkinen T, Tammela TLJ, Hakama M, Stenman U-H, Rannikko S, Aro J, Juusela H, Määttänen L and 
Auvinen A. Tumour characteristics in a population-based prostate cancer screening trial with prostate-
specifi c antigen. Clin Cancer Res 2003;9:2435-9
11. Hugosson J, Aus G, Lilja H, Loddong P and Pihl C-G. Results of a randomized, population-based study of 
biennial screening using serum prostate-specifi c antigen measurement to detect prostate carcinoma. Cancer 
2004;100:1397-1405
12. Potosky AL, Miller BA, Albertsen PC, Kramer BS. Th e role of increasing detection in the rising incidence of 
prostate cancer. JAMA 1995;273:548-52
13. Draisma G, Boer R, Otto SJ, Van der Cruijsen IW, Damhuis RAM, Schröder FH and De Koning HJ. Lead 
times and overdetection due to prostate-specifi c antigen screening: estimates from the European Randomized 
Study of Screening for Prostate Cancer. JNCI 2003;95:868-78
14. Auvinen A, Määtänen L, Stenman U-H, Tammela T, Rannikko S, Aro J, Juusela H and Hakama M. Lead-time 
in prostate cancer screening (Finland). Cancer Causes Control 2002;13:279-285
15. Bangma CH, Roemeling S, Schröder FH. Overdiagnosis and overtreatment of early detected prostate cancer. 
World J Urol 2007;25:3-9
16. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet 
Oncol 2004;5:101-06
17. Van Dijk MR, Steyerberg EW, Stenning SP, Habbema JDF. Survival estimates of a prognostic classifi cation 
depended more on year of treatment than on imputation of missing values. J Clin Epid 2006;59:246-53
18. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff  RO, Storme G, Bernier J, Kuten A, Sternberg 
C, Mattelaer J, Lopez Torecilla J, Pfeff er JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with 
immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer 
(an EORTC study): a phase III randomised trial. Lancet 2002;360:103-6.
19. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, 
Wiklund F, Fosså SD; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological 
Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-
7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301-8
56 Chapter 4
20. Desch CE, Penberthy L, Newschaff er CJ, Hillner BE, Whittemore M, McClish D, Smith T, Retchin S. Factors 
that determine the treatment for local and regional prostate cancer. Med Care 1996;34:152-162
21. Otto SJ, Schröder FH, and de Koning HJ. Low all-cause mortality in the volunteer-based Rotterdam section 
of the European randomised study of screening for prostate cancer: self-selection bias? J Med Screen 
2004;11:89-92
PART I I I
HOW TO SCREEN FOR 
PROSTATE CANCER?
Chapter 5
Is prostate-specifi c antigen velocity selective for clinically signifi cant 
prostate cancer in screening? ERSPC Rotterdam
Eur Urol 2009;55:385-92
Chapter 6
Can non-malignant biopsy features identify men at increased risk 
of biopsy-detectable prostate cancer at re-screening aft er four years? 
(ERSPC Rotterdam) 
BJU Int 2008;101:283-8
Chapter 7
False-negative prostate needle-biopsies: frequency, histopathologic 
features and follow-up 
Am J Surg Pathol 2010;34:35-43

Is prostate-specific antigen velocity 
selective for clinically significant prostate 
cancer in screening? ERSPC Rotterdam
Eur Urol 2009;55:385-92
Tineke Wolters, Monique J. Roobol, Chris H. Bangma and Fritz H. Schröder
CHAPTER 5
60 Chapter 5
Abstract
Background: Th e value of prostate specifi c antigen velocity (PSAV) in screening for prostate 
cancer and especially for clinically signifi cant PC is unclear.
Objective: To assess the value of PSAV in screening for PC. Specifi cally, the role of PSAV in 
lowering the number of unnecessary biopsies and reducing the detection rate of indolent PC 
was evaluated.
Design, setting and participants: All men included in the study cohort were participants in 
the European Randomized study of Screening for Prostate Cancer (ERSPC), Rotterdam section. 
Intervention: During the fi rst and second screening round, a PSA test was performed in 2217 
men, and all underwent a biopsy during the second screening round 4 years later.
Measurements: PSAV was calculated and biopsy outcome was classifi ed as benign, possibly 
indolent PC or clinically signifi cant PC.
Results and limitations: A total of 441 cases of PC were detected, 333 were classifi ed as 
clinically signifi cant and 108 as possibly indolent. Th e use of PSAV cut-off s reduced the number 
of biopsies but led to important numbers of missed (indolent and signifi cant) PC. PSAV was 
predictive for PC (OR 1.28, p=0.000) and specifi cally for signifi cant PC (OR 1.46, p=0.000) 
in univariate analyses. However, multivariate analyses using age, PSA, prostate volume, DRE 
and TRUS outcome and previous biopsy (yes/no) showed that PSAV was not an independent 
predictor of PC (OR 1.01, p=0.91) or signifi cant PC (OR 0.87, p=0.30). 
Conclusions: Th e use of PSAV as a biopsy indicator would miss a large number of clinically 
signifi cant PC cases with increasing PSAV cut-off s. In this study, PSAV was not an independent 
predictor of a positive biopsy in general or signifi cant PC on biopsy. Th erefore, PSAV does not 
improve the ERSPC screening algorithm.
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5.1 | Introduction
Screening for prostate cancer (PC) by means of a serum prostate-specifi c antigen (PSA) test has 
become widespread practice. Th e optimal PSA cut-off  level to indicate a prostate needle biopsy, 
however, is not easily identifi ed. An optimal balance is to be found in detecting signifi cant PC 
(sPC), while avoiding unnecessary biopsies and the detection of indolent disease (iPC) (PC 
which would not have been diagnosed in the absence of screening). Moreover, Th ompson et al1 
showed that PC is biopsy-detectable throughout the whole PSA-range. Th erefore, with the use 
of any PSA cut-off , cancers inevitably will be missed. However, lowering the biopsy threshold 
will lead to an increase in unnecessary biopsies and possibly an increased detection of iPC.
 To improve specifi city of PSA testing, PSA kinetic parameters, such as PSA-velocity (PSAV) 
has been studied extensively. PSAV is the change in PSA level during one year. Several studies 
have shown that PSAV is predictive of PC detection2-5 but others did not support this fi nding.6,7
In addition, d’Amico et al reported a signifi cantly higher chance of PC death aft er radical 
prostatectomy (RP)8 or radiotherapy9 in men with a PSAV >2.0 ng/ml in the year before 
diagnosis. Th ese fi ndings were supported by another study that found a signifi cantly higher 
median PSAV in men with relapse aft er RP than in men without relapse.10 Th ose studies suggest 
an association of PSAV with tumour aggressiveness and adverse outcome. If PSAV were able to 
distinguish sPC from iPC, this would be an important step forward in screening for PC. Some 
major concerns about screening, namely the large number of unnecessary biopsies and the high 
detection rate of iPC, could be decreased in part by a marker selective for sPC. 
 Th e aim of this study was to assess the value of PSAV as a predictor of biopsy outcome 
and tumour aggressiveness in a screened population. We evaluated the eff ects of applying a 
PSAV cut-off  level as a biopsy indicator in terms of relative sensitivity, specifi city and positive 
predictive value. In addition, the predictive value of PSAV for (signifi cant) PC in the whole 
cohort was calculated.
5.2 | Methods
5.2.1 | Study cohort
All men included in this study were participants in the European Randomized Study of 
Screening for Prostate Cancer (ERSPC), Rotterdam section. Th e ERSPC was conducted to show 
or exclude a signifi cant diff erence in PC mortality by screening for PC. 
 In the second round of the ERSPC Rotterdam (1997-2003), 12,529 men aged 55-74 yr were 
screened by means of a PSA serum test. PSA determinations were done with the Beckman-
Coulter Hybritech Tandem E Assay (Hybritech Incorporated, San Diego, CA). Aft er January 
2000, this assay was replaced by the automatic version (Beckman-Access; Beckman-Coulter, 
Inc., Fullerton, CA). A PSA >= 3.0 ng/ml prompted a systematic lateralized sextant prostate 
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needle biopsy. In 2502 men (20.0%) a PSA>= 3.0 was found and 2217 men (88.6%) were actually 
biopsied. Our study cohort consisted of those 2217 men who underwent a biopsy in the second 
screening round (Figure 1). Th is choice allowed us to study the value of PSAV in this selected 
cohort without any verifi cation bias, but it precluded an evaluation of the entire second-round 
population.
Men screened by PSA test in 
round 1 
N= 19,970 
Men screened by PSA test in 
round 2 
N= 12,529 
PSA < 3.0 ng/ml 
N=10,027 
PSA >= 3.0 ng/ml 
N=2,502 
Actually biopsied 
N=2,217 (88.6%) 
Included in study cohort 
N=2,217 
Figure 1 | Consort diagram: Method of patient selection. PSA = prostate-specifi c antigen.
* Signifi cant PC was defi ned as PC with a probability of indolence less than 70% according to the nomogram described by 
Steyerberg et al11
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 All men had been screened during the initial screening round four years earlier. Th erefore, 
two subsequent PSA levels with a four-year interval were available for calculating the PSA-
velocity (PSAV), which was calculated as the diff erence of the two PSA-levels divided by the 
exact time interval between the fi rst and second screening visit. 
 In all cancers found, the probability of indolent disease was assessed. Th e probability of 
iPCwas calculated using the nomogram described by Steyerberg et al.11 For the development 
of this nomogram, iPC was defi ned as pathologically organ-confi ned disease, tumour 
volume <0.5 ml and no Gleason pattern 4/5 based on radical prostatectomy specimens. Th e 
probability of iPC was calculated with the nomogram based on pre-treatment information: 
PSA, prostate volume, Gleason patterns, total mm cancerous and non-cancerous biopsy core 
tissue. If the calculated probability of iPC was >=70%, PC was prospectively defi ned as indolent. 
Th e remaining PC cases (including those not suitable for the nomogram based on the entry 
criteria11) were classifi ed as signifi cant disease. PSAV cut-off s of 0.15 to 1.0 ng/ml/yr as a biopsy 
indicator were simulated in addition to the actual biopsy indicator of a PSA-level >= 3.0 ng/
ml. Relative sensitivity and specifi city and the positive predictive value (PPV) were calculated. 
Because overdiagnosed cancers cannot be reliable identifi ed, all screen-detected cancers have 
to be included in the denominator for sensitivity. Th is reduces the value of sensitivity as a useful 
measure for clinically relevant disease. Th erefore, we added another measure: the ratio benign 
biopsies/delayed PC diagnoses.
 Th eoretically, PSA and subsequently PSAV can rise quickly due to (subclinical) prostatitis. 
Because the PSAV is based on two PSA measurements, a period of PSA rise due to prostatitis 
is not being accounted for. Th erefore, in addition to clinical data, the histological diagnosis of 
prostatitis was retrieved from the medical records. 
 Furthermore, follow-up and PC detection in the third screening round were evaluated. 
To account for PC cases missed by biopsy during the second screening round, PC detected 
during the third screening round were added to the cases detected during the second round and 
analyses were repeated.
5.2.2 | Statistical analyses
PSA, PSAV, age and prostate volume were assessed as continuous variables. Abnormal digital 
rectal examination (DRE) and transrectal ultrasonography (TRUS) outcome, having had a 
previous negative biopsy and prostatitis were assessed as binary variables.
 Diff erences in proportions were evaluated with a Student’s t-test (continuous variables, 
normal distribution), Mann-Whitney U-test (continuous variables, no normal distribution) or 
Chi-square test (binary variables). Univariate and multivariate logistic regression analyses were 
performed, the latter using a backward stepwise method. Parameters were rejected at a p-value 
>0.05. In all multivariate analyses the following variables were included: PSA level, age, prostate 
volume, DRE and TRUS outcome, and previous biopsy. For PSA and volume, a logarithmic 
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transformation was used to optimize the model fi t. For statistical analysis the statistical package 
for social sciences (SPSS 14.0; SPSS inc., Chicago, IL) was used. 
5.3 | Results
In the 2217 men who underwent a biopsy during the second screening round, 441 (19.9%) 
carcinomas were found. General characteristics of the study cohort are listed in Table 1. Of the 
441 PC diagnosed during the second round, 333 (75.5%) were classifi ed as signifi cant disease 
and 108 (24.5%) as possibly indolent. 
 Mean (median) PSAV was 0.47 (0.35) ng/ml/yr for the entire study population. PSAV-values 
are shown in Figure 2, depicted by the presence or absence of PC. Mean PSAV in men with PC 
was signifi cantly higher than in men without PC (0.61 resp 0.44 ng/ml/yr, p<0.001;Table 1). A 
negative PSAV was seen in 204 men(11.5%) with no PC, in 13 (12.0%) men with iPC, and in 10 
(2.1%) men with sPC.
Table 1 | General descriptives of study cohort.
Total group n=2217 PC n=441 No PC n=1776 p-value
Age (years, range 55-74)
PSA (ng/ml, >= 3.0ng/ml)
Prostate volume (ml)
Abnormal DRE
Abnormal TRUS
Previous biopsy
PSAV (ng/ml/yr)
Mean (median)
Mean (median)
Mean (median)
N (%)
N (%)
N (%)
Mean (median)
 67.2 (67.3)
  5.6 (4.5)
 52.6 (48.2)
479 (21.6)
385 (17.4)
953 (43.0)
  0.47 (0.35)
 67.1 (67.1)
  5.6 (4.4)
 44.0 (40.6)
143 (32.4)
107 (24.3)
116 (26.3)
  0.61 (0.39)
 67.2 (67.3)
  5.6 (4.5)
 54.7 (50.3)
336 (18.9)
278 (15.7)
837 (47.1)
  0.44 (0.34)
0.76*
0.15**
0.000**
0.000***
0.000***
0.000***
0.000**
* Student’s t-test
** Mann-Whitney U test
***Chi square test
5.3.1 | PSAV as a biopsy indicator
Th e eff ect of various PSAV cut-off  levels as a biopsy indicator on PC detection was assessed 
(Table 2). With increasing PSAV cut-off  levels, the PPV shows a tendency to increase (from 
21.8% with a cut-off  of 0.15 to 25.8% with a cut-off  of 1.00 ng/ml/yr). Relative specifi city 
increased signifi cantly, at the expense of the relative sensitivity (84.4 and 24.9% with a PSAV 
cut-off  of 0.15, 13.2 and 90.6% with a PSAV cut-off  of 1.00 ng/ml/yr). Th e ratio spared benign 
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biopsies/delayed cancer diagnoses decreased with increasing PSAV cut-off s, indicating a less 
benefi cial trade-off  in terms of avoiding unnecessary biopsies and delaying PC diagnoses with 
higher cut-off s. Th e features of the carcinomas found and missed using the PSAV cut-off s in 
addition to the PSA cut-off  of 3.0 ng/ml, are listed in Tables 3 and 4. Th e proportion of sPC 
rose with increasing PSAV cut-off  levels (79.6% with a cut-off  of 0.15 ng/ml/yr to 91.3% with 
a cut-off  of 1.00 ng/ml/yr), showing the ability of PSAV to discriminate between sPC and 
iPC. However, although the larger proportion of missed PC is likely to be indolent, rapidly 
increasing proportions of all signifi cant disease were missed with the use of a PSAV cut-off  as a 
biopsy indicator (Table 4).
 
  
  
  
  
  
  
 
Figure 2 | Prostate-specifi c antigen velocity (ng/ml/yr) in 
men without prostate cancer (PC) (n=1776), men with iPC 
(n=108) and men with sPC (n=333).
Th e boxes represent the interquartile range, the line in the box the 
median value. Th e tails of the boxes represent the 95% interval.
5.3.2 | PSAV and overall PC detection
PSAV was a signifi cant predictor of PC in univariate logistic regression analysis (OR 1.28, 
p=0.000). In a backward stepwise multivariate logistic regression analysis, PSA, prostate 
volume, DRE, TRUS and previous negative biopsy were included in the model. PSAV and age 
were omitted from the model, as they were not signifi cant predictors of PC detection (PSAV 
OR=1.01, p=0.913).
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Of the 1776 men with a non-malignant biopsy, 781 (44.0%) participated so far in the third 
screening round 4 years later, 598 biopsies were performed and 85 cases of PC were found (PPV 
14.2%). Adding those PC cases to the PC detected during the second round and repeating the 
analyses described above did not change outcome: although PSAV was a signifi cant predictor 
of PC detection in univariate analysis (OR 1.28, p=0.000), this parameter lost signifi cance in 
multivariate analysis (OR 1.013, p=0.907).
Table 2 | Performance of PSAV as predictor of biopsy outcome with varying PSAV cut-off  levels
biopsied PC (n) PPV (%) Rel. sens Rel. spec Ratio spared benign 
biopsy/delayed PC 
diagnosis
PSA >=3 2217 441 19.9 100.0 0.0
PSAV>=0.15 1705 372 21.8 84.4 24.9 6.4
PSAV>=0.25 1429 327 22.9 74.1 38.0 5.9
PSAV>=0.35 1116 249 22.3 56.6 51.2 4.7
PSAV>=0.50 750 168 22.4 38.1 67.2 4.4
PSAV>=0.75 381 78 20.5 17.7 82.9 4.1
PSAV>=1.00 225 58 25.8 13.2 90.6 4.2
Table 3 | Features of carcinomas found with varying PSAV cut-off  levels
Biopsied (n) PC (n) PC signifi cant 
(% of PC found)
PC indolent 
(% of PC found)
PSA >=3 2217 441 333 (75.5) 108 (24.8)
PSAV>=0.15 1705 372 296 (79.6) 76 (20.4)
PSAV>=0.25 1429 327 266 (81.3) 61 (18.7)
PSAV>=0.35 1116 249 209 (83.9) 40 (16.1)
PSAV>=0.50 750 168 143 (85.1) 25 (14.9)
PSAV>=0.75 381 78 73 (93.6) 5 (6.4)
PSAV>=1.00 225 58 53 (91.3) 5 (8.6)
5.3.3 | PSAV and sPC
All biopsy outcomes were divided in sPC (n=333) or iPC/no PC (n=1884) and the predictive 
ability of PSAV on signifi cant disease in the entire study cohort was assessed. In univariate 
analysis, PSAV was a signifi cant predictor of sPC (OR=1.46, p=0.000; Table 5). In multivariate 
analysis, PSA, age, prostate volume, DRE, TRUS and previous negative biopsy were included. 
In addition to age, PSAV was omitted from the model due to lack of signifi cance (OR=0.87, 
p=0.30) (Table 5). 
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Table 4 | Features of carcinomas missed with varying PSAV cut-off  levels
biopsied PC (n) missed Missed PC signifi cant 
(% of total cases of sPC)
Missed PC indolent 
(% of total cases of iPC)
PSA >=3 2217 0 0 0
PSAV>=0.15 1705 69 37 (11.1%) 32 (29.6%)
PSAV>=0.25 1429 114 67 (20.1%) 47 (43.5%)
PSAV>=0.35 1116 192 124 (37.2%) 68 (63.0%)
PSAV>=0.50 750 273 195 (58.6%) 78 (72.2%)
PSAV>=0.75 381 363 265 (79.6%) 98 (90.7%)
PSAV>=1.00 225 383 285 (85.6%) 98 (90.7%)
Table 5 | Predictive value of prostate-specifi c antigen velocity (PSAV) for detection of signifi cant prostate 
cancer (PC)* in uni- and multivariate analyses. CI=confi dence interval
Variable Univariate analysis Multivariate analysis
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
PSAV 1.54 (1.33-1.79) 0.000 1.01 (0.78-1.32) 0.939
Log PSA 1.96 (1.07-3.58) 0.029 5.66 (2.68-11.95) 0.000
Age 1.00 (0.97-1.02) 0.838 1.01 (0.98-1.04) 0.428
Log prostate volume 0.01 (0.01-0.03) 0.000 0.02 (0.01-0.04) 0.007
DRE 4.54 (3.51-5.87) 0.000 3.53 (2.64-4.72) 0.000
TRUS 3.43 (2.62-4.49) 0.000 2.20 (1.61-3.01) 0.000
Previous biopsy 0.41 (0.31-0.54) 0.000 0.43 (0.31-0.61) 0.000
5.3.4 | PSAV and prostatitis
Prostatitis was seen on biopsy in 177 men. In the total group, PSAV was not a predictor of 
prostatitis (OR1.14, p=0.125) in univariate analysis, but in men without PC (n=1776, n=171 
with prostatitis) PSAV was a signifi cant predictor (OR=1.28, p=0.015). Th e analyses on the 
predictive value of PSAV on (signifi cant) PC as described above were repeated with exclusion 
of all cases of prostatitis. Small, non-signifi cant changes were found for the odds ratios (data 
not shown).
5.4 | Discussion
Although some reports suggest that PSAV is a useful marker for aggressiveness in PC patients, 
this does not necessarily imply that PSAV is a useful marker for detecting aggressive PC in a 
screening setting.12,13 However, a recent report by Carter et al14 suggested that PSAV indeed was 
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a useful marker for identifying men at risk of deadly PC during the preclinical curable phase. 
We could not confi rm those results.
 Th e regression analyses make clear why the implementation of a PSAV cut-off  as a biopsy 
indicator in screening for PC is not feasible in this cohort: PSAV was not an independent 
predictor of PC detection on biopsy. Th is fi nding is in line with previous reports from our study 
group.7,15,16 More importantly, PSAV was not a signifi cant independent predictor of aggressive 
disease in the cohort (OR 1.10, p=0.55).
 Two main factors may negatively infl uence the predictive value of PSAV for detection of PC: 
missing PC with biopsy and subclinical prostatitis. Subclinical prostatitis has been reported to 
elevate PSA levels17 and may cause an increased PSAV. Th e eff ect of these possible confounding 
factors is shown in Figure 2: the upper range of PSAV values in the men without PC is similar 
to the range in men with PC, especially men with sPC. On the other hand, the lower range 
shows more spread to negative values than in men with PC. Missed PC at biopsy or prostatitis 
could explain this upper range in the men without PC detected. For this reason, men with 
PC detected during the third screening round, were scored as having PC as well. However, 
PSAV still was not a signifi cant predictor of PC detection in multivariate analysis (OR 1.013, 
p=0.907). Additionally, exclusion of all men with prostatitis in the subgroup without PC did not 
signifi cantly change test results. False-negative biopsy or subclinial prostatitis as an explanation 
for the absence of the predictive value of PSAV for PC or sPC consequently seems unlikely.
 It should be noted that our study diff ers in several aspects from the reports in which PSAV 
was described to be a predictor of PC aggressiveness and outcome. First of all, we studied a 
screened population, with cancers detected during the pre-clinical detectable phase. As 
previously described,7,13 it is likely that during this phase the PSAV does not yet show the 
signifi cant increase as assessed in studies including clinically detected PC. Furthermore, our 
cohort consisted of men aged 55-75. As age was shown to be related to the predictive value of 
PSAV5, this may further explain the discordant results as some studies included men in the age 
range of 41 to 94.3,4
 A third and very important diff erence is that all men in our cohort were biopsied. Th is is in 
contrast with other reports, in which only a part of the population (mostly with an indication 
for biopsy) has been biopsied.2-5,18 Th e remaining part is assumed not to have PC, which is not 
true. Clearly, the verifi cation bias that is inherent to this type of analysis will result in a higher 
predictive value of PSAV for the detection of PC.19 In our study every man was biopsied due to 
our patient selection method and verifi cation bias could be kept to a minimum. Our results are 
concordant with a study by Th ompson et al:6 in the control arm population of the PCPT trial 
all men were biopsied as well and PSAV lost its predictive value on PC detection in multivariate 
analyses. 
 Th e high mean PSAV in men without PC detected (0.44 ng/ml/yr) is a result of the patient 
-selection method: men with a PSA <3.0 ng/ml were excluded, as they were not biopsied. Earlier 
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reports from our study group showed that, when including those with low PSA levels, mean 
PSAV in men without PC was 0.09 ng/ml/yr.16 
 Nevertheless, there are some limitations. Most importantly, like every other retrospective 
analyses also this one is subject to verifi cation bias. Th is results from the fact the PSAV was not 
used as a biopsy indication. Only a PSA >= 3.0 ng/ml indicated a biopsy and cancers with a high 
PSAV but a PSA < 3.0 ng/ml in the second round remain undetected (Figure 1). Furthermore, 
not all men with a PSA >=3.0 ng/ml were biopsied (Figure 1), due to co-morbidity, medication 
use or refusal. Th is also adds to the verifi cation bias.
 Th e method of patient selection was based on the possibility to calculate a PSAV (at least 2 
PSA levels available). Our population consisted of men screened during the second round and 
therefore they were all screened before (during the fi rst round). Th is method of patient selection 
has two major consequences. First, this makes our cohort a pre-screened population, thereby 
restricting the applicability of our results. Secondly, the PSAV-calculations are only based on 2 
PSA values. PSA change may not be linear, which cannot be accounted for using a two-point 
method for PSAV-calculation. Furthermore, the impact of biological variation in PSA-values 
cannot be accounted for20. Th is limits our results. However, Connolly et al21 concluded that 
linear regression should be the method of choice, and that using two PSA values had a similar 
predictive value and may be adequate as long as measurements are separated by a suffi  ciently 
long time period. Th ese fi ndings are supported by a study of King et al.22 Th erefore, the method 
used in our study may be adequate for these circumstances.
 In this study, we explored whether PSAV could improve screening by identifying sPC and by 
reducing overdiagnosis. However overdiagnosis is not only based on PC features (and indolent 
disease), but also on patient related features (for example age and co-morbidity). Th erefore, 
even a non-indolent cancer may be over-diagnosed. Moreover, even if a cancer is classifi ed as 
indolent, this cancer may progress to more aggressive stages and become relevant. 
 Th e most ideal endpoint to defi ne indolent and signifi cant disease is PC-specifi c mortality. 
However, follow-up is this cohort is not long enough to consider this endpoint and a proxy had 
to be chosen. Clearly, using a proxy will infl uence the results. IPC was defi ned as a chance of 
indolence >= 70% based on probabilities calculated using a nomogram that was developed for 
this cohort.11 Th is 70% cut-off  is arbitrary. Th erefore, we assessed the predictive value of PSAV 
with varying probability cut-off s (range 0-80%). Little variation was seen in odds ratios and 
with all cut-off s PSAV lost signifi cance in multivariate analyses (data not shown). 
 Finally, even if men are biopsied, the true incidence of PC remains unknown as a biopsy 
may miss PC. For this reason, “relative” sensitivity and specifi city were calculated for the PSAV 
cut-off  levels.23
Despite its limitations, some points of strength of our study must be emphasized. Verifi cation 
bias was kept to a minimum by selecting a cohort in whom every man was biopsied. In addition, 
all men were biopsied following identical biopsy protocols.
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5.5 | Conclusion
In our screened cohort, PSAV was not an independent predictor of sPC. Using a PSAV cut-off  
as biopsy indicator would miss an important proportion of clinically sPC. Th erefore, PSAV 
does not improve the ERSPC screening algorithm. Although PSAV seems a possible marker for 
tumour aggressiveness and outcome in PC patients, its value as a predictor of clinically sPC may 
not be applicable in a screening setting.
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Abstract
Objectives: To identify pathological features in non-malignant sextant prostate needle biopsies 
and assess their predictive value for detecting prostate cancer (PC) on biopsy 4 years later.
Patients and Methods: We selected and reviewed the biopsy specimens of 121 men that were 
diagnosed as non-malignant during the fi rst screening round of the European Randomized 
Study of Screening for Prostate Cancer (ERSPC), Rotterdam section. Of these 61 (50.4%) were 
positive for PC during the second round (result of a matched random sample). Th e biopsies 
were indicated by prostate-specifi c antigen levels of >= 3.0 ng/ml. Specimens were scored for 
high-grade prostatic intraepithelial neoplasia (HG-PIN), active and chronic infl ammation (AI, 
ChI), biopsy core length and glandular core length. Th e predictive value of the pathological 
features fo rdetecting PC aft er 4 years was assessed.
Results: In the fi rst-round biopsies the incidence of HG-PIN was 7.1%; there was AI in 22.4% 
and CI in 51.0%. Th e mean core length was 9.3 mm and mean glandular core length 7.4 mm. 
Th e mean total biopsy length (sum of core lengths) was 56.3 mm and mean total glandular 
length (sum of glandular core lengths) was 44.6 mm. None of the pathological features in the 
initial round was signifi cantly related to PC detection in the second round.
Conclusions: In this study of non-malignant prostate biopsy specimens from a screened 
population, no pathological features could be identifi ed that were predictive for PC detection 
on biopsy 4 years later.
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6.1 | Introduction
With the introduction of serum prostate-specifi c antigen (PSA) measurement, screening 
for prostate cancer (PC) has become widespread practice. One of the important challenges 
in screening is the length of the screening interval. It should be short enough to prevent the 
occurrence of clinically important interval cancers and incurable tumours found at re-screening, 
but it should be long enough to avoid unnecessary biopsies and costs. Furthermore, men with 
features that are known to increase the risk of PC may benefi t from more frequent screening 
than men without those features. For identifying men at increased risk, next to clinical variables, 
histopathological features might be important. Can features of a non-malignant biopsy defi ne 
subgroups at increased risk of subsequent prostate cancer detection 4 years later?
 Several histological predictors of subsequent prostate cancer detection have been described. 
First, high-grade prostatic intraepithelial neoplasia (HG-PIN) is considered a premalignant 
lesion1. By contrast with earlier reports on its predictive value for adenocarcinoma,1-3 recent 
studies indicate that men with limited HG-PIN are probably not at increased risk of PC.3,4
 Second, active (AI) or chronic infl ammation (ChI) can be found in a biopsy. Although 
considered to have no direct clinical implications, these lesions may infl uence the risk of a 
prostate cancer diagnosis in the subsequent screening round. ChI is especially considered to be 
a risk factor for carcinoma,5 including prostatic carcinoma.6
 Finally, the sextant biopsy core length is a variable of biopsy quality and a greater total 
core length raises the cancer detection rate.7,8 Th erefore, it may be possible that a low total core 
length is not a good representation of the prostate and men with an initial benign biopsy with 
a low total core length have a higher risk of PC diagnosis during a subsequent screening round 
compared to men with a high total core length.
 Th us the aim of the present study was to evaluate the predictive value of features of a non-
malignant initial biopsy (PIN, infl ammation, and biopsy length) on having biopsy detectable 
prostate cancer 4 years later in a screened population.
6.2 | Patients and methods
6.2.1 | ERSPC and patient selection
We retrospectively evaluated prostate needle biopsy specimens of a screened population. Th e 
European Randomized Study of Screening for Prostate Cancer (ERSPC) is investigating the 
impact of screening on mortality and quality of life in men aged 55-75 years.9 In the Rotterdam 
section of the ERSPC, men randomized to the screening arm are screened every 4 years, i.e. a 
systematic lateralized sextant prostate needle biopsy prompted by an elevated PSA level (>=3.0 
ng/ml). 
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 Th e biopsy was taken using longitudinal and cross-sectional transrectal ultrasound 
guidance. In our institution, a lateralized biopsy strategy is used, based on the observation that 
sampling the lateral peripheral zone increases the prostate cancer detection rate.10,11 A seventh 
biopsy was taken when a hypo-echoic lesion was visible at TRUS.
 If there is an initial diagnosis of HG-PIN on biopsy, another biopsy is taken within 6 weeks. 
When no cancer is found on this immediate re-biopsy, men are enrolled in the regular screening 
programme (i.e. next screening visit aft er 4 years).
 In the fi rst screening round 1,850 men had a biopsy prompted by a PSA>= 3.0 ng/ml (May 
1997 to December 1999). Of the 1309 men without prostate cancer in the fi rst round, 584 
(44.6%) had a repeat biopsy during the second screening round 4 years later. In the second 
round, 61 prostate cancers were diagnosed and were included in the present study. Of the 523 
men in whom no prostate cancer was found at repeat screening, 60 men were randomly chosen 
and formed the control group of the present study. Th erefore, our study group comprised 121 
men, all with a non-malignant biopsy in the fi rst screening round ( Figure 1a).
No PC n=523  PC n=61  
N=1850
Biopsied in 
first screening 
round
N=584
Biopsied in 
second screening 
round
Randomly chosen 
to control group
N=60
Total group
N=121 Specimen not 
available for review
N=8 Specimen 
available for review
Missed diagnosis of 
ATYP or PC
N=15 excluded
 
Non-malignant 
biopsy
N=98
Included in study
N=98
Figure 1 |Consort diagram of patient selection. PC= prostate cancer, ATYP= atypical lesion suspect for 
prostate cancer.
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6.2.2 | Pathologic evaluation
All biopsy cores were labelled separately and processed as described previously8. At time of 
diagnosis, pathologists with no specialisation in uro-genital pathology had evaluated all samples. 
In the present study, the negative fi rst- and second-round biopsies were blindly reviewed by 
an uro-pathologist (GvL). Within the scope of the ERSPC protocol, all positive second-round 
biopsies had been confi rmed by another uro-pathologist (TvdK). Biopsy specimens from the 
fi rst round were scored for HG-PIN (as described)2. Furthermore, ChI and AI were scored; ChI 
was graded as negative (no or sporadic lymfocytes in stroma), mild (aggregates of lymfocytes, 
plasma cells and histiocytes in stroma, without infl ux in epithelial glands), severe (as mild, 
with infl ux in epithelial glands). AI was scored as negative (no neutrophilic granulocytes 
present), mild (sparse neutrophilic granulocytes in stroma, without infl ux in epithelial glands), 
severe (neutrophilic granulocytes in stroma, with infl ux in epithelial glands). Th e extent of 
infl ammation was scored as the number of biopsy cores positive for infl ammation. Th e total 
length of the needle-biopsies was measured manually with a ruler on the slides. In addition, 
the spatial distance between the most proximal and peripheral epithelial gland in the needle-
biopsies was determined (glandular length) to exclude non-prostatic tissues, i.e. colonic mucosa 
and fat tissue, from our measurements. All pathological data were matched with clinical data 
(age, PSA, PSA-density, DRE and TRUS outcomes and prostate volume) as assessed at the initial 
screening round. 
6.2.3 | Statistical analyses
For binary variables a chi-square test with continuity correction was used to assess diff erences 
(for small expected numbers, a Fisher’s exact test was used). For ordinal and continuous 
variables t-tests (normally distributed variables), Mann-Whitney U tests (non-normally 
distributed variables) and logistic regression analyses were used.
 Th e hypothesis that no diff erence or predictive value existed was tested using a two-sided 
assessment and rejected at a p-value <0.05.
6.3 | Results
Of the 121 men, both fi rst- and second-round biopsy specimens could be retrieved from the 
pathology archive of the Erasmus Medical Center Rotterdam for 113. Th e review by the uro-
pathologist showed 6 cases with a missed diagnosis of PC and 9 with missed atypical lesions 
suspect for adenocarcinoma (ATYP), all in fi rst-round biopsy specimen. Th ose cases were 
excluded from further analyses (see fi gure 1b), leaving 98 men for the present study, of whom 
44 (45%) were diagnosed with PC 4 years later. In men with cancer in this second screening 
round, advanced clinical stage (cT3-4) was seen in 1 man (2.3%). Th e biopsy Gleason sum score 
was 7 or more in 6 men (14%). 
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 Th e general descriptive data of the fi rst screening round are listed Table 1.
 Th e incidence rates of the pathologic features and analyses of PC detection rates 4 years later 
are summarized in Table 2.
Table 1 | Descriptive parameters at the time of initial biopsy: median and interquartile range (IQR) of age, 
PSA, PSA density, prostate volume, transition zone volume, DRE results and hypo-echoic lesion at TRUS 
(total group values and values depicted by presence or absence of PC at repeat screening).
Total group 
(n=98)
PC aft er 4 years 
(n=44)
No PC aft er 4 
years (n=54)
p-value 
(two-sided)
Age (years ) 
 median
 IQR
64.1
61.0-67.2
65.2
60.9-67.9
3.6
61.1-65.9
0.290*
PSA (ng/ml) 
 median
 IQR
4.10
3.30-5.10
4.30
3.63-5.75
4.05
3.30-4.90
0.207**
PSA density (nl/ml/gr) 
 median
 IQR
0.10
0.07-0.13
0.10
0.08-.014
0.09
0.07-0.12
0.100**
Prostate volume (ml) 
 median
 IQR
44.6
34.5-59.7
43.8
33.7-54.6
46.2
35.05-66.80
0.126*
Transition zone volume
 median
 IQR
24.5
18.4-35.5
22.5
17.7-33.8
26.3
18.65-44.65
0.207**
Abnormal DRE (%) mean 19.4 20.0 19.0 0.809 ***
Hypo-echoic lesion on TRUS (%) mean 15.3 9.0 21.0 0.123 ***
* Student’s t-test
** Mann-Whitney U test
*** Chi-square test
Table 2 | Incidence of the fi rst round pathologic lesions and the second round PC prevalence depicted by 
the presence or absence of this lesion. PC = prostate cancer, HG-PIN = high-grade prostatic intraepithelial 
neoplasia, ChI = chronic infl ammation, AI = active infl ammation.
Prevalence in total 
group (n=98)
PC incidence when 
lesion present
PC incidence when 
lesion absent
P-value (two-sided)
HG-PIN  7.1 %   (7/98) 42.9% 46.2% 1.00*
ChI 51.0% (50/98) 44.0% 48.0% 0.85**
AI 22.4 % (22/98) 50.0% 44.7% 0.85**
* Fisher’s exact test
** Chi square test with continuity correction
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6.3.1 | HG-PIN
All HG-PIN lesions found were focal lesions limited to one core; there was HG-PIN in 7 men 
(7.1%). As none of these cases was diagnosed during the original pathological examination, 
these were newly found HG-PIN cases. Th e PC-incidence aft er 4 years was the same for men 
with HG-PIN and men without HG-PIN (43% and 46%, p=1.00).
 
6.3.2 | Infl ammation
Of the 51% of men with ChI, 47% had mild infl ammation; there was a severe lympho-
plasmacytic infi ltrate in 4.1%. ChI was not predictive for detecting PC in the second screening 
round (Table 3). Clustering by degree (mild or severe) or extent of infl ammation (number of 
cores with ChI) had no signifi cant predictive value either (p=0.981 and p=0.577).
Th e incidence of AI was 22%, of which 21% was mild and 1.0% severe. AI was not predictive for 
detecting PC 4 years later (Table 3). Th ere was no signifi cant predictive value if AI was clustered 
by degree (p=0.897) or extent (p=0.526) of infl ammation.
Table 3 | Biopsy length parameters (mean, median and interquartile range (IQR)) for the total group and 
depicted by presence or absence of prostate cancer (PC) in the second screening round.
Total group 
(n=98)
PC aft er 4 years 
(n=44)
No PC aft er 4 years 
(n=54)
P-value 
(two-sided)
Core length mean
median
IQR
 9.3 mm
10.0 mm
 8.0-11.0 mm
 9.2 mm
10.0 mm
 8.0-11.0 mm
 9.4 mm
10.0 mm
 8.0-11.0 mm
0.47*
Glandular core length mean
median
IQR
 7.4 mm
 7.0 mm
 6.0-9.0 mm
 7.2 mm
 7.0 mm
 6.0-9.0 mm
 7.5 mm
 7.0 mm
 6.0-10.0 mm
0.21*
Total biopsy length mean
median
IQR
56.3 mm
57.0 mm
50.0-63.0 mm
55.6 mm
57.0 mm
50.0-62.0 mm
56.9 mm
57.0 mm
51.0-64.0 mm
0.59*
Total glandular biopsy length mean
median
IQR
44.6 mm
45.0 mm
39.0-51.0 mm
43.6 mm
45.0 mm
38.5-49.5 mm
45.5 mm
45.0 mm
39.0-52.5 mm
0.34*
* Student’s t-test
6.3.3 | Biopsy length
Th e eff ect of biopsy length is listed in Table 3; in 5 cores (0.8%) glandular structures were lacking. 
In 15 men, a seventh biopsy core was taken, prompted by a hypo-echoic lesion. Th e total biopsy 
length and total glandular length were calculated by adding the sextant biopsy core lengths, 
and values are for complete sextant biopsy cores only (96, thus with no possible seventh biopsy 
length or missing values). None of the biopsy length variables was predictive of subsequent PC. 
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Adding the length of the seventh biopsy to the sextant biopsy cores did not change the results 
(p=0.655 for total length and p=0.421 for total glandular length).
6.4 | Discussion
Aft er a non-malignant initial biopsy, a screening participant in the ERSPC will be screened 
further, following the regular screening schedule (re-screen aft er 4 years). However, non-
malignant initial biopsies might provide information that can be used to identify men at 
greater risk of prostate cancer detection in subsequent screening rounds. Th is information 
could possibly be used in optimizing future screening programmes. For example, men with 
pathological features at initial biopsy that are known to increase subsequent PC detection rate 
might benefi t from a more intense screening protocol than men without these features.
Th e aim of the present study was to identify possible predictive features of a non-malignant 
initial biopsy. None of the features assessed (HG-PIN, active and chronic infl ammation, biopsy 
length and glandular length) was a signifi cant predictor of PC detection in the next screening 
round, using a 4-year interval. 
 Th e 7 cases of focal HG-PIN evaluated in the study were newly diagnosed at re-evaluation, 
and hence those men had not been re-biopsied at initial screening (as described by the screening 
algorithm) but were biopsied at the second screening round four years later. In all cases the PIN 
at initial screen was confi ned to 1 biopsy core. Nevertheless, those men were at no greater risk 
of PC aft er 4 years (43% in men with HG-PIN and 46% in men without). Although there were 
too few cases to draw conclusions, these fi ndings are in agreement with recent review studies, 
which show that the risk of PC following a diagnosis of focal HG-PIN is only slightly higher 
than the risk of PC aft er a benign diagnosis, and questioning the need for repeat biopsy.3,4 
 ChI is frequently found in prostate biopsies12 and its role in prostatic carcinogenesis 
is currently being assessed.13,14 MacLennan et al6 recently published a study in which they 
evaluated the presence and degree of ChI in 177 prostate needle biopsies of men with clinical 
variables suspicious for malignancy. During a follow-up period of 5 years there was a higher 
incidence of cancer in men with ChI (20% vs. 6% in men without ChI). We could not confi rm 
these fi ndings, possibly because of the characteristics of the present study population, being all 
screen-detected prostate cancers, while that of McLennan et al comprised men with a clinical 
suspicion of malignancy. Furthermore, all the present participants had had a repeat biopsy 
during the follow-up and had a chance of being diagnosed with PC, even when no clinical 
suspicion was present. In the study of McLennan et al only 64% of men with ChI and 30% of 
men without ChI had had a repeat biopsy during the follow-up aft er an initial biopsy with no 
cancer (the reason for repeat biopsy was not described). Th erefore, their chance of a diagnosis 
of prostate cancer was smaller than in the present study, especially in men with no ChI. 
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 AI and its relation to PC has also been studied, especially when presenting clinically as 
prostatitis.13,1. However, the present goal was to evaluate the infl uence of AI found in biopsy 
specimens of men with no clinical signs of infl ammation. Men with AI had no signifi cantly 
greater risk of PC aft er four years than men without AI (50% vs. 45%, p=0.85). In 21 of 22 
men with AI, ChI was also present; this fi nding is in agreement with the results of Anim et al,16 
who found no AI without ChI during their review of prostate tissue specimens. As stated by 
Schatteman et al,12 both forms of infl ammation are probably dynamically related to each other. 
In multivariate analyses AI and ChI were not predictive of the PC detection rate (data not 
shown). In the present study, the presence of ChI or AI did not contribute to defi ning high-risk 
patients aft er four years, in this screening-based population.
 Finally, we analysed the predictive value of the lateralized sextant biopsy core length. We 
hypothesized that a higher total biopsy length would decrease sampling artefacts, resulting in 
a lower incidenceof PC aft er 4 years. However, no prognostic value of total biopsy length or 
total glandular length on cancer detection rate aft er 4 years could be identifi ed in this dataset. 
When we corrected biopsy length for the total prostate volume it was also not predictive for 
having a biopsy-detectable PC at repeat screening 4 years later. An explanation could be the 
small variance in core lengths in the specimens studied (IQR 8.00-11.00 mm). Iczkowski et 
al7 and Van der Kwast et al8 reported that a higher total biopsy length is related to a higher 
cancer detection rate on that same prostate biopsy. Th erefore, although not predictive for the 
PC detection rate four years later, biopsy length should be monitored by the urologist and the 
pathologist.
 Atypical lesions suspicious but not diagnostic of malignancy (ATYP) (i.e. atypical small 
acinar proliferations, ASAP) are known to be predictive of concurrent or subsequent prostate 
cancer.17-19 An aim of the present study was to assess the predictive value of ATYP (with no 
PC at immediate repeat biopsy) on the detection of PC four years later. However, there were 
no cases of ATYP without PC at immediate re-biopsy in the study population and thus the 
predictive value could not be evaluated.
 Previously, the relationship between atrophy and the incidence of PC in subsequent 
screening rounds in the ERSPC population (Rotterdam section) was assessed by Postma et al20. 
Th ey found no association of atrophy with the PC incidence, mainly because of its widespread 
occurrence. Th erefore, atrophy was not studied as a possible predictor of PC detection in the 
present study. 
 Th e features of the tumours found aft er 4 years in the present population were in general 
favourable for curative treatment and comparable to the features found during the second 
screening round of the ERSPC21, in which there wassignifi cant down-grading and down-
staging of PC. Th ese fi ndings support the view that there is no indication for a shorter screening 
interval in the present study population.
 Our study has some general limitations. Although our data are based on lateralized sextant 
biopsies, the current trend is to obtain more than six biopsy cores, to obtain more adequate 
82 Chapter 6
information on cancer presence and its features. One of the side-eff ects is that more clinically 
insignifi cant cancers are diagnosed. Th e ERSPC study protocol was designed in the early 1990s, 
when sextant biopsies were the ‘reference’ standard. Th e Rotterdam study group has decided 
that it will follow this protocol for reasons of data consistency. Second, there were relatively few 
patients in the present study; although this aff ects the power of the study, the study is unique 
because patients are very well characterized by clinical variables, review of all slides and the 
exclusion of minimal PC and ATYP that had been missed on the fi rst evaluation. Th e number 
of incidentally found minimal PC (n=6, 5%) and ATYP (n=9, 8%) at re-evaluation grossly 
overestimates the real prevalence of false-negative biopsies in the ERSPC, as the group was 
selected for patients with PC on the second screen. Th e prevalence of a false-negative diagnosis 
in the ERSPC was reported by Van der Kwast et al22, who found a false-negative biopsy outcome 
rate for adenocarcinoma of 4%. Combining ATYP and defi nite PC, in 6%-10% there was a 
missed lesion, the rate depending on the review pathologist. Th erefore, our fi ndings of missed 
lesions seem to be in agreement with earlier reports. However, the consequences of missing PC 
or ATYP are not yet entirely clear, and will be subject of further investigation. All the missed 
lesions in the present study were diagnosed during repeat screening rounds (Gleason scores =< 
7, cT-stadium =< 2A). Th ose cases were excluded, because they fell beyond the scope of this 
study.
 In this era of widespread screening for PC, the need for risk stratifi cation of possible 
screening candidates is increasing; non-malignant biopsy features could not identify high-risk 
subgroups in the present study. 
6.5 | Conclusions
In conclusion, we evaluated the predictive value of pathological features (HG-PIN, chronic and 
active infl ammation and biopsy core length and glandular core length) in a non-malignant 
prostate needle biopsy for detecting prostate in a screened population on biopsy taken 4 years 
later. None of these features were signifi cantly predictive of subsequent prostate cancer detection, 
and therefore no high-risk subgroups of PC-detection 4 years later could be identifi ed.
Non-malignant biopsy features and future prostate cancer risk  83
C
ha
pt
er
 6
References
1. Bostwick DG, and Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004;17:360-79
2. Keetch DW, P. Humphrey P, Stahl D, Smith DS and Catalona WJ. Morphometric analysis and clinical followup 
of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 1995;154(2):347-51
3. DeMarzo AM, Nelson WG, Isaacs WB and Epstein JI. Pathological and molecular aspects of prostate cancer. 
Lancet 2003;361:955-64
4. Epstein JI and Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical 
foci suspicious for carcinoma: Implications for patient care. J Urol 2006;175:820-34
5. Coussens LM and Werb Z. Infl ammation and cancer. Nature 2002;420:860-7
6. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI and Gupta S. Th e infl uence of 
chronic infl ammation in prostatic carcinogenesis: A 5-year followup study. J Urol 2006;176:1012-6
7. Iczkowski KA, Casella G, Seppala RJ, Jones GL, Mishler BA, Qian J and DG Bostwick. Needle core length in 
sextant biopsy infl uences prostate cancer detection rate. Urology 2002;59:698-703
8. Van der Kwast Th H, Lopes C, Santonja C, Pihl C-G, Neetens I, Martikainen P, Di Lollo S, Bubendorf L 
and Hoedemaeker RF. Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol 
2003;56:336-40
9. Roobol MJ, Kirkels WJ and Schröder FH. Features and preliminary results of the ERSPC (Rotterdam, the 
Netherlands). BJU Int 2003;92 suppl 2:48-54
10. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995;45:2-12
11. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for 
diagnosing carcinoma of the prostate. J Urol 1997;157:199-202
12. Schatteman PHF, Hoekx L, Wyndaele JJ, JeurisW and Van Marck E. Infl ammation in prostate biopsies of men 
without prostatic malignancy or clinical prostatitis. Eur Urol 2000;37:404-12
13. Palapattu GS, Sutcliff e S, Bastian PJ, Platz EA, DeMarzo AM, Isaacs WB and Nelson WG. Prostate 
carcinogenesis and infl ammation: emerging insights. Carcinogenesis 2004;26:1170-81
14. DeMarzo AM, DeWeese Th L, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB and Nelson WG. 
Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, 
prevention, and treatment. J Cell Biochem 2004;91:459-77
15. Roberts RO, Bergstralh EJ, Bass SE, Lieber MM and Jacobsen SJ. Prostatitis as a risk factor for prostate cancer. 
Epidemiology 2004;15:93-9
16. Anim JT, Kehinde EO, Prasad A, Sheikh M, Mojiminiyi OA, Ali Y and Al-Awadi K. Relationship between 
serum prostate specifi c antigen and the pattern of infl ammation in both benign and malignant prostatic 
disease in Middle Eastern men. Int Urol Nephrol 2006;38:27-32
17. Montironi R, Scattoni V, Mazzucchelli R, Lopez-Beltran A, Bostwick DG and Montorsi F. Atypical foci 
suspicious but not diagnostic of malignancy in prostate needle biopsies (Also referred to as “Atypical small 
acinar proliferation suspicious for but not diagnostic of malignancy). Eur Urol. 2006;50:666-74
18. Bostwick DG and Meiers I. Atypical small acinar proliferation in the prostate. Clinical signifi cance in 2006. 
Arch Pathol Lab Med 2006;130:952-7
19. Iczkowski KA. Current prostate biopsy interpretation. Criteria for cancer, atypical small acinar proliferation, 
high-grade prostatic intraepithelial neoplasia, and use of immunostains. Arch Pathol Lab Med 2006;130:835-
43
20. Postma R, Schröder FH and Van der Kwast Th H. Atrophy in prostate needle biopsy cores and its relationship 
to prostate cancer incidence in screened men. Urology 2005;65:745-9
21. Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF, Van der Kwast Th H, Kirkels WJ and Schröder FH. Tumour 
characteristics and prognostic factors in two subsequent screening rounds with four-year interval within 
prostate cancer screening trial, ERSPC Rotterdam. Urology 2006;68:615-20
22. Van der Kwast Th H, Lopes C, Martikainen PM, Pihl C-G, Santonja C, Neetens I, Di Lollo S, Hoedemaeker 
RF. Report of the patholgy committee: false-positive and false-negative diagnoses of prostate cancer. BJU I 
2003;92(suppl):62-5

False-negative prostate needle-biopsies: 
frequency, histopathologic features and 
follow-up 
Am J Surg Pathol 2010;34:35-43
Tineke Wolters, Th eodorus H. van der Kwast, Cornelis J. Vissers, Chris H. Bangma, 
Monique Roobol, Fritz H. Schröder, Geert J.L.H. van Leenders
CHAPTER 7
86 Chapter 7
Abstract 
Little is known about the frequency, histopathological characteristics and clinical consequences 
of false-negative prostate biopsies, i.e. biopsies classifi ed as benign but containing 
adenocarcinoma or atypical suspicious glands (ASAP). Objective of this study was to evaluate 
false-negative prostate biopsy in a prostate cancer screening setting. Prostate biopsy sets of 
196 participants of a screening trial which had been reported as ‘benign’ at initial diagnosis, 
followed by a diagnosis of adenocarcinoma in a subsequent screening round were reviewed by 
two urologic pathologists. Adenocarcinoma was identifi ed in 19 biopsy cores corresponding 
to 16 (8.2%) patients and ASAP in 24 cores, corresponding to 19 patients (9.7%). All missed 
prostate cancers were Gleason score 6 (3+3). Aft er correction for patient selection, the overall 
false-negative biopsy rate was estimated to be 2.4%; 1.1% for prostate cancer and 1.3% for 
ASAP. Clinicopathological features at the time of initial biopsy and of subsequent prostate 
cancer diagnosis did not diff er between patients with a false-negative or true benign biopsy. 
Relatively low number of atypical glands (<10 glands), intense intermingling with pre-existent 
glands or lack of architectural disorganization were the most prominent risk factors for a false-
negative diagnosis. Another potential pitfall was the presence of prostate cancer variants, since 
one adenocarcinoma was of foamy gland type and three of pseudo-hyperplastic type. Routine 
examination of at least one level of prostate biopsy sets at high magnifi cation and awareness 
of histologic prostate cancer variants might reduce the risk of missing or misinterpreting a 
relevant lesion at prostate biopsy evaluation. 
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7.1 | Introduction
Widespread PSA testing for prostate cancer has resulted in increased detection of small foci 
of adenocarcinoma on diagnostic needle-biopsies. Pathologists are therefore more oft en 
confronted with the presence of only a few atypical or malignant glands in diagnostic needle-
biopsies. Small lesions of malignant glands or glands suspicious for malignancy, i.e. atypical small 
acinar proliferations (ASAP)1 may be at increased risk to be overlooked, or to be misdiagnosed. 
Nevertheless, correct diagnosis of these lesions is required, because their presence may have 
clinical consequences.
 Th e presence of ASAP is reported in about 5% of prostate biopsies2 and warrant renewed 
and targeted needle-biopsies: the risk of cancer detection at re-biopsy is on average 40% aft er 
a diagnosis of ASAP in the fi rst biopsy.2,3 Th e diagnosis of minimal prostate cancer might be 
clinically relevant as well because signifi cant tumour may be found at radical prostatectomy 
aft er such a small prostate cancer lesion at biopsy.4,5 However, the recognition of a small focus 
of ASAP or minimal prostate cancer may be diffi  cult.5,6 
 Little is known about the frequency, histopathological characteristics and clinical 
consequences of false-negative prostate biopsies, i.e. biopsies in which an atypical or malignant 
lesion is missed. Nevertheless, study of missed lesions which have resulted in false-negative 
biopsies is important as this will lead to increased awareness and more accurate diagnosis of 
these challenging lesions. To provide more insight into false-negative prostate biopsy, a review 
study was performed of prostate biopsy specimens of participants in a large screening trial 
who were screened every four years. In this study, we assessed the frequency of false-negative 
prostate biopsies containing ASAP or carcinoma, their histopathological characteristics and 
potential clinical consequences.
7.2 | Materials and Methods
7.2.1 | Patient selection
All patients included in this study were participants in the screening arm of the ERSPC, 
Rotterdam section. First end-point results of the ERSPC have recently been published indicating 
a 20% mortality reduction due to screening7. Men in the age range of 55-74 were invited for 
screening every 4 years. From 1993 until May 1997, a PSA level >= 4.0 ng/ ml, an abnormal 
digital rectal examination (DRE) and/or transrectal ultrasound (TRUS) result prompted a 
lateralized sextant prostate biopsy. Hereaft er, a biopsy was only indicated by a PSA level >= 3.0 
ng/ ml. A lateralized sextant prostate needle biopsy was performed using TRUS guidance. If a 
hypo-echoic lesion was visible at TRUS, a seventh biopsy core was taken from this lesion. For 
all participants, written informed consent was obtained.8
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 To enhance the chance of fi nding missed lesions in the current study, we retrieved all patients 
from the Rotterdam ERSPC database who were diagnosed with prostate cancer in the second 
or third screening round (n=857) up to May 2008, and who had a previous biopsy diagnosis of 
benign prostate tissue (n=202, 23.6%). Clinical data and follow-up data were retrieved from the 
medical records.
7.2.2 | Histopathological processing of needle-biopsies
Prostate needle-biopsies were subjected to routine pathological processing with stretching 
of cores, inclusion of one core per cassette and H&E stainings on three levels.9 While all 
pathologists at the Department of Pathology participated in histological evaluation, the protocol 
required re-evaluation of all needle-biopsies signed-out as prostate adenocarcinoma, ASAP or 
prostate intraepithelial neoplasia (PIN) by a urologic pathologist (Th vdK, GvL) at the time of 
diagnosis. Needle-biopsies with a benign diagnosis including normal, hyperplasia, atrophy and 
infl ammation were generally not reviewed at that time.
7.2.3 | Review of biopsy specimens
For this study, the slides of previous benign biopsy specimens were retrieved from the 
archives and evaluated by two urologic pathologists (GvL, Th vdK). If suspicious or malignant 
glands were identifi ed, we manually counted the maximal number of atypical glands in the 
most aff ected level. For all false-negative biopsy cores the following histological criteria were 
recorded: number of atypical or malignant glands, architecture, cytoplasm, nucleus, nucleolus, 
intraluminal mucin, eosinophilic debris and crystalloids. In case of an uncertain diagnosis at 
re-evaluation, additional levels were cut and stained for H&E and immunohistochemically for 
basal cell keratins (34BE12) according to standard procedures.
7.2.4 | Statistical analysis
Diff erences between cases with and without a missed lesion were assessed using the Chi-square 
test for binomial variables and a Kruskal-Wallis test for continuous variables. Th e Fisher’s exact 
test was used in case of small numbers. A two-sided p-value<0.05 was considered statistically 
signifi cant.
 For statistical analysis the Statistical Package for Social Sciences (SPSS version 15.0; SPSS 
inc., Chicago, IL, USA) was used.
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7.3 | Results
7.3.1 | Population characteristics
Up to May 2008, a total of 857 patients were diagnosed with prostate cancer in the second 
(n=550) or third (n=307) screening round, of whom n=96 (17.5%) and n=106 (34.5%) men had 
a benign biopsy in the prior screening. Of these 202 cases, 196 (97.5%) biopsy specimens could 
be retrieved from the archive and were available for review. 
7.3.2 | Occurrence of relevant lesions in initially negative biopsy specimens
At initial review of the tissue slides, a total of 43 lesions consisting of atypical glands were 
identifi ed in 35 patients (17.9%), 11 of which were considered diagnostic for adenocarcinoma 
and 32 suspicious for adenocarcinoma (ASAP). In six of 43 biopsy cores, the atypical glands 
were located adjacent to high-grade PIN. A total of 17 all-round pathologists with variable years 
of diagnostic experience had signed out the initial “benign” pathology reports, indicating that 
missing of atypical glands was a general phenomenon.
 To establish a defi nitive diagnosis for lesions suspicious for adenocarcinoma or confi rm 
a diagnosis of adenocarcinoma, we obtained deeper sections from the original paraffi  n 
blocks for H&E and immunostaining for basal cells. In 23 cases no staining was performed as 
defi nitive diagnosis did not warrant additional staining in case of adenocarcinoma (n=7), or 
the staining would not be informative because atypical glands were not present anymore in the 
deeper sections (n=16). For one biopsy the representative block could not be retrieved form 
the archive, leaving 19 biopsy cores for additional evaluation. Based on the outcome of deeper 
sections and lack of basal cell staining, 8 suspicious foci were now considered diagnostic for 
adenocarcinoma, including two of six lesions adjacent to high grade PIN. In 7 atypical lesions 
no defi nitive diagnosis could be reached due to a low number of atypical glands negative for 
basal cells. In 4 cases, the presence of adenocarcinoma was confi rmed by absence of basal cells. 
Th erefore, the fi nal diagnosis was adenocarcinoma in 19 biopsy cores corresponding to 16 
(8.2%) patients and ASAP in 24 biopsy cores, corresponding to 19 patients (9.7%). All missed 
prostate cancer cases were Gleason score 6 (3 + 3).
 Th e rate of false-negative biopsy outcome was 17.9% in this subset of biopsied men diagnosed 
with prostate cancer during a subsequent screening round. Th is rate of false-negative biopsy 
outcome was extrapolated to the overall screening population. Of all screening participants 
in the ERSPC Rotterdam with a benign biopsy in the fi rst or second screening round, and a 
second biopsy during the subsequent screening round, on average 13.4% were diagnosed with 
cancer during the following, i.e. second or third, screening round. Based on this mean cancer 
incidence of 13.4% in men with a previous biopsy, we estimate that 2.4% (i.e. 17.9% of 13.4%) 
of all biopsied screening participants had a false-negative biopsy outcome; for prostate cancer, 
this rate was 1.1% and for ASAP 1.3%.
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7.3.3 | Histopathological characterisation of false-negative needle-biopsies
Th e histopathological characteristics of the missed cancers and ASAP are shown in Table 1. In 
28 patients the missed atypical and malignant glands were identifi ed in 1 core, in 6 patients in 
2 cores and in 1 patient in 3 cores. In 16 patients, the missed lesion was observed in the same 
biopsy core as the fi nal diagnostic lesion at the time of actual PC detection, in 14 patients the 
lesion was found in the same lobe, and in 4 patients the missed lesion and the fi nal malignant 
lesion were both identifi ed in the base or both in the apex of the prostate. Only in 1 patient a 
missed ASAP lesion was found in a core from the opposite side of the prostate compared to the 
location of actual PC detection during the subsequent screening round. 
 In four biopsy cores the missed lesion was easily identifi ed and no specifi c aspect could be 
identifi ed explaining why this lesion was missed. All other missed lesions showed at least one 
feature, which could explain why they were not diagnosed as such. Most common amongst 
these features were absence of architectural abnormality (n=21, 48.8%) and low number 
of atypical glands (less then 10 glands, n=22, 51.2%). Low number of glands was especially 
observed in the ASAP lesions, which consisted of median 5 glands compared to malignant 
lesions comprising a median of 17 glands (Table 1). Larger missed lesions consisting of more 
atypical glands generally resembled normal glands more closely at low magnifi cation or they 
were intensely intermingled with pre-existent glands (Figure 1, 2).
 Next to small size and lack of architectural abnormality, some other specifi c histopathological 
characteristics were observed that might explain why these lesions were missed or misinterpreted. 
One adenocarcinoma was of the foamy gland type and 3 lesions had atypical large-sized glands 
indicative for pseudo-hyperplastic prostate cancer, which can both be easily misinterpreted if 
one is not familiar with these variants (Figure 3). Four lesions were probably missed because 
they were small and were located at the border of a biopsy or in a small biopsy fragment. At 
low power, cases might have been less conspicuous due to normal gland size (n=16, 37.2%) or 
normal spacing between the glands (n=6, 14.0%). In one case, no defi nitive distinction between 
the atypical lesion and partial atrophy could be made. Th e most common fi ndings, which 
triggered our suspicion for the presence of an atypical lesion were architectural abnormality, 
presence of enlarged nuclei, prominent or conspicuous nucleoli, amphophilic cytoplasm and 
presence of intra-luminal eosinophilic secretions or crystalloids (Table 1). 
 In 12 of the 24 cores with ASAP, the diagnosis might have been modifi ed if 
immunohistochemistry could have been performed on the most relevant level. 
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Figure 1 | False-negative prostate biopsies with adenocarcinoma. A, B: Prostate cancer glands are 
architecturally arranged in a nodule reminiscent of benign tissue. In B two foci (arrowheads) of atypical 
glands are present adjacent to normal pre-existent glands. C, D: At high magnifi cation enlarged nuclei 
and conspicuous nucleoli (arrows) are visible, while cytoplasm is not conspicuous (D). E, F: Basal cells 
are absent (34BE12). In F the second focus of atypical glands also lacked basal cells (not shown); notice 
positive internal control (F). Both lesions were considered adenocarcinoma Gleason score 6 (3+3). Th e 
lesions were derived from two separate patients (A, C, E and B, D, F). Original magnifi cations: A, B H&E 
40x; C, D H&E 200x; E 34BE12 100x; F 34BE12 200x. For color images, see appendix page 181.
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Figure 2 | False-negative prostate biopsies with atypical glands suspicious for adenocarcinoma. A, B: Two 
(A; arrowheads) and one (B) atypical glands were discovered at low magnifi cation by their amphophilic 
cytoplasm and subtle architectural abnormality. C, D: At high magnifi cation, the suspicious glands 
revealed enlarged nuclei and prominent nucleoli (arrows). E, F: Th e atypical glands showed lack of basal 
cells (34BE12). Both lesions were considered highly suspicious for malignancy. Due to a low number 
of atypical glands no defi nitive diagnosis for malignancy was given. Th e lesions were derived from two 
separate patients (A, C, E and B, D, F). Original magnifi cations: A H&E 40x; B H&E 100x; C, D H&E 200x; 
E, F 34BE12 200x. For color images, see appendix page 182.
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Figure 3 | False-negative prostate biopsy with pseudohyperplastic (A, C, E) and foamy gland (B, D) 
prostate adenocarcinoma. A, C: Dilated glands with cytoplasmic amphophilia, enlarged nuclei and 
conspicuous nucleoli characterize pseudohyperplastic cancer. E: Basal cells are absent in 34BE12 staining; 
notice positive staining in pre-existent atrophic glands. Th e lesion might be missed as large-sized glands 
can be interpreted as benign or hyperplastic glands at low magnifi cation. B, D: Foamy gland cancer is 
characterized by architecturally disorganized glands with clear to foamy cytoplasm with some enlarged 
nuclei and sporadic nucleoli (arrow). Th e lesion might be missed as cytoplasmic amphophilia is not 
conspicuous at low magnifi cation and only some of the nuclei are atypical with prominent nucleoli at high 
magnifi cation. No immunohistochemical staining was performed on this lesion. Original magnifi cations: 
A, B H&E 40x; C, D H&E 200x; E 34BE12 200x. For color images, see appendix page 183.
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7.3.4 | Clinico-pathological follow-up of false-negative prostate biopsies
At the time of the fi rst biopsy, no diff erences were found between patients with a missed prostate 
cancer lesion, a missed ASAP lesion or “true benign” diagnosis (Table 2). 
 Patient and tumour characteristics at the time of prostate cancer detection are listed in Table 
3. None of the cases were diagnosed with positive lymph nodes or metastasis at the time of 
prostate cancer diagnosis. When these characteristics were stratifi ed by missed adenocarcinoma 
lesion, missed ASAP lesion and no missed lesion in the previous biopsy no signifi cant 
diff erences in tumour characteristics were observed. Overall, men with a false-negative biopsy 
seemed to be in a curable stage at the time of PC diagnosis. Strikingly, the six prostate cancers 
with a Gleason score >7 detected in the next screening round were all found in patients with a 
previous “true benign” biopsy (no missed lesion). 
Table 2 | Patient and tumour characteristics at the time of the previous benign biopsy. Characteristics are 
depicted for the total cohort and stratifi ed by previous biopsy review outcome, i.e. missed adenocarcinoma 
lesion (n=161), missed suspicious lesion (n=19), no missed lesion (n=161).
Total group 
n = 196
Missed PC lesion 
n= 16
Missed suspicious 
lesion  n = 19
No missed lesion 
n = 161
P value
Age mean (median) 64.4 (64.5) 65.1 (66.4) 65.1 (64.9) 64.2 (64.3) 0.438
PSA ng/ml 
mean (median)
 4.9 (4.3)  5.6 (4.9)  4.4 (4.0)  4.9 (4.3) 0.343
Volume ml 
mean (median)
46.1 (43.1) 51.4 (42.1) 44.3 (40.9) 45.8 (43.1) 0.667
Abnormal digital rectal 
examination
33 (16.8%)  4 (25%)  1 (5.3%) 28 (17.1%) 0.271
Visible lesion at 
transrectal ultrasound
20 (10.2%)  2 (12.5%)  1 (5.3%) 17 (10.6) 0.765
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Table 3 | Patient and tumour characteristics at the time of prostate cancer detection. Characteristics are 
depicted for the total cohort and stratifi ed by previous biopsy review outcome, i.e. missed adenocarcinoma 
lesion (n=16), missed suspicious lesion (n=19), no missed lesion (n=161).
Total group 
n = 196
Missed PC 
lesion n= 16
Missed suspicious 
lesion n = 19
No missed 
lesion n = 161
P value
Age mean (median) 68.5 (68.7) 69.3 (70.5) 69.3 (69.1) 68.4 (68.6) 0.426
PSA ng/ml mean (median)  7.4 (5.7)  7.8 (6.8)  7.4 (5.4)  7.3 (5.5) 0.852
Volume ml mean (median) 55.8 (51.5) 57.8 (46.2) 52.3 (51.2) 56.0 (51.9) 0.698
Clinical tumour stage 
 T1c 
 T2
 T3/4
127 (64.8)
 64 (32.7)
  5 (2.6)
10 (62.5)
 5 (31.3)
 1 (5.3)
13 (68.4)
 6 (31.6)
 0 (0.0)
104 (64.6)
 53 (32.9)
  4 (2.5)
0.853
Gleason score 
 <7 
 =7 
 >7
170 (86.7)
 20 (10.2)
  6 (3.1)
14 (87.5)
 2 (12.5)
 0 (0.0)
18 (94.7)
 1 (5.3)
 0 (0.0)
138 (85.7)
 17 (10.6)
  6 (3.7)
0.732
Number of positive cores 
 1 
 2 
 >2
118 (60.2)
 51 (26.0)
 27 (13.8)
9 (56.3)
4 (25.0)
3 (18.8)
13 (68.4)
 4 (21.1)
 2 (10.5)
96 (59.6)
43 (26.7)
22 (13.7)
0.923
Maximum tumour 
invasion per core 
 <50% 
 >=50%
172 (87.8)
 24 (12.2)
13 (81.3)
 3 (18.8)
17 (89.5)
 2 (10.5)
142 (88.2)
 19 (11.8)
0.701
7.4 | Discussion
In this study, a false-negative biopsy rate of 17.9% was found in screening participants who 
were subsequently diagnosed with prostate cancer: in 8.2% a prostate cancer lesion was missed 
and in 9.7% a lesion suspicious for adenocarcinoma. Aft er correction for the selection in this 
study, i.e. only men who were diagnosed with PC 4 years later during the subsequent screening 
round, the overall false-negative biopsy rate was estimated to be 2.4% in men who underwent 
a prostate biopsy. For this calculation it was assumed that in case of a second negative biopsy, 
the preceding biopsy was not false-negative, which is supported by a previous review study 
reporting no ASAP or carcinoma in 54 men with a second negative biopsy.10
 Th e true incidence of false-negative prostate biopsy outcome is unknown and publications 
on this topic are scarce. Kronz et al11 identifi ed missed lesions at a consultation service, including 
high-grade PIN in 2.7% of the biopsies submitted for review. Th ey considered this percentage 
an underestimation, since only selected biopsies were submitted for consultation. In a study 
by Van der Kwast et al,12 two pathologists reviewed 141 prostate biopsy sets from a screened 
population, including 127 originally reported as benign and 14 reported as malignant. When 
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prostate cancer and ASAP were combined, one review pathologist reported missed lesions in 
6.3% of the biopsies and the other in 10.2%. Th e opposite scenario, i.e. calling a benign lesion 
carcinoma, has been described as well. Th e rate of overcalling a lesion has been reported to be 
about 1.2%,13,14 but this phenomenon was not assessed in the current study.
 Several histological explanations for the occurrence of false-negative needle-biopsy 
examination were identifi ed. Th e majority of false-negative biopsies contained lesions with 
minimal architectural abnormality and were very small. Additionally, some lesions consisted 
of glands of normal size and spacing. To enhance the chance of fi nding small atypical foci we 
screened one level of a needle-biopsy at 10x objective magnifi cation and the other levels on 
4x. In this way, even one or two glands that may initially be overlooked at low magnifi cation 
screening can be identifi ed by their cytologic atypia or presence of abnormal luminal contents. 
It seems thus important to examine at least one level of prostate biopsies at high magnifi cation 
even if no abnormalities are observed at low magnifi cation. Furthermore, 4 of a total of 19 
(21%) prostate cancer lesions showed specifi c characteristics of foamy gland adenocarnioma15 
or atypical large-sized glands typical for pseudo-hyperplastic prostate cancer,16 which may be 
diffi  cult to recognize for a pathologist without special interest in urologic pathology. Missing 
such a specifi c entity at prostate biopsy is probably more diffi  cult to prevent, but increasing the 
awareness of these histological variants could improve their identifi cation. 
 Other explanations for the occurrence of false-negative prostate needle biopsies may be 
found in factors other than histopathological characteristics. Although the possibility could be 
entertained that during the earlier years of the screening study more atypical lesions would be 
missed than in later years, our analysis did not support such a “learning curve” (data not shown). 
Inter-observer variability may also explain the reporting of false-negative needle-biopsies. It is 
well known that pathologists with special interest in urologic pathology are more confi dent in 
interpretation of small atypical lesions. Aft er review by a urologic pathologist, atypical lesions 
can be reclassifi ed as malignant in 2.2%-45.1% and as benign in 5.2%-16.7%.2,6,9 In addition, 
the two review pathologists may have reported a false-negative atypical lesion as carcinoma 
or suspicious more frequently as they were aware of the fi nal outcome due to the study design. 
Since consensus of the diagnosis was reached between the two pathologists for all cases, we 
think that this inter-observer variability and detection bias was minimal.
 Th e majority of patients with a false-negative biopsy outcome seemed to be in a curable 
stage at the time of actual prostate cancer detection, even though 16 of 35 patients with a false-
negative biopsy were classifi ed as having a missed prostate cancer lesion 4 years prior to the 
eventual diagnosis. In only 2 of these 16 patients the diagnostic biopsy revealed a Gleason score 
7 adenocarcinoma. Th is favorable outcome aft er a false-negative biopsy can be explained by two 
reasons. First, all men were enrolled in a screening program and were re-biopsied 4 years aft er 
the false-negative biopsy. Cancers in such a screening program are detected in a pre-clinical 
phase, with an estimated lead time of on average 10 years in our population3. Secondly, almost 
all missed lesions were small and all missed prostate cancer lesions were Gleason score 6 (3 
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+ 3). Consequently, missing a lesion in this particular setting may not necessarily negatively 
infl uence patient outcome. 
 Studies on false-negative or -positive diagnosis in pathology might be confronting to 
patients and doctors. Nevertheless, they refl ect quality measures for daily clinical practice and 
off er opportunities to improve logistic and clinical expertise. In this study, the overall rate of 
false-negative biopsy was estimated to be 2.4%, of which 1.1% represented prostate cancer and 
1.3% an atypical lesion suspicious for adenocarcinoma. Although missing a small suspicious 
or malignant lesion did not necessarily negatively infl uence patient outcome in this screening 
setting, the clinical eff ect of missing an atypical lesion in other settings is unclear. A relatively 
low number of atypical glands, intense intermingling with pre-existent glands or subtle 
architectural abnormality were potential risk factors for false-negative interpretation together 
with the occurrence of unusual histological variants such as pseudohyperplastic and foamy 
gland cancer. Routine examination at high magnifi cation of at least one level of each prostate 
biopsy core, even in absence of abnormalities at low magnifi cation, might reduce the number of 
false-negative prostate biopsies.
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Abstract
Background: Th e independent prognostic value of tumour volume in radical prostatectomy 
(RP) specimens is controversial and it remains a matter of debate whether the pathologist 
should report a measure of tumour volume. In addition, tumour volume might be of value in 
substaging of pathological tumour stage (pT2) prostate cancer (PC).
Objective: To assess the prognostic value of PC tumour volume.
Design, setting and participants: Th e cohort consists of 344 participants of the European 
Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam section whose PC 
was treated with RP. Mean time of follow-up was 96.2 months. 
Measurements: Tumour volume was measured in totally embedded RP specimens with a 
morphometric, computer-assisted method and assessed as a continuous variable, as relative 
tumour volume (tumour volume divided by prostate volume) and in a binary fashion (>= or 
< than 0.5ml). Th ese variables were related to PSA progression, local recurrence or distant 
metastasis and PC-related mortality using univariate and multivariable Cox proportional 
hazards analyses. Th e analyses were repeated in the subgroup with pT2 tumours.
Results and limitations: Tumour volume was related to tumour stage, Gleason score, seminal 
vesicle invasion and surgical margin status. In univariate analyses, tumour volume and relative 
tumour volume were predictive for all outcome variables. In multivariable analyses, including 
age, tumour stage, Gleason score, seminal vesicle invasion and surgical margin status, neither 
tumour volume nor relative volume were independent predictors of progression or mortality. 
Tumour volume>=0.5ml was predictive for PSA recurrence and local and/or distant progression 
in univariate analyses, but not in multivariable analyses. Tumour volume was not predictive for 
recurrence or mortality in univariate or multivariable analyses in the pT2 subgroup.
Conclusions: Tumour volume did not add prognostic value to routinely assessed pathological 
parameters. Th erefore, there seems to be little reason to routinely measure tumour volume in 
RP specimens.
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8.1 | Introduction
Th e relation of prostate cancer (PC) tumour volume with pathological features at radical 
prostatectomy specimens, PC progression and mortality has been reported by several 
independent study groups.1-5,8 However, whether tumour volume or a derivate of tumour volume 
should be included in the pathology report of radical prostatectomy specimens, remains subject 
of debate. Th is is due to the fact that the independent prognostic value of tumour volume, i.e. 
aft er correction for other pathological parameters like tumour stage, Gleason score, seminal 
vesicle invasion and surgical margin status, is controversial. Some studies report independent 
prognostic value of tumour volume aft er correction for other routinely used parameters,1,3,7,8 
while others fi nd opposite results2,5,6 (Table 1).
 Th erefore, although the prognostic value of tumour volume is not in doubt, the question 
is whether tumour volume adds value to the prognosticators tumour stage, Gleason score, 
seminal vesicle invasion and surgical margin status. Th is is an important discussion: if tumour 
volume does not add value to the more easily accessible data on tumour stage, Gleason score, 
seminal vesicle invasion and surgical margin status, there would be no need to report tumour 
volume.
 One explanation for the discordant data on the independent prognostic value of tumour 
volume may be the diff erences between the cohorts in the reported studies. Th e studies that 
showed independent value, more oft en described a cohort with unfavorable tumour features1,8 
(Table 1) compared to the more contemporary studies that failed to show similar results.2,6,9 
Th erefore, subgroup analyses in cases with high-risk PC will be done in this study to see whether 
the prognostic value of tumour volume is higher in this particular subset.
 A second explanation may be the use of diff erent tumour volume variables. Some use 
tumour volume as a continuous variable, log transformed or not1,2,5,6 while others use relative 
tumour volume, i.e. the percentage of the prostate volume invaded by tumour3,5,7 or use cut-
off  values, defi ning two or three categories.8,9 Two studies suggested that the relative tumour 
volume was more strongly associated with prognosis than tumour volume.10,11 In order to deal 
with these diff erences, we studied tumour volume as a continuous variable, as relative tumour 
volume and as a binary variable in the current study.
 Finally, we considered that tumour volume might be of help in the substaging of pathological 
tumour stage 2 (pT2) prostate cancer. Th e current subclassifi cation of pT2 PC,12 distinguishes 
unilateral PC invading less than half a lobe (pT2a), more than half a lobe (pT2b) and bilateral 
tumour invasion (pT2c). Th is classifi cation lacks uniform criteria for assigning a substage, 
especially in distinguishing pT2a from pT2b PC and lacks clinical relevance: the pathological 
substaging of pT2 tumours has no prognostic value.13,14 In order to assess whether tumour 
volume may be useful to diff erentiate separate prognostic groups within the set of pT2 tumours, 
we performed a subgroup analysis for pT2 PC.
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8.2 | Methods
8.2.1 | Patient selection
All men included in the study were participants in the screening arm of the Rotterdam section 
of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Up to May 
1997 a lateralized sextant prostate needle biopsy was indicated by a PSA >= 4.0 ng/ml, or a 
suspicious digital rectal examination or transrectal ultrasound. Hereaft er, only a PSA >=3.0 
ng/ml prompted a biopsy. All patients diagnosed with PC during the fi rst screening round or 
during the early re-screening round 1 year later and treated with radical prostatectomy were 
selected for the analysis, resulting in a total of 424 cases. For 344 (81.1%) cases the prostate 
cancer volume was known and those were included in the cohort. All patients were treated 
between November 1993 and June 2000 and none received adjuvant therapy.
8.2.2 | Pathologic examination
RP specimens were processed following the protocol described before.15 In short, aft er fi xing 
the specimens, they were inked, cut at 4mm intervals perpendicular to the rectal surface. Th e 
apical slice is cut parasagitally at 2-3 mm intervals. Th e sections were divided in halves or 
quadrants to fi t routine used cassettes for paraffi  n embedding. Th e whole prostate was sampled. 
Pathological tumour stage, Gleason score, surgical margin status (SM) and presence of seminal 
vesicle invasion (SVI) were assessed. Tumour areas were marked at each slide and measured 
using a computerized morphometric analysis.16 Subsequently the volumes were calculated by 
multiplying the area by the slice thickness. No separate calculations were made for tumour 
present in consecutive or non-consecutive slides. Since it was shown in a side-study (personal 
communication RFH) that fi xation and processing of the RP specimens did not result in 
signifi cant reduction of the tissue volume, shrinkage factor was not taken into account for the 
calculation of tumour volume.
 Staging was done according to the 1992 TNM classifi cation. Th e pT4 cases showed tumour 
invasion of the detrusor muscle. Seminal vesicle invasion was separately analyzed, because this 
feature might also be present in pT4 prostate cancer in addition to the pT3c cancers.
8.2.3 | Follow-up
Patients were followed aft er RP by serial PSA measurements every 3 months during the fi rst year 
aft er RP, every 6 months in the second year and yearly aft er 2-3 years. Biochemical recurrence 
was defi ned as a PSA > 0.2 ng/ml.17 Local recurrence was defi ned as disease recurrence proven 
by biopsy or recorded as local recurrence in the medical records by the treating urologist. 
Metastasis was indicated by suspicious bone scintigraphy, MRI or CT scans. Total follow-up 
time was defi ned as the time from RP to death or last visit date. Time to recurrence was defi ned 
as the time of RP to the time of the fi rst signs of recurrence. When no signs or recurrence were 
registered, cases were censored at the time of the last follow-up visit or date of death. Th e cause 
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of death was established by an independent committee18 and subsequently scored as PC-related 
or intercurrent cause of death.
8.2.4 | Statistical analysis
Univariate and multivariable Cox proportional hazards regression model analyses were 
performed to evaluate the value of the possible predictors on biochemical recurrence, local 
recurrence or metastasis and PC-related mortality. Tumour volume was assessed as a 
continuous variable. Additionally, relative tumour volume was calculated as tumour volume 
divided by prostate volume and multiplied by 100%. Tumour volume was also categorized in 
low and high volume groups using the cut-off  of 0.5 ml, based on the cut-off  suggested by 
Stamey for indolent PC.19 Th e base model resulting from the multivariable Cox analyses, using 
age, pT-stage, Gleason score, SVI and surgical margin status, was compared to the extended 
models, using one of the tumour volume related parameters in addition to the base model, with 
the likelihood ratio test. Th e analyses were repeated on 2 subgroups: high-risk PC (any of the 
following:pT3 or pT4, Gleason>=8, or positive surgical margins) and pT2 PC.
 We analyzed the data using the statistical package for social sciences, version 15.0 (SPSS 
15.0, Chicago, IL). Statistical signifi cance was defi ned as a two-sided p-value<0.05.
8.3 | Results
8.3.1 | Pathologic characteristics
At the time of RP, mean (median) age was 63.6 (64.0) years. Th e pathologic characteristics 
found at RP are listed in Table 2. Advanced PC (pT3/4) was found in 82 (23.8%) patients and 
high-grade cancer (Gleason score>=8) in 11 (3.2%) patients. Mean (median) tumour volume 
was 1.05 (0.66) ml, with a range from 0.001 to 13.48 ml. Tumour volume was related to pT-
stage, Gleason score, seminal vesicle invasion and surgical margin status (p<0.001, Table 2).
 Th e mean (median) time of follow-up was 96.2 (98.0) months, with a range of 0 to 161 
months. Th e number of events of biochemical and local progression, metastasis and PC specifi c 
mortality are described in Table 3.
8.3.2 | PSA recurrence
A total of 57 patients (16.6%) showed biochemical progression aft er a mean (median) period 
of 46.8 (43.0) months. Patients with biochemical progression had a signifi cantly higher tumour 
volume (1.60 versus 0.95 ml, p=0.018). All routinely assessed variables, i.e. tumour stage, 
Gleason score, seminal vesicle invasion and surgical margin status, were predictive for PSA 
recurrence in univariate analysis (Table 4 and Figure 1). In univariate Cox regression, tumour 
volume was a signifi cant predictor of PSA recurrence: HR 1.26 (95% CI 1.12-1.42), p<0.001. 
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Relative tumour volume (HR 1.10 (95% CI 1.05-1.16), p<0.001) and tumour volume>0.5ml 
(HR 2.25 (95% CI 1.21-4.18) p=0.010) were predictive as well. 
 In multivariable analyses, none of the tumour volume related variables remained a signifi cant 
predictor of PSA recurrence: HR of 0.95 (95%CI 0.82-1.11), p=0.517. Th e results for tumour 
volume are shown in table 4. Relative tumour volume and tumour volume >=0.5 ml showed 
similar results: HR 1.00 (95%CI 0.94-1.06) p=0.971 and HR 1.26 (95% CI 0.63-2.52) p=0.517. 
Additionally, the base model did not signifi cantly improve by adding one of the tumour volume 
variables (p>0.50).
Table 2 | Pathologic characteristics at radical prostatectomy, prostate tumour volume and number of events 
per subgroup in 344 radical prostatectomy specimens. pTstage= pathologic tumour stage, SVI= seminal 
vesicle invasion, SM=surgical margins
N (% of total) Tumour volume mean (median) in ml P-value
pTstage
 T2
 T3a/b
 T3c
 T4
262 (75.9)
 60 (17.4)
  4 (1.16)
 18 (5.0)
0.80 (0.52)
1.46 (1.17)
2.48 (2.21)
2.97 (1.68)
0.000*
SVI
 Yes
 No
 6 (1.7)
338 (98.3)
2.11 (1.61)
1.03 (0.64)
0.006**
Gleason score
 <=6
 3+4=7
 4+3=7
 >=8
213 (61.9)
102 (29.7)
 18 (5.2)
 11 (3.2)
0.89 (0.54)
1.04 (0.78)
1.98 (1.25)
2.80 (2.42)
0.000*
SM
 Positive
 Negative
 84 (23.8)
260 (76.2)
1.62 (1.20)
0.87 (0.55)
0.000**
* Kruskal-Wallis test
** Mann-Whitney test
8.3.3 | Local recurrence and distant metastasis
A total of 15 patients (4.4%) showed local recurrence and/or distant metastasis. Seven patients 
(2.0%) showed local recurrence aft er a mean (median) period of 58.3 (57.0) months and six 
patients (1.7%) were diagnosed with distant metastasis aft er a mean (median) period of 80.9 
(88.0) months in the screened group. Two (0.6%) patients showed both local recurrence and 
metastasis aft er 24 and 52 months. Th ese men had a signifi cantly higher tumour volume than 
patients without local recurrence or metastasis (2.40 ml versus 0.99 ml, p=0.004). 
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Table 3 | Numbers of biochemical recurrence, local recurrence, metastasis and prostate cancer (PC) specifi c 
mortality stratifi ed by pathological features in the total cohort, n=334. pTstage= pathologic tumour stage, 
SVI= seminal vesicle invasion, SM=surgical margins.
N 
(% of total)
Biochemical 
recurrence N 
(% of subgroup)
Local recurrence
N 
(% of subgroup)
Metastasis
N 
(% of subgroup)
PC specifi c 
mortality N 
(% of subgroup)
pTstage
 T2
 T3a/b
 T3c
 T4
262 (75.9)
 60 (17.4)
  4 (1.16)
 18 (5.0)
31 (11.8)
14 (23.3)
 3 (75.0)
 9 (50.0)
5 (1.9)
0 (0.0)
0 (0.0)
4 (22.2)
2 (0.8)
2 (3.3)
0 (0.0)
4 (22.2)
2 (0.8)
0 (0.0)
0 (0.0)
4 (22.2)
SVI
 Yes
 No
  6 (1.7)
338 (98.3)
 5 (83.3)
52 (15.4)
1 (16.7)
8 (2.4)
1 (16.7)
7 (2.4)
1 (16.7)
5 (1.5)
Gleason score
 <=6
 7 (3+4)
 7 (4+3)
 >=8
213 (62.5)
102 (29.7)
 18 (5.2)
 11 (3.1)
19 (8.9)
22 (21.6)
11 (61.1)
 5 (45.5)
2 (0.9)
3 (2.9)
2 (11.1)
2 (18.2)
2 (0.9)
0 (0.0)
4 (22.2)
2 (18.2)
1 (0.5)
0 (0.0)
3 (16.7)
2 (18.2)
SM
 Positive
 Negative
 84 (23.8)
260 (76.2)
32 (38.1)
24 (9.2)
6 (7.1)
3 (2.6)
3 (3.6)
5 (1.9)
1 (1.2)
5 (1.9)
Total 344 (100) 57 (16.6) 9 (2.6) 8 (2.3) 6 (1.7)
Table 5 shows that in univariate analysis, tumour volume was a signifi cant predictor of local 
recurrence and/or metastasis. In multivariable analysis however, tumour volume was no longer 
signifi cant. Similar results were found for relative tumour volume and tumour volume >=0.5 
ml: in univariate analysis, relative tumour volume and tumour volume >=0.5 ml were both 
signifi cant predictors of local recurrence and/or metastasis (HR 1.15 (95% CI 1.07-1.24), 
p=0.000 and HR 8.34 (95% CI 1.10-63.49), p=0.041 respectively. In multivariable analysis, both 
relative tumour volume and tumour volume>=0.5 ml were no longer signifi cantly predictive 
(HR 1.04 (95% CI 0.94-1.15) p=0.457 and HR 4.50 (95% CI 0.52-38.60), p=0.171 respectively). 
Th e predictive base model did not signifi cantly improve aft er including any tumour variable 
(p>0.10).
8.3.4 | PC related mortality
A total of 58 patients died during follow-up. Six deaths(10.3%) were PC-related, 47 (81.0%) due 
to intercurrent disease and for 5 (8.6%) cases no cause of death was established yet. Men who 
died from PC had a signifi cantly higher tumour volume than those who died of intercurrent 
disease or were still alive at the time of last follow-up visit (2.32 ml versus 1.03 ml, p=0.009). 
Th e number of events was very small, leading to statistical diffi  culties. In order to get a rough 
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estimation of the value of tumour volume, we performed the regression analyses nonetheless. 
In univariate analysis, tumour volume and relative tumour volume were predictive for PC. In 
multivariable analyses, both variables lost statistical signifi cance. Tumour volume >=0.5 ml was 
not signifi cantly predictive for PC mortality in univariate analysis nor in multivariable analysis. 
No improvement of the model was found by adding one of the tumour volume variables to the 
model (p>0.50).
Table 4 | Univariate and multivariable Cox proportional hazards model for PSA recurrence. RP= radical 
prostatectomy, SVI= seminal vesicle invasion, HR= hazard ratio, CI= confi dence interval.
Univariate analysis 
HR (95% CI)
p-value Multivariable analysis
HR (95% CI)
p-value
Age at RP 1.14 (1.07-1.22) 0.000 1.10 (1.03-1.17) 0.008
Pathologic stage
 T2
 T3a/b
 T3c
 T4
baseline
1.83 (0.97-3.46)
9.61 (2.93-32.57)
5.50 (2.61-11.57)
0.061
0.000
0.000
baseline
1.03 (0.53-2.00)
1.17 (0.12-11.37)
2.24 (0.85-5.92)
0.928
0.891
0.103
SVI
 No
 Yes
baseline
9.38 (3.73-23.59) 0.000
baseline
2.32 (0.43-12.46) 0.327
Gleason score
 <=6
 7 (3+4) 
 7 (4+3)
 >=8
baseline
2.43 (1.31-4.49)
9.20 (4.35-19.45)
6.56 (2.44-17.63)
0.005
0.000
0.000
baseline
1.65 (0.86-3.19)
5.95 (2.60-13.64)
2.66 (0.79-8.93)
0.135
0.000
0.14
Surgical margins
 Negative
 Positive
baseline
4.69 (2.76-7.96) 0.000
baseline
3.84 (2.15-6.85) 0.000
Tumour volume 1.26 (1.12-1.42) 0.000 0.95 (0.82-1.11) 0.517
8.3.5 | Value of tumour volume in high-risk PC and pT2 PC
In patients with high-risk PC (n=130), 41 (31.5%) showed PSA recurrence, 7 (5.4%) showed 
local recurrence, 6 (4.6%) had distant metastasis and 4 (3.1%) men died from PC. Th e results 
of the univariate and multivariable analyses are shown in Table 6: although tumour volume was 
predictive for PSA recurrence, local recurrence and the combination of local recurrence and/or 
distant metastasis, no independent statistical signifi cance was reached for any of the endpoint 
variables in the multivariable analyses. Similar results were shown for relative tumour volume 
and tumour volume >=0.5ml and the predictive models were not improved.
 Finally, the analyses were repeated in patients with pT2 PC (n=262), in which 67 (25.6%) 
men had pT2a, 7 (2.7%) men pT2b and 188 (71.8%) pT2c. In this group, 3 (1.1%) patients 
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had a Gleason score >=8 and 46 (17.6%) had positive surgical margins. Th irty-one (11.8%) 
patients showed biochemical progression, 5 (1.9%) patients local recurrence, 2 (0.8%) patients 
showed distant metastasis and 2 (0.8%) died from PC. Tumour volume was not predictive for 
any of the outcome variables in univariate or multivariable analyses and the predictive model 
did not improve (p>0.50). Th e same results were found for relative tumour volume and tumour 
volume >=0.5ml (data not shown). In multivariate analysis, surgical margin status was the only 
signifi cantly predictive factor for PSA recurrence (OR 5.2 (95% CI 2.4-11.2), p<0.001). Tumour 
substage (pT2a, pT2b or pT2c), Gleason score and age were not predictive in multivariable 
analysis (data not shown). 
 
Figure 1a Figure 1b
 
Figure 1c Figure 1d
Figure 1 | Survival curves of routinely assessed pathological characteristics, with time to PSA progression 
in months. 1a: Time to PSA progression stratifi ed by tumour stage. 1b: Time to PSA progression stratifi ed 
by Gleason score. 1c: Time to PSA progression stratifi ed by seminal vesicle invasion. 1d: Time to PSA 
progression stratifi ed by surgical margin status.
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Table 5 | Univariate and multivariable Cox proportional hazards model for local and/or distant recurrence. 
RP= radical prostatectomy, SVI= seminal vesicle invasion, HR= hazard ratio, CI= confi dence interval.
Univariate analysis
HR (95% CI)
p-value Multivariable analysis
HR (95% CI)
p-value
Age at RP 1.09 (0.97-1.23) 0.130 0.96 (0.84-1.11) 0.595
Pathologic stage
 T2
 T3a/b
 T3c
 T4
baseline
0.89 (0.18-4.34)
0.00 (0.00- . )
12.97 (4.35-38.67)
0.887
0.987
0.000
baseline
0.37 (0.07-1.99)
0.00 (0.00- . )
3.82 (0.81-18.07)
0.248
0.984
0.091
SVI
 No
 Yes
baseline
6.39 (1.43-28.49) 0.015
baseline
4.20 (0.51-34.80) 0.183
Gleason score
 <=6
 7 (3+4)
 7 (4+3)
 >=8
baseline
1.33 (0.30-5.97)
13.98 (3.90-50.06)
8.90 (1.62-49.00)
0.712
0.000
0.012
baseline
0.81 (0.16-4.16)
8.55 (1.87-39.14)
8.16 (1.28-52.01)
0.799
0.006
0.026
Surgical margins
 Negative
 Positive
baseline
3.26 (1.18-9.00) 0.023
baseline
4.13 (1.25-13.59) 0.020
Tumour volume 1.40 (1.20-1.63) 0.000 1.06 (0.85-1.33) 0.609
Table 6 | Hazard ratios (HR) resulting from univariate and multivariable Cox proportional hazards analyses 
of tumour volume in cases with high-risk PC (defi ned as any of the following:pT3 or pT4, Gleason>=8, 
or positive surgical margins) per endpoint variable. Th e HR’s resulting from the multivariable analyses are 
corrected for age, T-stage, presence of seminal vesicle invasion, Gleason score, and surgical margin status.
Tumour volume Univariate analysis
HR (95% CI)
p-value Multivariable analysis 
HR (95% CI)
p-value
PSA recurrence 1.16 (1.01-1.33) 0.032 1.06 (0.90-1.24) 0.496
Local recurrence 1.31 (1.09-1.59) 0.004 1.20 (0.91-1.59) 0.206
Distant metastasis 1.14 (0.89-1.46) 0.286 0.90 (0.60-1.35) 0.617
Local recurrence and/or distant 
metastasis
1.31 (1.11-1.56) 0.002 1.18 (0.94-1.47) 0.150
PC related mortality 1.21 (0.93-1.59) 0.165 0.97 (0.59-1.59) 0.907
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8.4 | Discussion
Tumour volume is an important prognostic factor for prostate cancer progression and 
mortality. However, in this study tumour volume did not add predictive value to routinely 
assessed pathological parameters, like tumour-stage, Gleason score, seminal vesicle invasion 
and surgical margin status. 
 A possible explanation for the discrepant results in literature concerning the independent 
predictive value of tumour volume is the cohort selection. For example, the study by Stamey et 
al reports on a pre-PSA era cohort with Gleason pattern 4/5 in 85%, seminal vesicle invasion 
in 18% and a mean tumour volume of 4.66 ml. In the current study, those rates were 37.5%, 
1.7% and the mean (median) tumour volume was 1.05 (0.66) ml. However, even in our 
subset analysis of patients with high-risk PC, tumour volume did also not show independent 
prognostic value in multivariable analyses. Additionally, we excluded all insignifi cant tumours 
(organ-confi ned without Gleason pattern 4/5 and tumour volume < 0.5ml, n=98, 28.5%) and 
repeated all analyses (data not shown). In this subgroup of signifi cant PC (n=246, 71.5%), no 
independent predictive value of tumour volume was found for any of the outcome parameters.
 Furthermore none of the diff erent methods of tumour volume assessment, i.e. continuous 
tumour volume, relative tumour volume or tumour volume>=0.5ml, resulted in independent 
prognostic value in this study. Tumour volume was also assessed on a log-transformed scale 
(data not shown), which produced similar results. In conclusion, none of the tumour volume 
based variables showed additional value to the routinely used parameters of tumour stage, 
Gleason score and surgical margin status in the RP specimen. 
 Th is lack of prognostic signifi cance of tumour volume also held true for pT2 PC, in which 
surgical margin status was the only parameter with independent prognostic value for PSA 
recurrence. Tumour substage was not prognostic either (data not shown). Th is is in line with 
previous reports demonstrating the lack of prognostic signifi cance of pT2 subclassifi cation.13,14 
 Although tumour volume did not add prognostic value to other pathological parameters, 
this does not necessarily mean that tumour volume has no value at all. Since tumour volume 
correlates well with pathological tumour stage and RP Gleason score, this may be of help 
in pretreatment planning. In this situation, only clinical and biopsy specimen parameters 
are available for decision making and pathological tumour stage and RP Gleason score are 
unknown. Magnetic resonance imaging (MRI) is showing promising results in measurement 
of prostate tumour volume,20,21 although it is not yet optimal.22,23 If these MRI-based tumour 
volume measurements would correlate to the pathological characteristics at RP specimens to 
the same extent as the planimetric tumour volume measurements reported in this study, these 
tumour volumes may be of help in the pretreatment risk assessment and subsequent treatment 
choice. In addition, it is important for the surgeon to receive some feedback information on 
the size of the tumour. Furthermore, we have previously shown that the estimated proportion 
of high-grade cancer has independent prognostic value, contrary to overall tumour volume.24 
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However, a detailed calculation of tumour volume does not seem necessary and an estimation of 
the percentage of the prostate volume involved by carcinoma or a maximum tumour diameter 
will be suffi  cient.
 Some strong points of this study are worth mentioning. Firstly, tumour volume was assessed 
in a very accurate manner, by computer-assisted morphometric analysis. Th is method is 
laborious and therefore not a valid option for routine use. Several surrogate parameters have 
been described with a good correlation with tumour volume, for example visual estimation, 
positive-block ratio, point-count or grid method or measuring maximal tumour diameter.25-32 
Secondly, follow-up time was relatively long, with a mean (median) time of follow-up of 96.2 
(98.0) months and clinical outcome data on local recurrence, metastasis and mortality were 
available. Th is is a major advantage compared to other studies with much shorter follow-up 
(Table 1).
 Simultaneously, some limitations must be noted. No data were available on multifocality 
and tumour volume of the index tumour. It seems reasonable to assume that one tumour focus 
of 1.0 ml shows a diff erent behavior than 2 foci of 0.5 ml. Th is may also be important in pT2 
substaging: a large unilateral tumour focus can be assigned a lower pathological stage than two 
small bilateral foci in the current staging system. Data of volume of the separate tumour foci 
may be helpful in improving the pT2 substaging. 
A second limitation is the small number of events of local recurrence, metastasis and PC related 
mortality. Th is may cause statistical diffi  culty in reaching the signifi cance level and over fi tting. 
However, for PSA recurrence, which reached an occurrence rate of 16.6% (57 cases), no statistical 
signifi cance could be reached either. Finally, it should be noted that all PC cases in the current 
cohort were detected by screening and were thus subject to a lead-time. Th erefore, these cases 
may not be totally comparable to clinically detected cases. On the other hand, their pathological 
features may resemble more closely the cancers detected by PSA testing, a widespread practice 
in most western countries. For this reason we consider our fi ndings of relevance for the ongoing 
discussion on the inclusion of a tumour volume parameter in standard pathology reporting of 
radical prostatectomy specimens.
8.5 | Conclusions
In this study tumour volume did not add prognostic value to routinely assessed pathological 
parameters, like tumour-stage, Gleason score, seminal vesicle invasion and surgical margin 
status. Th erefore, there seems to be little reason to include tumour volume in RP specimens 
routinely in the pathology report.
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Abstract
Background: Th e identifi cation of clinically insignifi cant prostate cancer (PC) could help 
avoid overtreatment. Currently, the most frequently used criteria for insignifi cant PC employ a 
tumour volume (TV) threshold of <0.5 ml.
Objectives: To reassess the TV threshold for clinically insignifi cant PC using data of the 
prevalence screening round of a randomized trial and to critically assess its prognostic value.
Design, setting and participants: Th e rate of insignifi cant PC was calculated by modeling life 
time risk estimates of PC diagnosis in screened and non-screened participants of a randomized 
PC screening trial.
Measurements: Using life time risk estimates, 50.8% of screen-detected PC were calculated to 
be clinically insignifi cant and the 49.2% largest TV of 325 prostatectomy specimens were used 
to determine the threshold TV for clinically insignifi cant prostate cancer. Th e predictive value 
of various TV thresholds for biochemical progression, in addition to stage and grade, were 
analyzed using Cox proportional hazards analyses. 
Results and limitations: Th e TV threshold for clinically insignifi cant PC was found to be at 
least 0.70 ml in our screened population of men aged 55-75 years. Although patients with a 
TV>0.70ml were at increased risk of biochemical progression (HR 2.89, p<0.001), in the 
selection of men with possible insignifi cant PC, i.e. organ-confi ned PC without Gleason pattern 
4/5, TV was not predictive for biochemical recurrence. Th is study was limited fi rstly by a more 
favourable pre-treatment risk profi le of the study cohort compared to the entire population, 
resulting in an underestimation of the TV threshold. Secondly, all patients were surgically 
treated and true signifi cance of the PC cannot be established.
Conclusions: Clinically insignifi cant prostate cancers likely includes organ confi ned PC without 
Gleason pattern 4/5 with a volume up to at least 0.70 ml. Th e lack of prognostic impact of TV 
in addition to stage and grade raises doubt about the inclusion of this parameter as a criterion 
for insignifi cant prostate cancer. 
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9.1 | Introduction
Population-based screening for prostate cancer (PC), using a prostate-specifi c antigen (PSA) 
test, has led to a dramatic increase in incidence of insignifi cant PC.1 Insignifi cant PC is PC 
diagnosed in the absence of symptoms, which would not have caused disease-specifi c morbidity 
or mortality during the patient’s life. Given the sharp increase in PC incidence and the harmful 
eff ects of overtreatment, the identifi cation of insignifi cant cancers is now a high priority in PC 
screening practice.2 
 Currently, the most frequently used criteria for insignifi cant PC include organ-confi ned 
PC, absence of Gleason pattern 4/5 and a maximum tumour volume (TV) of 0.5 ml in radical 
prostatectomy (RP) specimens.3 It is well established that signifi cantly worse patient outcome 
is observed when a PC displays extracapsular extension or high grade PC, independent of 
other prognostic factors.4,5 Th e <0.5 ml TV threshold is based on incidentally detected PC in 
a radical cystoprostatectomy series, published by Stamey et al6 based on a 8% life time risk to 
be diagnosed with clinically signifi cant PC. Th e largest tumour foci in his cystoprostatectomy 
series were considered as the most aggressive and these largest foci all had tumour volumes of 
0.5 ml or higher. Whether the same threshold would apply to a screen-detected prostate cancer 
patient cohort is unclear. Th e assumption that TV is an important prognosticator for PC is 
questionable, especially since the largest tumour foci are not necessarily the most signifi cant 
tumours. Possibly, larger tumours could be considered clinically insignifi cant as well7. To our 
knowledge, no other study on an independent population has been performed to confi rm the 
0.5 ml TV threshold. 
 In this study, we applied at fi rst the approach used by Stamey et al to our cohort of participants 
of a randomized screening trial (European Randomized Screening study of Prostate Cancer – 
Section Rotterdam) to estimate the TV threshold for clinically insignifi cant PC. Secondly, we 
made an attempt to evaluate the validity of the incorporation of a TV threshold in the defi nition 
of insignifi cant PC. Th is was done by assessing the prognostic value for biochemical recurrence 
aft er RP in patients with organ-confi ned prostate cancer without Gleason pattern 4/5 of the 
conventional 0.5 ml and the newly found TV threshold.
9.2 | Methods
9.2.1 | Study population
A total of 1014 patients were diagnosed with PC during the fi rst screening round of the 
Rotterdam section of the European Randomized Study of Screening for Prostate Cancer 
(ERSPC). According to the screening protocol, a lateralized sextant prostate biopsy was induced 
by a prostate-specifi c antigen (PSA) serum level >= 4.0 ng/ml, an abnormal digital rectal 
examination or a abnormal transrectal ultrasound (TRUS) up to May 1997. From May 1997, 
only a PSA>=3.0 ng/ml prompted a biopsy.
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 Of these 1014 patients, 400 (39.5%) were primarily treated with RP. For 75 (18.8%) patients 
the data on pathological tumour stage, Gleason score and prostate tumour volume were 
incomplete and these patients were excluded from the analyses. Th erefore, the study cohort 
consisted of 325 (81.3%) patients who were all treated between November 1993 and June 2000.
 By assessing only patients treated with RP, a selection of the total screened population is 
made. To examine the validity of the use of cancer characteristics in the selection of patients 
treated with RP the proportion of low, intermediate and high risk PC according to the d’Amico 
criteria8 of all cancers of the screening arm was compared to those treated by RP. 
9.2.2 | Radical prostatectomy specimens and pathologic examination
RP specimens were processed in toto following the protocol described before.9 In short, aft er 
fi xing the specimens, they were inked, cut at 4mm intervals perpendicular to the rectal surface. 
Th e apical slice is cut parasagitally at 4mm intervals. Th e sections were divided in halves or 
quadrants to fi t routine used cassettes for paraffi  n embedding. Pathological tumour stage, 
Gleason score, and surgical margin status were assessed. Tumour areas were marked at each 
slide and measured using a computerized morphometry.10 Subsequently the volumes were 
calculated by multiplying the area by the slice thickness. In a side-study we showed (personal 
communication RFH) that fi xation and processing of the RP specimens did not result in 
signifi cant reduction of the tissue volume. Th erefore, a shrinkage factor was not taken into 
account for the calculation of TV. Staging was done according to the 2002 TNM classifi cation. 
Th e pT4 cases showed tumour invasion of the detrusor muscle. 
9.2.3 | TV thresholds
Stamey assessed a TV threshold for clinically insignifi cant PC using the life time risk of 8% for 
a man to be clinically diagnosed with prostate cancer and observed a threshold of 0.5 ml.6 We 
employed essentially the same approach to assess a TV threshold for insignifi cant PC using 
predicted life time risks obtained in the micro simulation model MISCAN, based on data of 
the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer 
(ERSPC).11 Th e predicted life time risk of prostate cancer in a screening situation similar to our 
screening protocol (i.e. every 4 years, men aged 55-75 years) was 130 per 1000 men (13.0%), 
compared to a predicted life time risk of 64 per 1000 men (6.4%) of a clinically detected prostate 
cancer. Th us, of all screen-detected cancers only 49.2% (64 of 130) would have been clinically 
detected. Th e new TV threshold was established by considering the 49.2% largest TV in our 
cohort of screen-detected cancers clinically relevant. Th e predictive value for biochemical 
recurrence of the TV threshold was assessed in the entire study population and in a selection 
of patients with possibly insignifi cant PC, i.e. patients with organ-confi ned disease without 
Gleason pattern 4/5.
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9.2.4 | Follow-up
Patients were followed aft er RP by serial PSA measurements every 3 months during the 
fi rst year aft er RP, every 6 months in the second year and yearly aft er 2-3 years. Biochemical 
recurrence was defi ned as a PSA > 0.2 ng/ml.12 Metastasis was indicated by suspicious bone 
scintigraphy, MRI or CT scans. Total follow-up time was defi ned as the time from RP to death 
or last visit date. Time to recurrence was defi ned as the time of RP to the time of the fi rst signs 
of recurrence. When no signs of recurrence were registered, cases were censored at the time of 
the last follow-up visit or date of death. Th e cause of death was established by an independent 
committee13 and subsequently scored as PC-related or intercurrent cause of death.
9.2.5 | Statistical analysis
Proportions were compared with a Fisher’s exact test. Univariate Cox proportional hazards 
regression model analyses were performed to evaluate the predictive value for biochemical 
recurrence of the traditional TV threshold, the new TV threshold and TV as a continuous 
variable in addition to stage and grade related criteria (i.e. organ-confi ned and no Gleason 
pattern 4/5) for insignifi cant PC. Th e data were analyzed using the statistical package for social 
sciences, version 15.0 (SPSS 15.0, Chicago, IL). Statistical signifi cance was defi ned as a two-
sided p-value<0.05.
9.3 | Results
9.3.1 | Overall characteristics of the cohort
Th e distribution of low, intermediate and high risk cancer in the screening arm and the 325 
cases treated with RP was signifi cantly diff erent: the surgically treated cases were skewed to a 
lower risk profi le (Table 1). Th e overall characteristics of the 325 cases who underwent RP are 
listed in Table 2. TV ranged from 0.001 ml to 13.48 ml. Among these 325 men, 128 (39.4%) had 
a TV<0.5 ml. Using the rate of 49.2% for clinically signifi cant disease, a new TV threshold of at 
least 0.70 ml was found. A total of 160 (50.8%) patients had a TV<0.70 ml.
 Follow-up data were available for 322 (99.1%) patients and the median (mean) period 
of follow up aft er the prostate cancer diagnosis was 98 (96.1) months. A total of 54 (16.8%) 
patients showed PSA progression aft er a median (mean) period of 35 (43.9) months. 
 A total of 174 (53.5%) patients had organ-confi ned disease without Gleason pattern 4 or 
5 (table 3) and 16 (9.2%) patients showed biochemical progression. Cox proportional hazards 
models showed that patients with organ-confi ned disease without Gleason pattern 4/5 were 
at signifi cantly lower risk of biochemical progression (HR 0.35, 95% CI 0.20-0.63, p<0.001) 
than patients with extra capsular tumour growth and/or Gleason pattern 4/5. Th e numbers 
of metastasis and PC specifi c mortality were too small to perform Cox regression analyses: 1 
patient presented with metastasis during follow-up and no PC specifi c mortality was observed 
in men with organ-confi ned disease without Gleason pattern 4/5.
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Table 1 | Comparison of the distribution of low, intermediate and high risk prostate cancer (PC) in 
the selected 325 cases treated with radical prostatectomy and the unselected men of the screening arm 
(n=1014). Low risk was defi ned as clinical tumour (cT) stage =< T2a and PSA=< 10 ng/ml and Gleason 
score = 6. High risk was defi ned as cT stage T2c or higher or a PSA-level >20 ng/ml or Gleason score >=8. 
Th e remaining cases (cT stage T2b or a Gleason score of 7 or a PSA level >10 ng/ml and <= 20 ng/ml) were 
defi ned as intermediate risk.
All PC cases 
n=1014
RP selection 
n=325
Not included in the 
selection n=689
p-value
Low risk  455 (44.9%) 187 (57.5%) 268 (38.9%) <0.001
Intermediate risk  223 (22.0%)  73 (22.5%) 150 (21.8%)
High risk  336 (33.1%)  65 (20.0%) 271 (39.3%)
Total 1014 (100%) 325 (100%) 689 (100%)
Table 2 | Characteristics of the total cohort of 325 patients treated with RP and of the 174 cases with organ 
confi ned disease without Gleason pattern 4/5. PSA = prostate-specifi c antigen, pT=pathological tumour 
stage.
Features Screen detected PC: total cohort
No. (%) of cases
Organ confi ned prostate cancer 
without Gleason pattern 4/5
No. (%) of cases
No of cases 325 174
Age in years, mean (range) 63.6 (55.2-75.5) 63.2 (55.2-73.1)
PSA (ng/ml), mean (range) 6.2 (0.8-43.0) 5.5 (0.8-37.0)
PSA density (ng/ml/ml), 
mean (range)
0.17 (0.02-1.01) 0.14 (0.02-0.93)
Focality
Monofocal 91 (28.0) 45 (25.9)
Multifocal 222 (68.3) 121 (69.5)
unknown 12 (3.7) 8 (4.6)
Gleason score
≤ 6 202 (62.2) 174 (100)
7 (3+4) 96 (29.5)
7 (4+3) 16 (4.9)
8 to 10 11 (3.4)
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Table 2 | Continued
Features Screen detected PC: total cohort
No. (%) of cases
Organ confi ned prostate cancer 
without Gleason pattern 4/5
No. (%) of cases
pT (TNM system 2002)
pT2a 63 (19.4) 47 (27.0)
pT2b 7 (2.2) 3 (1.7)
pT2c 180 (55.4) 124 (71.3)
pT3a 55 (16.9)
pT3b 4 (1.2)
pT4 16 (4.9)
Surgical margin status
Negative 243 (74.8) 148 (85.1)
Positive 81 (24.9) 25 (14.4)
unknown 1 (0.3) 1 (0.6)
Tumour volume (cc)
Mean (median) 1.07 (0.66) 0.76 (0.47)
Range 0.001-13.48 0.001-6.34
Table 3 | Progression and mortality rates for the total study cohort and for the selection of patients with 
organ-confi ned without Gleason pattern 4/5. PC=prostate cancer
Total cohort
N=322
Organ-confi ned PC and no Gleason 
pattern 4/5
N=172
Biochemical progression 54 (16.8%) 16 (9.3%)
Metastasis  8 (2.5%)  1 (0.6%)
Overall mortality 54 (16.8%) 29 (16.9%)
PC specifi c mortality  5 (1.6%)  0 (0%)
9.3.2 | Tumour volume as a criterion of clinically insignifi cant PC
Th e 0.7 ml TV threshold was a signifi cant predictor for biochemical progression in the entire 
study population: HR 2.88, 95% CI 1.59-5.24, p<0.001. In the selection of 174 patients with 
organ-confi ned prostate cancer and no Gleason pattern 4/5, TV ranged from 0.001 ml to 6.34 
ml, 92 (52.9%) had a TV<0.5ml and 111 (63.8%) had a TV<0.70ml. None of the thresholds 
showed prognostic value in any of the analyses (Table 4). 
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Table 4 | Th e prognostic value of a tumour volume threshold: results of Cox proportional hazards analyses 
in patients with organ-confi ned PC and without Gleason pattern 4/5. PC=prostate cancer, TV=tumour 
volume
Number of patients 
with organ confi ned PC 
without Gleason pattern 
4/5
Biochemical progression Hazard ratio (95% 
confi dence interval)
p-value
TV<0.5ml
TV>=0.5 ml
91
81
 9 (9.9%)
 7 (8.6%)
1 (reference)
0.89 (0.33-2.39)
0.818
TV<0.7ml
TV>=0.7ml
110
62
11 (10.0%)
 5 (8.1%)
1 (reference)
0.82 (0.29-2.37)
0.719
TV (continuous 
variable)
172 16 (9.3%) 0.55 (0.22-1.37) 0.198
9.4 | Discussion
In this fi rst study attempting to confi rm the previously reported TV threshold of 0.5 ml for 
clinically insignifi cant PC, we found a TV threshold for insignifi cant PC of 0.70 ml. Th e 
threshold was assessed using life time risks of prostate cancer diagnosis that were specifi cally 
modelled for the studied population. Th is method was similar to the design of Stamey6 who 
observed a lower threshold of 0.5 ml, the threshold which is nowadays widely used as a criterion 
in the defi nition of insignifi cant PC. Th e diff erence in thresholds may very well be explained by 
the diff erent study cohorts: screen-detected PC in patients, aged 55-75 years with a PSA>=3.0 
ng/ml in our cohort compared to patients who had a cystoprostatectomy for bladder carcinoma 
without prior history of prostate cancer. Our results suggest that tumours larger than 0.5 ml 
could be insignifi cant as well, with volumes at least up to 0.70 ml.
 It is very likely that our threshold of 0.70 ml as determined by the approach taken by Stamey6 
is an underestimation. First, it should be noted that patients of our cohort treated with RP are 
a selection of all patients with prostate cancer detected in the screening program. A diff erent 
distribution of low and high risk PC was observed in the selection of patients treated by RP 
compared to the total cohort of patients diagnosed with PC during the fi rst screening round. 
Since they represented a selection of more favorable tumours as compared to the entire series 
of screen detected cancers, the TV threshold of 0.70 ml may be too restrictive and much on the 
safe side.
 Secondly, it is commonly accepted that PC with extracapsular extension and/or Gleason 
scores > 6 should be considered clinically signifi cant. Most studies agree that Gleason score 
and pathological stage are stronger determinants of biological behaviour of PC than TV. As 
a consequence, one could argue that the threshold for insignifi cant PC should be extracted 
from the selection of patients with organ-confi ned PC and no Gleason pattern 4/5 only. IN the 
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present population, a TV threshold of 2.50 ml was observed aft er repeating the analysis in this 
selection of patients. 
 Th is view is corroborated by our fi nding that TV was not useful for the diff erentiation 
between men with or without biochemical progression, in patients with organ confi ned disease 
without Gleason pattern 4/5. Patients with a low TV were at a similar risk of biochemical 
progression as patients with larger TV. Th is is not surprising: although TV is related to Gleason 
score and tumour stage,14-16 several studies, including one on the same set of patients used for 
this report, demonstrated a lack of independent prognostic value for biochemical and clinical 
progression.17-21 Th is suggests that a TV threshold might not be eff ective for the identifi cation 
of insignifi cant PC. Th e use of a TV threshold might unnecessarily exclude patients with higher 
TV from active surveillance strategies. On the other hand, patients with small TV might 
mistakenly be reassured.
 Overall, the selection of organ-confi ned PC with no Gleason pattern 4/5 seems to represent 
the most important step in the identifi cation of patients with favourable prognosis aft er RP. Th is 
was illustrated by the fact that only 1 patient showed metastasis during follow-up and none of 
the patients died of prostate cancer aft er selecting for organ-confi ned disease without Gleason 
pattern 4/5. Th is selection seems therefore very useful for the identifi cation of insignifi cant PC. 
Which factors will be valuable in further diff erentiation between insignifi cant and clinically 
relevant PC in this low-risk group remains unknown, but TV did not seem valuable in this 
diff erentiation. 
 Some limitations are worth mentioning. Since all patients in the current study were 
treated with RP, we cannot possibly know the natural course of the disease in this patient 
series. Although biochemical progression aft er RP would suggest that the tumour probably is 
not insignifi cant, a rising PSA does not necessarily indicate its clinical signifi cance as it may 
occur in the absence of any symptoms.23,24 Additionally, in absence of any progression aft er 
treatment, the true signifi cance of the tumour is unknown. Th e lack of prognostic value of TV 
in patients with organ-confi ned PC without Gleason pattern 4/5 and treated with RP might also 
be interpreted as RP being a very eff ective therapy in this selection of patients regardless of TV, 
as stated recently by Lee et al.25
 A second limitation is that in the present study cohort total TV was assessed, while the 
report by Stamey was based on the index TV. For a selection of 100 consecutive men in the 
present study, index TV was known and repeating the analyses showed a TV threshold of 0.55 
ml (data not shown). Index TV was available for 37 men in the selection of organ-confi ned PC 
with no Gleason pattern 4/5 and ranged up to 4.3 ml. Although numbers are too small to draw 
valid conclusions, no prognostic value of TV was observed in this selection either. Finally, the 
same arguments as mentioned above for the 0.70 ml threshold apply to consider this 0.55 ml 
threshold an underestimation. 
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9.5 | Conclusions
Using life time risk rates for our screened cohort, a minimum total tumour volume threshold for 
insignifi cant PC of 0.70 ml was observed. Th is suggests that insignifi cant PC includes tumours 
larger than 0.5 ml, especially since the threshold of 0.70 ml is an underestimation, because 
it was based on a study cohort with a more favourable risk profi le than the overall screening 
cohort. Additionally, tumour volume could not predict adverse outcome aft er prostatectomy in 
men with organ confi ned prostate cancer without Gleason pattern 4/5. Th erefore, we question 
the validity of the incorporation of TV as a criterion for insignifi cant prostate cancer.
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Summary
Objectives: To assess the additional prognostic value of EZH2, MIB-1, p27kip1 and BMI-1 on 
needle-biopsies from men with low-riskprostate cancer, as this disease in needle biopsies shows 
a heterogeneous clinical outcome, and while it is known that the expression of molecular tissue 
markers EZH2, BMI-1, MIB-1, and p27kip1 are predictive for clinical outcome aft er radical 
prostatectomy (RP), their value in prostate biopsies is largely unknown. 
Patients and Methods: Th e study included men participating in a screening study, diagnosed 
with low-risk prostate cancer and subsequently treated with RP. Immunohistochemical staining 
for EZH2, MIB-1, p27kip1 and BMI-1 on the needle-biopsies were (semi)quantitatively scored 
and expression levels were related to signifi cant disease at RP. Clinical low-risk prostate cancer 
was defi ned as prostate specifi c antigen (PSA)<=10ng/ml, clinical T-stage=<2, biopsy Gleason 
score<=6, a PSA density<0.20 ng/ml/g and two or fewer positive cores. Signifi cant PC at RP was 
defi ned as presence of any of extracapsular extension, Gleason pattern 4/5, or tumour volume 
>= 0.5 ml. 
Results: In all, 86 biopsy specimens were included; there was high EZH2 expression (>1.0%) in 
42% and a low p27kip expression (<90%) in 63%. Signifi cant disease was present in 44 (51.2%) 
RP specimens. A high EZH2 (odds ratio 3.19, p=0.043) and a low p27kip1 (odds ratio 4.69, 
p=0.036) were independent predictors for signifi cant prostate cancer at RP.
Conclusions: Th e determination of EZH2 and p27kip1 on diagnostic needle-biopsies supports 
the selection of men with indolent prostate cancer at RP. Especially p27kip1 could improve the 
pretreatment risk assessment of patients with low-risk prostate cancer. 
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10.1 | Introduction
Th e pretreatment risk assessment of prostate cancer (PC) is important to guide clinical decision 
making, and is based on clinical and pathological characteristics, e.g. PSA level, clinical tumour 
stage, number of positive biopsy cores and biopsy Gleason score. PC classifi ed as low-risk 
disease has a high probability of being clinically insignifi cant, i.e. not causing any symptoms, 
or death. However, some cases classifi ed as low-risk show more aggressive behaviour, urging 
radical treatment.1 Unfortunately, the identifi cation of patients at risk of harbouring signifi cant 
PC is diffi  cult.
 To better assess the aggressiveness of prostate cancer before treatment, the use of 
molecular biomarkers on needle biopsy specimens might off er additional predictive value. 
Various immunohistochemical markers at radical prostatectomy (RP) had additional value 
in determining tumour aggressiveness and PSA relapse aft er RP. Several independent groups 
reported prognostic value for EZH2, BMI-1, p27kip1 and MIB-1 at radical prostatectomy 
specimens.2-14 While these markers have predictive value in this setting, their most important 
clinical value could be patient stratifi cation for therapeutic decision-making.
 Th erefore, in the present study, we investigated the expression of EZH2, BMI-1, p27kip1 and 
MIB-1 in diagnostic needle-biopsies from men with low-risk PC, and the predictive value of 
these markers for signifi cant disease in RP specimens.
10.2 | Patients and Methods
10.2.1 | Patient selection
All patients included in this study were participants in the screening arm of the European 
Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam section. Men aged 
55-74years were invited for a screening visit every 4 years. Until May 1997, a PSA level of 
>= 4.0 ng/ml or an abnormal DRE and/or TRUS result prompted a lateralized sextant prostate 
biopsy. From May 1997, a biopsy was only indicated by a PSA level >= 3.0 ng/ml. 
 Patients were defi ned as having low-risk PC according to the criteria in the international 
active surveillance study PRIAS15, i.e. a PSA level of <= 10 ng/ml, clinical T-stage=<2, a PSA 
density of <0.20 ng/ml/g, a Gleason score of<7 and two or fewer 2 positive cores. 
 All 151 men with low-risk PC who had a RP between 1993 and 2008 at Erasmus Medical 
Center Rotterdam were selected. To enhance the chance of fi nding residual tumour in paraffi  n 
blocks, biopsy tissues had to contain at least 2 mm of PC (100 samples). For 98 of 100 cases the 
tissue blocks could be retrieved from the archive. Th e core containing the largest amount of PC 
was selected. All original biopsy specimens were reviewed by a urogenital pathologist (GvL) 
and in 12 (12.2%) cases the Gleason score was upgraded, due to interobserver variability and 
updated criteria for Gleason grading.17 Th ose cases were excluded, leaving 86 cases suitable for 
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the present study. Preoperative clinical and pathological data on the diagnostic biopsies and RP 
specimens were obtained from the ERSPC database., in which the number of positive cores and 
estimated maximum percentage tumour invasion per biopsy were recorded. 
10.2.2 | Pathological assessment of the diagnostic biopsies and RP specimens
All diagnostic biopsy cores were labelled and processed separately, as described previously17. 
RP specimens were processed following the ERSPC procedure18. Briefl y, aft er fi xing the 
specimens, they were inked, cut at 4 mm intervals and totally embedded. Pathological stage, 
Gleason score and surgical margin status were assessed, and tumour volume was measured 
using a computerized morphometric analysis.19 PC was classifi ed as signifi cant if there were any 
of extracapsular extension (EPE, which includes seminal vesicle invasion), Gleason pattern 4/5, 
or a tumour volume>= 0.5 cc.20
10.2.3 | Immunostaining
For immunostaining, sections (4 μm) were cut and deparaffi  nized through xylene and 100% 
ethanol. Sections were immunostained using the Envision system (DAKO, Glostrup, Denmark). 
Briefl y, endogenous peroxidase activity was quenched for 20 minutes in 0.3% H2O2 /PBS. 
Antigen was retrieved by placing the slides in a microwave (600 W) for 15 minutes in a pH9 
Tris-EDTA buff er (Klinipath, Duiven, Netherlands). Aft er cooling, the slides were rinsed with 
Tris-HCL pH 7.5 (Klinipath, Duiven, Netherlands) and incubated with the primary antibody at 
an optimal dilution. Incubation was for 1 hour at room temperature for EZH2 (clone 11/EZH2, 
DB transductions laboratories; 1:250), MIB-1 (clone M7240, DAKO; 1:50) and p27 (clone 
NCLp27, Novocastra; 1:40). For BMI-1 (clone F6, Millipore; 1:50), incubation was performed 
overnight at 4oC. Th e slides were rinsed with Tris-HCL followed by a 30-minute incubation 
with goat anti-rabbit (EZH2) or goat anti-mouse (p27, MIB-1, BMI-1) antibody from the 
Envision kit. Th e antigen antibody complexes were visualized with 3,3’-diaminobenzidine 
tetrahydrochloride (DAB+) chromogen diluted in substrate buff er (Dako REAL Envision 
Detecting system), during two incubations of 5 minutes. All slides were counterstained with 
haematoxylin (Klinipath 4085.9005, Duiven, Netherlands). 
10.2.4 | Quantifi cation process
For p27kip1 and for BMI-1 the positive nuclei were assessed relative to the total number of tumour 
cells at a scale of 0-100%. For EZH2 and MIB-1, the percentage of positive tumour nuclei of the 
total number of tumour cells in the whole core was calculated aft er actual visual counting of all 
positive and all negative cells. Th is very accurate quantifi cation method was applied because of 
low expression of these immunostains.
 All biopsy cores were scored independently by two investigators (TW and GvL) in a blinded 
fashion. When scores were discrepant, consensus was reached in a combined session. Th e 
staining intensity was scored for EZH2 and BMI-1 as weak (only visible at high magnifi cation), 
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moderate (visible at low magnifi cation) or strong (strikingly positive at low magnifi cation). 
However, as for both EZH2 and BMI-1 intensity was weak in more than 95%, intensity was not 
included in further analyses. 
10.2.5 | Statistical analysis
Logistic regression analyses were used to assess the predictive value of the immunostainings 
for signifi cant PC. Analyses were used in univariate and multivariable settings, the latter using 
a backward stepwise method; variables were rejected at a p-value >0.05. In all multivariate 
analyses the following variables were included: PSA level, age, prostate volume, PSA density, 
clinical tumour (cT) stage (T1c or T2), number of positive cores (one or two) and maximum 
tumour invasion in the biopsy core.
 For the immunostaining scores an optimum threshold was chosen based on optimum 
predictive value, because thresholds previously might not apply to the current cohort due 
to sample selection of low-risk PC. For independent predictive immunomarkers, the actual 
additional value was assessed by comparing the base model including PSA, age, prostate volume, 
PSA density, cT-stage, number of positive cores and maximum tumour invasion per core, with 
the extended model also including the respective immunomarker, using the likelihood ratio 
test. Th e area under the receiver-operator curve (AUC) was used to express the performance of 
the model. All statistical analyses were done using SPSS version 15.0 (SPSS Inc, IL, USA). In all 
tests, a two-sided p<0.05 was considered to indicate signifi cance. 
10.3 | Results
10.3.1 | Clinical and pathological characteristics
Table 1 shows the clinical and needle-biopsy characteristics; in the RP specimens, EPE was 
found in 9 (10.4%) cases and the Gleason score was upgraded from 6 to 7 in 16 (18.6%) cases 
(Table 2). In all, 44 (51.2%) cases fulfi lled the criteria of signifi cant disease on RP. 
 Th e PSA density and the maximum PC invasion per core were signifi cant univariate 
predictors of signifi cant PC at RP (Table 3). In multivariable analysis, both factors remained 
independent predictors, while all other variables were excluded from the model due to lack of 
signifi cance (Table 3). Th e area under the curve was 0.744 (95% confi dence interval (CI) 0.616-
0.871) for this model.
10.3.2 | Immunostaining results 
Analysing EZH2 staining, 12 cases did not contain residual tumour and in 2 the immunostaining 
was considered false-negative based on complete absence of staining, leaving 72 (83.7%) cases 
for further analyses. EZH2 was expressed in nuclei of both normal and malignant cells. Its 
expression level was generally low, with a median(range) value of 1.1% (0-6.0%) in malignant 
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cells. An EZH2 level of >1.0% was assessed as the optimum theshold and was present in 30 
(41.7%) cases. 
Table 1 | Preoperative clinicopathologic characteristics.
Characteristic Low-risk PC
Total cohort 86 (100%)
Age at diagnosis (yrs)
 Mean
 Median
 Range
63.5
63.8
55.5-71.6
PSA value at diagnosis (ng/ml)
 Mean
 Median
 Range
 4.5
 4.2
 0.8-10.0
Prostate volume (ml)
 Mean
 Median
 Range
42.8
36.3
17.6-144.7
Clinical T-stage
 T1c
 T2a
 T2b
 T2c
 T3/4
45 (52.3%)
31 (36.0%)
 6 (7.0%)
 4 (4.7%)
-
Number of positive biopsy cores
 1
 2
 >2
33 (38.4%)
53 (61.6%)
-
Maximum tumour invasion
 =<10%
 10-50%
 >50%
16 (18.6%)
58 (67.4%)
12 (14.0%)
 In MIB-1 stained biopsies, 13 cases showed no remaining tumour and in 2 the staining was 
false-negative, leaving 71 cases for the analyses. MIB-1 was expressed at low levels in benign 
and malignant nuclei. Th e median (range) expression was 2.4 (0.2-24.8) %. For MIB-1 the 
threshold was 3.0%, and 25 (35.3%) cases expressed >3.0% MIB-1 positive nuclei.
 In p27kip1-stained specimens, 17 (19.8%) cases had no tumour and in 9 (10.5%) the staining 
was false-negative, leaving 60 (69.8%) for analyses. Th e median p27kip1 expression was 87.5% 
(range 20%-100%). Th e threshold for p27kip1 was set at <90%, which was present in 38 (63.3%) 
cases.
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 BMI-1 staining could be scored in 69 (80.2%) specimens; there was no tumour in the 
remaining 17. Th e median BMI-1 expression was 80% (range 40%-93%), and the threshold for 
BMI-1 was set at >70% positive cells, which was present for 50 (72.5%) cases. Examples of all 
markers are shown in fi gure 1.
Table 2 | Radical prostatectomy characteristics. *Signifi cant disease was defi ned as extracapsular extension, 
or Gleason pattern 4/5, or tumour volume > 0.5ml.
Characteristic
Total cohort 86 (100%)
Pathological T-stage
 T2a
 T2b
 T2c
 T3
 T4
22 (25.6%)
 4 (4.7%)
51 (59.3%)
 5 (5.8%)
 4 (4.7%)
Gleason score
 <7
 =7
 >7
71 (81.4%)
15 (18.6%)
-
Seminal vesicle invasion
 Yes
 No
 1 (1.2%)
85 (98.8%)
Extracapsular extension
 Yes
 No
 5 (5.8%)
81 (94.2%)
Surgical margins
 Negative
 Positive
77 (89.5%)
 9 (10.5%)
Tumour volume (ml)
 Mean
 Median
 Range
0.63
0.43
0.003-5.04
Signifi cant disease*
 No
 Yes
42 (48.8%)
44 (51.2%)
10.3.3 | Th e predictive value of immunostaining in low-risk PC
Th e distributions of Gleason score 7, EPE, tumour volume of >=0.5 ml and overall signifi cant 
PC are shown for each immunomarker in Table 4. In univariate analysis, low expression of 
p27kip1was signifi cantly related to a higher probability of signifi cant PC (OR 3.29, 95% CI 1.09-
9.95, p=0.035). For high EZH2 expression there was a trend to a higher probability of signifi cant 
PC in univariate analysis, although this was not statistically signifi cant (OR 2.30, 95% CI 0.88-
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6.03, p=0.089. When EZH2 or p27kip1 were included in the multivariable model with backward 
exclusion, both remained statically signifi cant predictors of signifi cant PC at RP. Th e area under 
the curve increased to 0.828 (95% CI 0.714-0.941) and 0.821 (95% CI 0.708-0.935) respectively. 
However, the predictive accuracy did not improve with the addition of either EZH2 or p27kip. 
Including both immunomarkers simultaneously in the model showed that EZH2 and p27kip had 
independent predictive value (Table 5). Th e predictive model signifi cantly improved (p<0.05) 
with the inclusion of both markers. Th e area under the curve for this model including both 
immunomarkers was 0.863 (95% CI 0.763-0.964). BMI-1 and MIB-1 expression were not 
predictive for signifi cant at RP. 
Figure 1 | Various expression levels of the immunomarkers. A: High EZH2 expression, 400x. B: Very 
low EZH2 expression, 200x. C: High MIB-1 expression, 400x. D: Low MIB-1 expression, 400x. E: High 
p27kip1 expression, 400x. F: Low p27kip1 expression, 200x. E: High BMI-1 expression, 400x. F: Low BMI-1 
expression, 200x. For color images, see appendix page 184.
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Table 3 | Predictive value of the preoperative variables, excluding immunostaining scores, for signifi cant 
PC at RP (n=86). OR= odds ratio, CI= confi dence interval, n.s.= not signifi cant
Variable Univariate OR (95% CI) signifi cant 
PC
Multivariable OR (95% CI) 
signifi cant PC
Age 1.03 (0.92-1.15) p=0.578 n.s.
PSA 1.19 (0.95-1.50), p=0.124 n.s.
PSA density 2.21 (1.26-3.86), p=0.006 2.11 (1.18-3.79), p=0.012
Prostate volume 1.00 (0.98-1.02), p=0.989 n.s.
Tumour stage 1.00 (0.43-2.34), p=0.992 n.s.
Number of positive cores 1.77 (0.74-4.26), p=0.203 n.s.
Maximum PC invasion 1.03 (1.01-1.06), p=0.012 1.03 (1.004-1.06), p=0.025
Table 4 | Distribution of Gleason score 7 at RP, extraprostatic extension (EPE), tumour volume >=0.5ml 
and signifi cant prostate cancer (PC) per immunomarker in patients with low-risk prostate cancer.
Total Gleason 7 at RP EPE Tumour volume >= 
0.5ml
Signifi cant PC
EZH2
 <1%
 >=1%
42
30
5 (11.9%)
7 (23.3%)
2 (4.8%)
4 (13.3%)
17 (40.5%)
13 (43.3%)
18 (42.9%)
19 (63.3%)
MIB-1
 <=3%
 >3%
46
25
5 (10.9%)
7 (28.0%)
4 (8.7%)
2 (8.0%)
18 (39.1%)
11 (44.0%)
22 (47.8%)
14 (56.0%)
p27kip1
 >=90%
 <90%
22
38
5 (22.7%)
4 (10.5%)
1 (4.5%)
5 (13.2%)
 5 (22.7%)
19 (50.0%)
 7 (31.8%)
23 (60.5%)
BMI-1
 <=70%
 >70%%
19
50
4 (21.1%)
7 (14.0%)
4 (21.1%)
3 (6.0%)
10 (52.6%)
16 (32.0%)
10 (52.6%)
22 (44.0%)
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Table 5 | Predictive value of the immunostainings for signifi cant PC at RP. Odds ratio’s (OR) and 95% 
confi dence interval (95%CI), resulting from the univariate and multivariable regression analyses. OR= 
odds ratio, CI= confi dence interval, n.s.= not signifi cant
Variable Univariate OR (95% CI) Multivariable OR (95% CI) 
including 1 immunomarker
Multivariable OR (95% CI) 
including all immunomarkers
EZH2 >1% 2.30 (0.88-6.03)
P=0.089
3.19 (1.04-9.78)
P=0.043
11.52 (1.91-69.37)
P=0.008
MIB-1 >3.0% 1.39 (0.52-3.70)
P=0.511
n.s. n.s.
P27 <90% 3.29 (1.09-9.95)
P=0.035
4.69 (1.11-19.88)
P=0.036
5.78 (1.14-29.29)
P=0.034
BMI-1 >70% 0.71 (0.25-2.04)
P=0.522
n.s. n.s.
10.4 | Discussion
One of the major current challenges in prostate cancer care is to fi nd a reliable method to 
diff erentiate signifi cant PC from indolent disease before RP. Th e present study showed that 
men with low-risk PC before treatment and high EZH2 expression (>1.0 %; OR 3.19; p=0.043) 
or low p27kip1expression (<90%; OR 4.69; p=0.036) at biopsy had a signifi cant higher chance 
of harboring signifi cant PC at RP. To the best knowledge, the value of these immunostains in 
biopsy specimens of men with low-risk PC has not been reported before, and can possibly help 
in treatment stratifi cation.
 Th e Polycomb-group of genes are important in maintaining cell identity and regulation of 
the cell cycle.21 Overexpression of the Polycomb-group genes EZH2 and BMI-1 is associated 
with poor prognosis in several human tumours, including prostate cancer.3,5,21-23 EZH2 is over-
expressed in hormone-refractory and/or metastatic disease compared to localized PC1,22 and 
has a predictive value for progression and survival aft er prostatectomy.1,3-6 EZH2 was found 
to be associated with adverse pathological characteristics by some investigators,4,23 although 
others could not confi rm these results22. In our study of men with low-risk PC, a high EZH2 was 
predictive for signifi cant PC at RP. 
 p27kip1 belongs to the Cip/Kip family of cyclin dependent kinase inhibitors (CDKIs), which 
are important in regulating cell-cycle processes. Loss of these inhibitors leads to deregulation 
of the cell cycle and uncontrolled proliferation.24 Loss of p27kip1 expression in PC at RP has 
been associated with a higher risk of biochemical recurrence and decreased survival,7-9 and a 
high Gleason score.7,9,25,26 Th omas et al25 reported similar fi ndings for loss of p27kip1 expression 
on biopsy specimens: low expression (<30%) was related to a high Gleason score and more 
advanced pathologic stage, and there was a trend towards a higher probability of biochemical 
recurrence. Furthermore, low biopsy p27kip1 expression (<50%) was an independent predictor 
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of clinically signifi cant PC at RP in a study by Vis et al.27 Th e present study yielded parallel 
results: low expression of p27kip1 was independently predictive of signifi cant PC, even though 
only low-risk patients were included. 
 MIB-1 is an antibody targeting Ki-67 antigen, which is a proliferation marker of cells in 
the G1 phase. A high Ki-67 expression at RP has been associated with a high GS and advanced 
stage,6,14,28,29 biochemical progression aft er treatment8,11-13 and PC related death.14 For Ki-67, 
there are several studies also on biopsy tissue, with similar results.8,30-33 In the present study, 
MIB-1 expression was not predictive of signifi cant PC. 
 An important diff erence between immunohistochemical studies are the threshold values 
used to defi ne high or low expression. For example, the defi nition of low p27kip1 ranges from 
10% to 50%. Th e threshold of 90% in the present study is much higher, which can be explained 
by tissue selection: only low-risk PC was included, instead of RP tissue with all Gleason scores. 
Th erefore, the most unfavourable tumours were excluded from this study, which most probably 
are those with the lowest p27kip1 expression. In the present patients, only 5 had a p27kip1 <50%. 
Interestingly, the reported threshold of 1% for EZH2 is in concordance with the value used in a 
RP study by one of the authors.4 
 While cut-off s were applied in most immunohistochemical studies, we do not suggest 
using strict threshold values in clinical practice. Although there is a signifi cant diff erence in 
the tumour characteristics of patients below or above the threshold, using them will lead to 
missing relevant men with indolent disease. Th is is shown in table 4: e.g. for EZH2, applying the 
threshold and excluding men with high expression from active surveillance would exclude 11 
patients with insignifi cant PC. A more promising application of immunomarkers might be in 
nomograms predicting the individual chance of signifi cant PC at RP. Th ese markers might be of 
help in diff erentiating between patients eligible for active surveillance and patients more prone 
to progression and subsequent need for radical treatment. Th e use of MIB-1 in this particular 
setting was recently described, with a signifi cant predictive value of this marker in biopsy 
tissue.31,32 However, before EZH2 and p27kip1 can be implemented in routine clinical care, more 
evidence will be needed to confi rm their value in biopsy specimens, preferably in a prospective 
study.
 Th e present study has several limitations. First, an important problem arises with the 
threshold of 1.0% for EZH2. Deciding whether the expression is 0.5% or 1.5% is not easy. 
Counting of positive and negative cells is warranted, but time-consuming. Furthermore, most 
EZH2 staining was weak, making it more susceptible to a subjective interpretation. Also, at least 
2 mm of prostate cancer tissue was studied to avoid a very high discard rate. However, in smaller 
PC lesions, establishing a 1% expression might be impossible because at least 100 cells seem to 
be required to assess such a low expression. Although EZH2 was a independent predictor of 
signifi cant PC, further evaluation on the feasibility of using EZH2 in routine clinical practice is 
needed.
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Th e present study was also limited because it was retrospective, using archived tissue blocks. 
Th is had several consequences. First, due to the updated Gleason scoring consensus16 and 
interobserver variability , 12 cases initially assigned a Gleason score 6 were now judged as 
Gleason score 7. Because our aim was to diff erentiate between possibly indolent and signifi cant 
PC, we excluded specimens with Gleason score 7, as those are by defi nition not classifi ed as low-
risk disease. Th is could cause a bias, from excluding a part of the cohort. Second, by selecting 
patients with at least 2 mm of tumour we improved the chance of fi nding residual tumour for 
immunostaining and excluded patients with a high a priori chance of having indolent disease. 
Despite of our selection, 12-17 cases per marker no longer had tumour in the biopsy. However, 
In routine diagnostic tests, tissue from all 3 biopsy levels initially cut, are directly available for 
additional immunohistochemistry, solving this problem. Th ird, the numbers of cores available 
for additional immunostaining are relevant; only one core per sextant biopsy was used for 
immunostaining, to preserve as much as possible of the valuable tissue database. Staining of all 
positive cores possibly leads to a more reliable staining score and a higher predictive value of 
the marker expression scores. Finally, the relatively few samples assessed might have impaired 
the statistical power to assess the predictive value of the immunomarkers. We also intended to 
assess the predictive value of the markers for biochemical recurrence aft er RP, defi ned as PSA 
>0.2 ng/ml aft er RP, but only 7 (8.1%) patients had a biochemical recurrence, and no valid 
statistical testing was possible (data not shown).
 In conclusion, the expressions of EZH2 and p27kip1 in biopsy specimens were independent 
predictors of signfi cant PC at RP in men with low-risk disease. Th e determination of p27kip1on 
diagnostic needle-biopsies might prospectively support therapeutic decision making. 
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General discussion
Prostate cancer shows a very diverse clinical course. Some men present with extensive disease, 
rapid progression and mortality. Cure is out of reach already at the moment of diagnosis. 
On the other hand, some cases do not induce symptoms or mortality and do not surface 
during a mans life. Th e existence of these latter cases is known through autopsy studies and 
cystoprostatectomy studies. Autopsy studies have shown an overall incidence of latent prostate 
cancer of 19-39% in entirely processed prostate specimens1-4 with the highest incidence rates in 
the highest age ranges: up to 86.6% in men aged 81-95 years.3 Similar high rates of incidentally 
detected prostate carcinoma of 14.2%-54.0% are described in radical cystoprostatectomy series 
of patients treated for muscle invasive bladder carcinoma and no evidence of prostate cancer at 
the time of surgery.5-10 Th is illustrates the heterogeneity of prostate cancer: a high prevalence of 
indolent prostate cancer which oft en remains undetected and in other men the occurrence of 
aggressive disease causing serious symptoms and even mortality. 
 In the pre PSA era, prostate cancer was mostly diagnosed aft er a suspicious rectal 
examination, which was performed because a patient presented with complaints, or due to 
symptoms caused by metastasized disease. Additionally, prostate cancer cases were detected 
incidentally in transurethral resection tissue or in cystoprostatectomy specimens. Th e majority 
of prostate cancer cases were thus clinically signifi cant and a large proportion of these men died 
of their disease. With the introduction of PSA as a serum test for detection of prostate cancer, 
diagnosis was shift ed to an earlier stage of disease. Th is was even further enhanced by reducing 
the PSA threshold to prompt a prostate biopsy to a total level of 4.0 ng/ml and subsequently to 
2.5 ng/ml.11,12 Additionally, systematic biopsies were introduced, improving the overall prostate 
cancer detection.13 As a consequence, prostate cancers were now diagnosed in absence of 
symptoms or suspicious fi ndings, except for an elevated serum PSA value. Th ereby, population-
based screening became feasible and the eff ect of screening is subject of large trials.14,15
 In 2009, the European Randomized Study of Screening for Prostate Cancer showed a 
signifi cant mortality reduction of 20% in the screening arm.14 In this general discussion, the 
studies addressed in this thesis will be discussed in the perspective of the question ‘how to 
screen for prostate cancer’. First, the role of prostate cancer treatment in both study arms will 
be discussed. Th e second part focuses on improvement of screening strategies, especially 
screening markers, the screening interval, and future directions. Next, the characterization and 
identifi cation of clinically insignifi cant prostate cancer will be addressed and fi nally the possible 
role of prevention and imaging in screening for prostate cancer is discussed.
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Th e reduction of disease specifi c mortality due to screening for prostate 
cancer 
Th e role of prostate cancer treatment
Screening advances the moment of diagnosis, increasing the probability of detecting the cancer 
in a curable phase. Consequently, treatment will be advanced as well, causing a shift  to more 
radical treatment modalities like radical prostatectomy or radiotherapy, instead of hormonal 
treatment or watchful waiting.16 However, if a treatment shift  towards more aggressive 
treatment modalities would occur between the screening and control arm independent of the 
expected shift  due to stage and grade migration, a mortality reduction in favour of the screening 
arm could be caused by this treatment shift  alone. Th e mortality reduction in the screening 
arm could then no longer be related to eff ect of screening but to the eff ect of treatment. Th is 
possible treatment bias was addressed in Chapter 4. A small systematic diff erence in treatment 
between both trial arms was observed in patients with high risk PC, aft er correction for several 
important factors like age, PSA, tumour stage and grade: a participant in the screening arm was 
more likely to be treated with surgery than with any other treatment modality compared to a 
participant in the control arm. Whether this could result in a mortality diff erence is uncertain, 
but if a diff erence would occur it is likely to be small. Moreover, if this indeed would result in 
a mortality reduction, it is yet unclear which arm would be most likely to benefi t. Although a 
benefi t in favour of the control arm might seem contra intuitive, this indeed may be possible 
due to changing treatment patterns over time. For high-risk prostate cancer, important insights 
have been provided by studies reported during the last years. For example, a combination 
therapy of radiotherapy and hormonal treatment has shown to be superior to radiation or 
hormones alone.17,18 Prostate cancer cases are detected in the control arm later in time than 
in the screening arm, due to lead time produced by screening. It was observed in the ERSPC 
cohort, aft er correction for age, stage and grade, that patients with high risk disease in the 
control arm were signifi cantly more oft en treated with combination therapy than patients with 
high risk disease in the screening arm. Th erefore, patients in the control arm might theoretically 
benefi t more from new insights on optimal treatment which reduces prostate cancer specifi c 
mortality because they are detected at a later point in time. 
 If future new prostate cancer treatments improve disease specifi c survival, the control 
arm may benefi t more than the screening arm and the eff ect of screening on mortality might 
seem smaller than it actually is. Future studies within the ERSPC should therefore continue to 
monitor treatment patterns in both arms over time and their possible eff ect on prostate cancer 
mortality. 
 Overall, the mortality reduction observed due to screening is not caused by a systematic 
treatment bias. But if a treatment bias indeed were responsible for most of the mortality 
reduction due to more aggressive treatment in the screening arm, independent of tumour stage 
and grade, this could possibly indicate that treatment in general should be more aggressive and 
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screening would not necessarily be eff ective. However, this was not observed and screening 
indeed reduces prostate cancer mortality. Th erefore, the following part of the thesis will focus 
on the question: how to screen for prostate cancer?
Improving screening strategies
Part II of this thesis aims at the improvement of the currently used screening protocol. Especially, 
the prevention of unnecessary biopsies and the selective detection of signifi cant prostate cancer 
while avoiding the detection of clinically insignifi cant prostate cancer is important for the 
improvement of screening protocols.
Th e screening marker
At present, screening is PSA based and if the PSA level exceeds the threshold of 3.0 ng/ml a 
prostate biopsy is performed. However, a lot of unnecessary biopsies are performed due to lack 
of specifi city of PSA for prostate cancer. It has been previously shown that in repeat screening 
the association between rising PSA levels and rising prostate cancer risk is lost.19 Th is is probably 
due to the presence of benign enlargement of the prostate (BPH), which induces higher levels 
of PSA. Aft er a PSA based screen the PSA level might be stronger related to prostate volume 
than presence of cancer during a next screen20. Th is is confi rmed in the ERSPC data: prostate 
volume is an important negative predictor for prostate cancer detection particularly in repeat 
screening21. 
 Th e change in PSA level during time, i.e. PSA velocity, has been suggested to be a better 
screening marker than PSA. PSA velocity was suggested to diff erentiate between BPH and 
prostate cancer in a large longitudinal study22 and showed to have prognostic value in prostate 
cancer patients treated surgically or with radiotherapy.23,24 However, PSA velocity did not improve 
the performance of PSA alone in our screening program as a biopsy indicator (Chapter 5).Th is 
was observed for prostate cancer detection in general as well as for clinically signifi cant prostate 
cancer. For the defi nition of clinically signifi cant disease, the risk of clinically signifi cant disease 
according to the Epstein criteria was used25. Although the tumour volume threshold used in 
these criteria was not a useful criterion for diff erentiating between indolent and aggressive 
prostate cancer in a later report published by our study group, using the traditional criteria 
does improve comparability with other studies. Additionally, a more recent report on the use of 
PSA velocity as a screening test by Vickers et al26 used a biopsy Gleason score >= 7 as a single 
criterion for aggressive disease and showed results similar to our data: PSA velocity was not 
selective for aggressive prostate cancer. 
 Th is report by Vickers26 included Rotterdam ERSPC data, with PSA measured every 4 years 
and Swedish ERSPC data, with PSA measurements at a 2-year interval, but the interval did not 
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infl uence the predictive value of PSA velocity. Additionally, PSA velocity did not add prognostic 
information on prostate cancer detection in the Prostate Cancer Prevention Trial (PCPT) 
study, in which the PSA was measured yearly.27 Consequently, the time interval between PSA 
measurements to calculate the PSA velocity did not explain the absence of additional predictive 
value of PSA velocity in addition to PSA. In conclusion, PSA velocity will probably not improve 
the screening protocol for prostate cancer detection overall nor for selectively detecting 
aggressive disease.
 It should however be emphasized that the results described in Chapter 5 holds true for men 
with PSA levels equal to or higher than 3.0 ng/ml. Only those men were biopsied, so only for 
those men the predictive value of PSA velocity for biopsy detectable prostate cancer could be 
evaluated. Hypothetically, PSA velocity might improve screening protocols in the PSA ranges 
below 3.0 ng/ml. In the Prostate Cancer Prevention Trial (PCPT) participants were biopsied 
irrespective of PSA value at the end of the study, which creates a good opportunity to assess the 
value of PSA velocity on the whole PSA range: PSA velocity did not add prognostic information 
for prostate cancer detection.27 Th is was confi rmed in a subset of ERSPC participants enrolled 
in side studies within the ERSPC in which biopsies were performed in PSA ranges below 
3.0 ng/ml; no additional value of PSA velocity was observed.28 Th erefore, PSA velocity as a 
biopsy indicator in the lower PSA ranges will probably not improve specifi city of the screening 
protocol.
 Other PSA related markers for prostate cancer detection have been extensively studied. 
PSA kinetics, which for example include PSA slope and PSA doubling time in addition to 
PSA velocity29 and PSA isoforms, for instance total and free PSA, human kallikrein, pro-PSA 
and nicked PSA,30 have been reviewed for their use as possible screening tests. Although 
some markers like proPSA and human kallikrein 2 did show some additional value to PSA 
particularly in the PSA range 4.0-10.0 ng/ml, none could replace PSA and improve sensitivity 
and specifi city. PSA based markers are still under investigation. It is likely that future screening 
will continue to be PSA based, probably using PSA in combination with other markers, due to 
low costs, widely available valid assays and a large experience with PSA-based prostate cancer 
care. 
 Extensive research on new markers that are not PSA related is done and includes for 
example the gene-fusion TMRSS2:ERG,31 prostate cancer antigen 3 (PCA3),32,33 circulating 
tumour cells,34 and exosomes35 amongst many others. An important issue for all markers under 
investigation, is the verifi cation bias (or attribution bias). Generally, new markers are tested in 
cohorts of men who are biopsied based on a elevated PSA or other abnormal tests, for example 
an suspicious digital rectal examination. Of course, these cohorts are most easily accessible and 
will therefore oft en be the fi rst step taken in a evaluation of a new marker. It should be kept in 
mind though, that these studies are subject to attribution bias and prospective evaluation of 
promising markers in unbiased cohorts is needed before general statements can be made.
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 An ideal marker would have high sensitivity and specifi city for clinically signifi cant disease. 
However, no such marker has been discovered yet: neither TMPRSS2:ERG nor PCA3, or any 
other marker, seem to be able to replace PSA while improving its performance. Moreover, all 
of the current knowledge on prostate cancer diagnosis mainly relies on PSA based cohorts and 
subsequent treatment decisions. Most likely, future screening strategies will rely on a set of 
markers instead only on PSA level. For example, PCA3 seems useful in avoiding unnecessary 
repeat biopsies, which also has been observed in the Rotterdam ERSPC screening protocol 
(personal communication M.J. Roobol). In addition, the combined use of TMRPSS2:ERG with 
PCA3 showed higher predictive accuracy for prostate cancer detection than PCA3 alone.36 To 
be suitable as a screening test, a new marker has to be easily detectable, mostly in body fl uids 
like blood or urine, a valid and robust test should be available and costs should be limited. If a 
marker meets these requirements and improves screening with PSA alone, it could be added to 
screening protocols. 
 
Th e screening interval
Next to off ering screening with a fi xed PSA threshold to indicate a prostate biopsy, a fi xed 
screening interval of 4 years is applied in the Rotterdam section of the ERSPC. Th is may be too 
short for some, but too long for other cancers. It might be possible to establish an individual 
screening interval based on individual patient information. As an example, it has been shown 
by Roobol et al that men with an initial PSA below 1.0 ng/ml can safely be re-screened aft er an 
interval of 8 years instead of 4 years.37 Chapter 6 also addresses the possibility of individualizing 
screening intervals, based on biopsy information. None of the addressed features in non-
malignant biopsies, including the presence of high-grade prostatic intraepithelial neoplasia 
(PIN), were predictive for prostate cancer detection in the next screening round. Th us, no 
recommendations for the adjustment of the screening interval based on these characteristics 
could be made based on these data. However, one specifi c result needs further discussion. 
Th e screening protocol of the ERSPC Rotterdam advices an immediate re-biopsy within six 
weeks if high grade PIN is observed in the prostate biopsy. However, the cancer detection 
rate at immediate rebiopsy is not increased in patients with HG-PIN.38,39 No increased risk at 
subsequent screening rounds aft er 1 or 4 years was observed either aft er a previous diagnosis 
of HG-PIN in Chapter 6 and by Vis et al.38 It is worth noting that the cohort of participants 
described in Chapter 6 was not immediately rebiopsied aft er this detection of HG-PIN (these 
cases were newly found at review for the study), but only aft er 4 years. Although numbers are 
small and only focal presence of HG-PIN was observed, these fi ndings questions the need of the 
immediate re-biopsy within 6 weeks. Some studies reported that an increased risk of prostate 
cancer detection was only observed in wide-spread presence of high-grade PIN, not in focal 
high grade PIN40,41 while most report no eff ect of extensiveness of HG-PIN on subsequent cancer 
detection.42 No diff erence in cancer detection rate was found in men with HG-PIN in only one 
biopsy core, or more extensive presence of HG-PIN in the Rotterdam cohort either.43 Th is held 
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also true for participants who refused the immediate re-biopsy. Furthermore, the cancer cases 
detected aft er a previous diagnosis of HG-PIN showed favourable features, which was described 
in the study by Vis and co-workers as well.38 Concluding, the need of the immediate re-biopsy in 
the screening protocol needs to be evaluated. An immediate re-biopsy may not be required and 
probably can safely be postponed in a screening setting. Further evaluation is needed, possibly 
fi rst by comparing the Rotterdam data with those from Sweden, where the immediate re-biopsy 
has already been omitted (personal communication prof. Dr. Hugosson).
 Contrary to a diagnosis of HG-PIN, the presence of atypical lesions suspicious for prostate 
cancer, also known as atypical small acinar proliferations or ASAP, does warrant a re-biopsy 
due to a high cancer detection rate of about 40%,42 also in a screening program.38,39 Th e 
consequences of omitting the immediate re-biopsy aft er ASAP at initial biopsy, although not 
deliberately, are described in Chapter 7. No negative impact was observed, but these results 
cannot be generalized to all ASAP lesions: the ASAP lesions described in Chapter 7 were 
initially missed because they were mostly small and less suspicious. Th erefore, they probably 
are a favourable selection of ASAP lesions in general. Th us, these results should not question the 
need for immediate re-biopsy and should not lead to reconsideration of the current guideline 
to perform an immediate rebiopsy, especially since prostate cancer at immediate re-biopsy may 
show aggressive features. For example, in participants of the ERSPC with an ASAP lesion at 
initial biopsy, 40% were diagnosed with prostate cancer of which 20% had a Gleason score of 7 
or higher.38
 In addition to the eff ect of missing an ASAP lesion, Chapter 7 describes the occurrence 
of false-negative biopsies for prostate cancer. In 16 patients, around 1.1% of all men biopsied, 
malignant glands remained undetected in the biopsy cores. Aft er a delay of four years these men 
were re-biopsied during the next screening round and diagnosed with prostate cancer. Overall, 
no negative eff ects in terms of a higher rate advanced tumour stages or Gleason scores >=7 were 
observed in men with a missed prostate cancer lesion compared to participants with a previous 
benign diagnosis. Similar to the undiagnosed ASAP lesions, these prostate cancer foci are a 
selection of small cancers and are not representative for all prostate cancer cases. Most were 
small, consisting of only a few glands, confi ned to 1 or 2 cores and well diff erentiated with a 
Gleason score of 6. Th ese results might be supportive of active surveillance for selected prostate 
cancer cases. Four years of natural history were observed, without interventions, and all cases 
seemed to be in a curable stage at the time of detection.
 Furthermore, this study provided insights in the type of ASAP and malignant lesions that 
were at risk of being missed during pathological review of biopsy specimens. Th is is important 
educational information, which may reduce the rate of false-negative prostate biopsies.
Future screening strategies
Th e results of Chapter 5 and Chapter 6 showed that neither PSA velocity nor histopathological 
fi ndings at a previous biopsy seemed to improve the screening protocol. However, it is very likely 
that results from previous screening visits will be incorporated in a future screening strategy. For 
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example, PSA might also be used as a marker for risk assessment of developing prostate cancer 
in the future. Th e PSA level has been reported to be predictive for prostate cancer detection, as 
much as 25 years before diagnosis.44 An increase in the total PSA level of 1 ng/ml was associated 
with an increase in odds of detecting cancer of 3.69. Th is was also observed when only advanced 
cases were selected for analysis: 66% of advanced prostate cancers occurred in men with a total 
PSA level in the highest quintile (0.9 ng/ml or higher) measured before the age of 50 and total 
PSA was a strong predictor of advanced cancer (AUC 0.791, p<0.0001)45. In future screening 
strategies, this may imply a baseline PSA measurement, for example at the age of 40, which then 
could guide further individual screening intensity.
  In addition to age, other patient related factors like co-morbidity,46 family history,47,48 and 
race49 will possibly be incorporated in future screening strategies as well because all of them 
infl uence the risk of dying from prostate cancer. Based on the combined evaluation of data 
obtained at previous screening visits, patient related factors and a set of markers for prostate 
cancer, a decision whether to perform a prostate biopsy will probably be made in the future. 
Furthermore, an individualized interval can be established at which re-screening would be 
reasonable. Such an individualized protocol has been described by Roobol et al,50 using a risk 
calculator based on the ERSPC data.21 Th is calculator included prostate volume, digital rectal 
examination outcome and transrectal ultrasound in addition to PSA. Individualization of the 
screening protocol using this calculator resulted in a considerable reduction of biopsies of 
33% at the cost of missing 13% of all detected prostate cancer cases of which 79-81% could be 
considered as possibly indolent. Another example of such a risk calculator is provided based 
on data from the Prostate Cancer Prevention Trial.51 Further exploration of other screening 
markers, prostate cancer risk factors and intervals will help to improve individual-based 
screening strategies. In these future screening programs, prostate cancer risk reduction,52,53 
advanced imaging techniques54-56 or other aspects that are currently not implemented in the 
ERSPC screening protocol, may have a role. Th ese aspects all may decrease the number of 
unnecessary biopsies. Most importantly, future screening protocols should not only aim at 
early diagnosis of prostate cancer, but aim selectively at early diagnosis of clinically signifi cant 
prostate cancer.
 
Defi nition and identifi cation of indolent prostate cancer
With the introduction of the PSA test, and especially with the introduction of screening using 
this PSA test, the detection of prostate cancer has increased. Th is increase is particularly 
observed in detection of small, well-diff erentiated prostate cancers with a low risk for morbidity 
or mortality.57 A considerable part of these prostate cancers cases will probably cause no 
morbidity or mortality and may have gone undetected in absence of screening. Th e terminology 
used for these cases is diverse and can be confusing. First a short description of the terms 
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“clinically insignifi cant prostate cancer” and “indolent prostate cancer” will be given to improve 
understanding of the diff erences and to clarify the use of these terms in the following sections.
  Th e term “clinically insignifi cant prostate cancer” is oft en used and defi nes prostate cancer 
that will not cause morbidity or mortality during life. Th e fact that these cases do not cause 
harm results from favourable tumour characteristics or from other, patient-related factors like 
age, or a combination. Th e subgroup of clinically insignifi cant cases that do not cause morbidity 
or mortality because of very favourable tumour characteristics, even in men with long life 
expectancy, is sometimes called “indolent prostate cancer”. Indolent prostate cancer thus refers 
to prostate cancer that will not cause any morbidity or mortality based on favourable tumour 
characteristics, irrespective of patient related factors. However, some refer to these cases using 
“clinically insignifi cant prostate cancer”. Especially in older reports, clinically insignifi cant is 
mostly used25,58 and more recent studies oft en use the terms intermixed. Th e diff erentiation 
between tumour-related factors and patient-related factors is a recent trend, and the term 
indolent disease is mostly used in more recent studies. 
 In this discussion, “indolent prostate cancer” is used for cases that do not cause morbidity 
or mortality because of very favourable tumour characteristics and subsequent low risk of 
progression, even in young men with long life expectancy and no co-morbidity. Clinically 
insignifi cant prostate cancer will be used for all cases that cause no morbidity or mortality. Th is 
includes indolent prostate cancer, but also prostate cancer that harbour more aggressive features 
but do not cause harm due to competing causes of death, like high age or severe co-morbidity. 
For example, a prostate cancer that contains Gleason pattern 4 disease is not indolent, but may 
very well be clinically insignifi cant in an 80-year old man. Th e third part of this thesis focuses 
especially on the identifi cation of indolent disease using pathological criteria based on radical 
prostatectomy specimens, and the identifi cation of indolent prostate cancer prior to treatment.
What are the criteria for indolent prostate cancer?
Th e most accurate tumour characteristics available are those observed in radical prostatectomy 
specimens, which are known to be prognostic for progression and mortality.59,60 Th e criteria 
for indolent prostate cancer most oft en used are subsequently based on radical prostatectomy 
specimens and include tumour stage, Gleason score and tumour volume. Inclusion of tumour 
volume as a criterion for indolent prostate cancer was suggested by Stamey58 and Epstein.25 
Although they both used the term “clinically insignifi cant”, we will refer to these favourable 
cancers as “indolent”, in line with the previously described defi nitions. It seems logical to 
include a tumour volume threshold in the defi nition of indolent prostate cancer: tumour 
volume is an important prognostic factor for progression and mortality when assessed as a 
single prognosticator.61-63 Additionally, one may assume that larger tumours are more easily 
identifi ed and more likely to produce symptoms compared to small tumours. 
 However, whether the measurement of tumour volume actually adds prognostic value in 
multivariable analyses to more routinely assessed parameters in radical prostatectomy specimens 
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like tumour stage and Gleason score is subject of debate.61,63 Moreover, determination of tumour 
volume is very time-consuming. In Chapter 8 was shown that tumour volume did not have any 
additional predictive value for patient outcome aft er correction for tumour stage and grade 
in our study of 344 radical prostatectomy specimens with a mean follow-up of 96 months. 
Obviously, the determination of tumour volume may be valuable for research purposes, but for 
clinical care settings, we suggest not to routinely measure tumour volume.
 Th ese results of Chapter 8 triggered us to further explore the prognostic value of tumour 
volume in the identifi cation of indolent disease. Th e method that Stamey used to calculate the 
tumour volume threshold for indolent prostate cancer was used in Chapter 9 to reassess this 
threshold value. Based on life-time risk estimates, a tumour volume threshold of 0.7 ml was 
found in the screened population in Rotterdam. Although the diff erence with the threshold 
of 0.5 ml might seem small, the proportion of men with a tumour volume =<0.7 ml was 
considerably higher than the proportion of patients with a volume=<0.5ml: 50.8% versus 
39.4%. Unfortunately, for the majority of the study population, only a total tumour volume was 
available. Although many studies on tumour volume did not explicitly describe whether total 
or index tumour volumes are studied, the diff erentiation might be important. In Chapter 9, the 
tumour volume threshold was also assessed specifi cally for index tumour volumes, which were 
available for a selection of 100 men, and a threshold of 0.55 ml was observed. Th is is remarkably 
similar to the traditional threshold of 0.5 ml, although the proportion of men with a tumour 
volume below the threshold increased from 47% for the 0.5 ml threshold to 52% for the 0.55 ml 
threshold.
 It is important to understand that the reported thresholds in Chapter 9 are underestimating 
the true tumour volume threshold. Two arguments are shortly described in the discussion of 
the Chapter: fi rst, the surgically treated patients were a favourable selection of prostate cancer 
patients in the screening arm of the ERSPC. Th erefore, it is likely that overall tumour volume 
in the entire screened cohort was higher than in this selection of surgically treated patients, and 
the assessed threshold was an underestimation. Second, one might argue that Gleason score an 
tumour stage are more important parameters to determine patient outcome. It is commonly 
accepted, as described in the criteria for indolent prostate cancer by Epstein,25 that only organ 
confi ned disease without Gleason pattern 4/5 can be considered possibly indolent. In the 
study population, 53.5% had organ confi ned prostate cancer with no Gleason pattern 4 or 5. 
We calculated that 50.8% of the study population had indolent prostate cancer, according to 
the life time risk estimates for this population. Th erefore, almost patients with organ-confi ned 
prostate cancer and no Gleason pattern 4/5 had possibly indolent disease and a tumour volume 
threshold of 2.5 ml was assessed.
 In addition to a reassessment of the tumour volume threshold, the prognostic value of 
the threshold was evaluated to assess the eff ectiveness of such a threshold in addition to the 
tumour stage and grade criteria for indolent prostate cancer. Biochemical progression was 
assumed to be a sign of signifi cant prostate cancer in Chapter 9. It should be realized however, 
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that this is only a surrogate endpoint. Biochemical progression does not necessarily lead to 
symptoms or mortality. However, biochemical progression can be seen as a surrogate for 
clinically signifi cant disease, because symptoms and mortality are most usually preceded by 
biochemical progression. Th is was also observed in our study (data not shown): not all patients 
with biochemical progression showed signs of metastasis or died of prostate cancer which may 
be caused by short follow-up, but all cases with metastasized disease or disease specifi c death, 
were observed to have biochemical progression as well. 
 It was shown that in organ-confi ned disease without Gleason pattern 4/5, tumour volume 
was not predictive of biochemical progression. Th ese results are in line with the results described 
in Chapter 8. If we assume that biochemical progression indicated clinically signifi cant disease, 
the results in Chapter 9 suggest that a tumour volume threshold does not diff erentiate between 
clinically insignifi cant or clinically signifi cant disease, and tumour foci larger than 0.5 ml or 0.7 
ml could be insignifi cant as well. Th is is an important result, because a considerable number 
of patients with well-diff erentiated, organ-confi ned disease have a tumour larger than 0.5 ml 
(in our study 47% of all patients with organ-confi ned prostate cancer without Gleason pattern 
4/5) and are possibly unnecessarily treated. On the other hand, not all organ-confi ned prostate 
cancer with a Gleason score below 7 will be insignifi cant: in our study 16 (9.2%) patients 
showed biochemical progression. Th erefore, other criteria are needed to further diff erentiate 
between insignifi cant and relevant disease within this selection of organ-confi ned prostate 
cancer without Gleason pattern 4/5. 
 Th e absence of additional prognostic value of tumour volume aft er correction for tumour 
stage and grade does not necessarily mean that tumour volume has no role in prostate cancer 
care at all. As was mentioned in the discussion of Chapter 8 as well, tumour volume may 
improve pre-treatment risk stratifi cation due to the association of tumour volume with tumour 
stage and tumour grade at radical prostatectomy. If tumour volume could reliably be measured 
prior to treatment using imaging techniques, it would be valuable in future studies to assess 
the independent prognostic value of tumour volume aft er correction for other pre-treatment 
characteristics. Clinical tumour stage and clinical Gleason score have less prognostic value than 
stage and grade assessed in radical prostatectomy specimens. Th erefore, hypothetically, tumour 
volume may indeed add prognostic value to these pre-treatment factors.
 Two limitations of the study described in Chapter 9 are important to mention, even though 
they have already been briefl y discussed in the discussion of this article as well. Firstly, the 
natural course of the disease has been altered due to treatment of all patients and the true 
clinical relevance of the tumour cannot be established anymore. Whether a tumour is clinically 
insignifi cant can only be defi ned at the time the untreated patient has died. At that moment it 
is known whether the tumour has caused symptoms or death and could have safely been left  
undiagnosed. Th is limitation is inherent to the use of radical prostatectomy specimens for the 
identifi cation of indolent prostate cancer.
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Secondly, another disadvantage of using prostatectomy-based criteria to identify indolent 
prostate cancer is that the patient needs to be treated before the tumour can be classifi ed 
as possibly indolent or not. Assessing tumour aggressiveness is however most important in 
the pre-treatment phase when the choice for a particular treatment is made. At this point, 
overtreatment could be avoided by identifi cation of indolent disease, and preferably all clinically 
insignifi cant disease, and by off ering non-invasive active surveillance strategies to those cases, 
although this is a second choice approach. Research has aimed at predicting the presence of 
indolent disease at radical prostatectomy specimens with the use of pre-treatment data, like 
PSA, clinical tumour stage and histopathological features.64,65 Unfortunately, this pre-treatment 
risk assessment is rather inaccurate.66,67 
Th e pre-treatment identifi cation of indolent prostate cancer
A possible method to improve the pre-treatment identifi cation of indolent prostate cancer is the 
use of immunohistochemistry on prostate biopsy specimens. Th e use of immunohistochemistry 
as a marker for prostate cancer prognosis has been described for a large number of diff erent 
markers in radical prostatectomy specimens. Due to the prognostic value of these markers, 
they might be of help in the identifi cation of indolent disease. However, their value on 
biopsy specimens, or more specifi cally on biopsies with low-risk prostate cancer, is largely 
undetermined for most markers. In Chapter 10, the value of four promising immunomarkers 
was assessed in men eligible for active surveillance: EZH2, BMI-1, MIB-1 and p27kip1. For the 
cohort selection, the entrance criteria of the PRIAS study were applied,68 thus the study cohort 
consisted of patients who would actually be off ered active surveillance. 
 Can immunohistochemistry be of help in improving the pre-treatment risk assessment? Th e 
results of our study described in Chapter 10 are promising: the use of immunohistochemistry 
for EZH2 and p27kip1 added prognostic value to the routinely used parameters like PSA and 
clinical tumour stage: the area under the curve for predicting signifi cant disease at radical 
prostatectomy (according to the Epstein criteria25) using clinicopathological data only was 0.74 
and increased to 0.86 aft er addition of EZH2 and p27kip1 (p<0.05). Apparently, in spite of 
the use of narrow criteria used in the selection of this cohort, some markers demonstrated a 
suffi  cient wide range of expression to separate high and low expression levels. On the other 
hand, the use of an expression cut off  like the cut off s defi ned in Chapter 10, will misclassify 
relevant numbers of patients. Th e most ideal immunomarker would show expression in all 
cases of signifi cant cancer and no expression in all patients with indolent cancer, but up to now 
such immunomarkers have not been discovered. Th e known immunomarkers may however 
be of help in identifying indolent prostate cancer using several markers simultaneously or 
in combination with other clinicopathological data, for example in nomograms. Th e use of 
multiple immunomarkers combined with clinicopathological data has been described in a 
Swedish watchful waiting cohort: the combination of immunomarkers and clinicopathological 
data (area under the curve 0.78) improved the prognostic value for prostate cancer mortality 
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of clinicopatholgical data alone (area under the curve 0.71, p=0.04) and seemed promising in 
distinguishing indolent from aggressive prostate cancer.69 
 Th e use of immunomarkers may be hampered by diff erences in laboratory techniques and 
marker assays. It is important to consider this limitation when results from diff erent centres 
are compared. However, standardizing techniques will solve this problem and general use of a 
immunomarkers is possible, as has been shown for example for the basal cell markers 34BE12 
and p63. Th ese are widely accepted and used in case of doubt in the diagnosis of prostate cancer, 
especially in biopsy specimens.70
 Another, more general, limitation of the use of biopsy tissue is worth mentioning. Only 
a small sample of the malignant tissue is available for examination, while prostate cancer 
may show a very heterogenic aspect. Th e tumour may harbour aggressive features, which the 
prostate biopsy does not reveal. Th is is illustrated by the undergrading of prostate cancer at 
biopsy. In about 30% the actual Gleason score observed at radical prostatectomy, in which the 
whole tumour is examined, is higher than the biopsy tumour grade.71 Due to this sampling 
error, all characteristics assessed on biopsy specimens including immunomarkers should be 
interpreted with this possible sampling artefact in mind. 
Future management of indolent and clinically insignifi cant prostate cancer
Th e current pre-treatment selection of men with indolent prostate cancer is rather inaccurate. 
Th is is demonstrated by considerable rates of possible cancer progression observed in patients 
enrolled in active surveillance studies, who were enrolled in the study because of a high 
probability of indolent disease. For example in the PRIAS study, a considerable percentage of 
27% are excluded from the study aft er 2 years due to signs of progression, despite the selection 
criteria at entrance of the study.72 Clearly, this rate is also infl uenced by the defi nition of the 
trigger mechanisms, i.e. signs of progression which should prompt radical treatment and which 
still are under investigation. Th e inaccurateness of selection of indolent disease based on pre-
treatment criteria was also demonstrated by the results of Chapter 10: 50% of patients suitable 
for active surveillance showed features of clinically signifi cant disease according to the Epstein 
criteria.25 However, it must be considered that all included patients were treated by radical 
prostatectomy and this selection might not be totally comparable to the overall population 
complying with the PRIAS criteria due to selection bias.
 Data on the natural history of low risk prostate cancer are not available, fi rstly because it 
has long been standard practice to treat these tumours and secondly because indolent prostate 
cancer is a relatively new entity.73 However, more accurate selection criteria for patients with 
indolent prostate cancer are needed and should not predict radical prostatectomy features, 
but the risk of morbidity and mortality. Currently, we are able to identify low risk prostate 
cancer, based on PSA and pathological characteristics. Although these cases are indeed more 
likely to show an indolent clinical course, still some of these low-risk cases are lethal even aft er 
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immediate treatment. Th e best alternative approach for assessing these criteria for indolent 
disease would probably be in active surveillance studies, in which low risk prostate cancers cases 
are closely monitored.68,74,75 Additional prognostic markers within this low-risk group, amongst 
which EZH2 and p27kip1 described in Chapter 10 seem promising,76 are needed to further 
diff erentiate individual cancer behaviour.73 In addition to the currently used criteria that aim 
at identifying indolent disease, it is essential to study other factors like age and co-morbidity to 
identify clinically insignifi cant disease as a whole. Although these patient related factors do not 
refl ect tumour aggressiveness, they do infl uence the risk of prostate cancer mortality and thus 
are associated with clinical signifi cance, and the need for radical treatment. For example, in an 
80-year old patient a small degree of Gleason pattern 4 might be accepted and still be defi ned as 
clinically insignifi cant disease, as was suggested by Stamey.77 Th erefore, to avoid overtreatment, 
not only patients with indolent disease should be considered as suitable for active surveillance, 
but all patients harbouring clinically insignifi cant prostate cancer.
Epilogue
Prevention of morbidity and mortality caused by prostate cancer is the fi nal goal in prostate 
cancer care. Screening was shown to contribute to reaching this goal, but with considerable 
adverse eff ects. A signifi cant mortality reduction was observed due to screening for prostate 
cancer, but still 214 of 72,890 (0.3%) men in the screening arm died of prostate cancer compared 
to 326 of 89,353 (0.4%) in the control arm.14. Th us, of 5 prostate cancer patients who would 
have died of prostate cancer if they were not screened, still 4 died of their disease despite the 
off er of screening. Simultaneously, large numbers of screened men experience the downsides 
of screening, for example undergoing prostate biopsies or even unnecessary invasive treatment 
for indolent tumours. Th e balance between arguments for and against screening is not, yet, 
convincingly in favour of screening. Th e major challenge of optimizing the screening strategy 
will hopefully increase the benefi ts and especially decrease the harmful adverse eff ects. Only 
then, screening will become an established modality of care in the management of prostate 
cancer.
 In this thesis it was shown that the reported mortality reduction in the screening arm 
indeed is caused by screening and not, or only marginally, by a treatment bias. Th is opens the 
possibility to focus on improvement of screening strategies. 
 Several studies aiming to improve screening strategies are described in this thesis. In short, 
the following conclusions are drawn:
 – PSA velocity is not a useful biopsy indicator for prostate cancer in general, nor for possibly 
aggressive prostate cancer.
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 – Th e presence or absence of non-malignant biopsy features, like infl ammation or biopsy core 
length, could not detect patients at increased risk for a prostate cancer diagnosis and were 
not useful in the individualization of screening intervals.
 – Th e overall false-negative biopsy rate was estimated to be as low as 2.4%; 1.1% for prostate 
cancer and 1.3% for ASAP. Th is indicates accurate examination of the biopsies and high 
sensitivity for detecting prostate cancer during histopathological examination by the 
pathologist.
 Screening will thus not be improved by the use of PSA velocity, neither by non-malignant 
biopsy features, nor by better histopathological examination. Further eff orts in the search for 
optimal screening strategies should focus on other aspects to guide biopsy indication and 
individual screening intervals to improve screening for prostate cancer.
 In addition to improving screening strategies, this thesis focuses on better defi nition and 
identifi cation of indolent prostate cancer, which led to the following statements:
 – Tumour volume at radical prostatectomy is not an independent prognostic factor in prostate 
cancer outcome. It is not useful to routinely report tumour volume in the pathology report. 
 – Indolent tumours may be larger than 0.7 ml.
 – A tumour volume threshold in the defi nition of indolent prostate cancer is questionable. 
 – Determining the expression level of EZH2 and especially p27kip1 helps to identify patients 
that harbour aggressive tumour features among men with low-risk prostate cancer. 
 Although raising the tumour volume threshold could help avoid the unnecessary treatment 
of indolent prostate cancer, the use of any tumour volume threshold in the identifi cation of 
indolent prostate cancer remains debatable. Pathological tumour stage and grade are still the 
most important criteria for indolent disease. More research on pre-treatment criteria for indolent 
disease is needed and should not focus on associations with prostatectomy characteristics, but 
on the risk of morbidity and mortality if tumours are left  untreated. Immunohistochemistry 
may be of help in this pre-treatment stage, particular EZH2 and p27kip1 reported in this thesis, 
but prospective studies of these markers are needed to confi rm their prognostic value. Finally, 
to avoid overtreatment, we should aim not only to identify indolent disease but all clinically 
insignifi cant prostate cancers. Age-specifi c criteria could improve this selection of clinically 
insignifi cant prostate cancer cases.
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Summary
Th e European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown 
that screening for prostate cancer reduces prostate cancer specifi c mortality. In Part I of this 
thesis, background information on prostate cancer (Chapter 1) and the ERSPC (Chapter 
2) is provided. Some issues concerning screening for prostate cancer currently prevent the 
population-wide introduction of screening. Th e scope of this thesis, outlined in Chapter 3, was 
to improve screening strategies by addressing the following issues: 
1. the role of study arm on treatment choice
2. improving the current screening protocol
3. improving the identifi cation of indolent prostate cancer to prevent overtreatment
In Chapter 4 (Part II) was shown that study arm played a statistically signifi cant but minor role 
in treatment selection. Th is small diff erence in treatment between the study arms of the ERSPC 
was particularly observed in patients with high-risk PC: a control subject was more likely to 
receive radiotherapy, active surveillance or hormonal therapy instead of radical prostatectomy 
than a screening subject, but no major diff erences in other treatment choices were seen. Th is 
indicates that an eff ect of diff erent treatment between arms on PC mortality may be possible but 
probably will be small. Th erefore, these results show that a mortality reduction in the ERSPC 
based solely on unequal treatment in both arms is very unlikely.
 Part III focuses on the improvement of the current screening protocols. Th e value of PSA 
velocity in a screening setting was assessed in Chapter 5. In our screened cohort, PSA velocity 
was not an independent predictor of clinically relevant prostate cancer. Using a PSA velocity 
cut-off  level as a biopsy indicator would miss an important proportion of clinically relevant 
prostate cancer cases. Th erefore, PSA velocity could not improve the ERSPC screening protocol.
 Th e predictive value for prostate cancer detection in the subsequent screening round was 
evaluated for high-grade prostatic intraepithelial neoplasia (HG-PIN), chronic and active 
infl ammation and biopsy core length and glandular core length (Chapter 6). In this study, none 
of these features proved to be signifi cantly predictive of subsequent prostate cancer detection 
and therefore no high or low risk subgroups of PC-detection 4 years later, which could improve 
screening protocols, could be identifi ed. 
 In Chapter 7, adenocarcinoma was identifi ed in 16 (8.2%) patients and atypical lesions 
suspicious for malignancy in 19 patients (9.7%) in a cohort of 196 screening participants whose 
biopsy specimens were originally classifi ed as benign. Aft er correction for patient selection was 
estimated that in 2.4% of all biopsied screening participants a (possibly) malignant lesion was 
missed during histopathological examination of the biopsy specimens; 1.1% for prostate cancer 
and 1.3% for atypical small lesions suspicious for malignancy. Men with a false-negative biopsy 
seemed to be in a curable stage at the time of PC diagnosis and the low overall rate of false-
negative biopsies indicates accurate examination of the biopsy specimens.
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 In Part IV, an eff ort is made to improve the diff erentiation between indolent prostate cancer 
and clinically relevant prostate cancer. First, we showed that tumour volume has no independent 
prognostic value in men treated with radical prostatectomy (Chapter 8), aft er correction 
for tumour stage, grade and surgical margin status. Additionally to the lack of independent 
prognostic value, tumour volume is a time-consuming measurement and is highly dependent 
on laboratory processes and methods of measurement. We therefore recommend that tumour 
volume should not routinely be reported in the pathological reports.
 Th e lack of independent prognostic value of tumour volume resulted in a following study 
of tumour volume. In Chapter 9, the commonly used tumour volume threshold for indolent 
prostate cancer of 0.5 ml was reassessed in a screened population and the additional predictive 
value of a tumour volume cut-off  for the identifi cation of indolent prostate cancer was assessed in 
addition to stage and grade criteria. A threshold of 0.7 ml was observed, but tumour volume was 
not a useful criterion for the identifi cation of biochemical progression in patients with organ-
confi ned PC without Gleason pattern 4/5: patients with larger tumours were not at increased 
risk of biochemical progression. Th is suggests that a tumour volume cut off  may not be eff ective 
in the identifi cation of indolent prostate cancer in addition to stage and grade criteria.
 Finally, we aimed to improve the pretreatment identifi cation of indolent prostate cancer, 
using immunohistochemistry on prostate biopsy specimens containing low-risk prostate 
cancer (Chapter 10). Four immunohistochemical stainings, which all have predictive value 
for patient outcome when analyzed on radical prostatectomy specimens, were evaluated on 
biopsy specimens: EZH2, p27kip1, BMI-1 and MIB-1. Although MIB-1 and BMI-1 did not show 
predictive value for the presence of relevant disease on radical prostatectomy specimens, p27kip1 
and EZH2 were independent predictors of relevant prostate cancer. Th erefore, these markers 
may improve the pretreatment identifi cation of patients with indolent prostate cancer.
 Th e fi ft h part of this thesis summarizes and discusses the studies described in the previous 
chapters and puts them into perspective. 
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Samenvatting
De European Randomized Study of Screening for Prostate Cancer (ERSPC) heeft  aangetoond 
dat vroege opsporing, of screening, naar prostaatkanker de sterft e aan deze ziekte vermindert. 
In Deel I van dit proefschrift  wordt achtergrondinformatie beschreven over prostaatkanker 
(Hoofdstuk 1) en de ERSPC (Hoofdstuk 2). Onduidelijkheden en negatieve neveneff ecten 
van screening naar prostaatkanker verhinderen op dit moment de invoering van landelijke 
screeningsprogramma’s. Het doel van dit proefschrift , welke wordt beschreven in Hoofdstuk 
3, was de verbetering van de screeningsstrategieën door enkele van deze problemen omtrent 
screening te belichten: 
1. De rol van studiearm in de keuze van prostaatkankerbehandeling
2. De verbetering van het huidige screeningsprotocol
3. De verbetering van identifi catie van indolente prostaattumouren
In Hoofdstuk 4 (Deel II) is aangetoond dat studiearm een statistisch signifi cante, maar zeer 
kleine rol speelt in de therapiekeuze voor prostaatkanker binnen de ERSPC. Dit verschil werd met 
name gezien bij patiënten met hoogrisico prostaatkanker: een deelnemer in de controlearm had 
een grotere kans om behandeld te worden met radiotherapie, active surveillance of hormonale 
therapie dan met radicale prostatectomie vergeleken met een deelnemer in de interventiearm. 
Er werden geen verschillen in de overige therapiekeuzes gezien. Dit betekent dat een eff ect van 
verschil in behandeling tussen beide studiearmen op de prostaatkankermortaliteit mogelijk is, 
maar hoogstwaarschijnlijk zeer klein zal zijn. Een mortaliteitsreductie in de ERSPC op basis 
van ongelijke behandeling alleen is onwaarschijnlijk. 
 Deel III richt zich op de verbetering van de huidige screeningsprotocollen. De waarde van 
PSA velocity in een screeningssituatie wordt beschreven in Hoofdstuk 5. PSA velocity was geen 
onafh ankelijke voorspeller van klinisch relevante prostaatkanker in een gescreend cohort. Het 
gebruik van een PSA velocity grenswaarde als indicatie voor het nemen van prostaatbiopten 
zou een aanzienlijk deel van de klinisch relevante prostaatkankergevallen missen. Het gebruik 
van PSA velocity leidde niet tot verbetering van het huidige ERSPC-screeningsprotocol. 
 De voorspellende waarde voor prostaatkankerdetectie in de volgende screeningsronde werd 
onderzocht voor de aanwezigheid van de volgende parameters in prostaatbiopten: high-grade 
prostatic intraepithelial neoplasia (HG-PIN), chronische en actieve ontsteking, totale bioptlengte 
en de bioptlengte van het deel dat daadwerkelijk glandulair weefsel bevat (Hoofdstuk 6). 
Geen van de onderzochte parameters was voorspellend voor prostaatkankerdetectie in tijdens 
het volgende screeningsonderzoek en er konden geen hoog- of laagrisicogroepen worden 
geïdentifi ceerd. Verbetering van het screeningsprotocol mogelijk lijkt niet haalbaar door 
gebruik van deze parameters.
  Hoofdstuk 7 beschrijft  de detectie van adenocarcinoom in 16 (8.2%) patiënten en 
atypische laesies verdacht voor maligniteit (ASAP) in 19 patiënten (9.7%) in een cohort van 
196 deelnemers wiens biopten initieel werden geclassifi ceerd als benigne. Na correctie voor 
de patiëntselectie werd geschat dat in 2.4% van alle gebiopteerde deelnemers een (mogelijk) 
maligne laesie was gemist tijdens het histopathologisch onderzoek: in 1.1% een maligne laesie 
en in 1.3% een atypische laesie verdacht voor maligniteit. De patiënten met een gemiste laesie 
in een eerder prostaatbiopt leken allen in een curatief ziektestadium te verkeren op het moment 
van daadwerkelijk prostaatkankerdiagnose. De lage frequentie van vals-negatieve biopten duidt 
op een nauwkeurig histopathologisch onderzoek van de prostaatbiopten.
 Deel IV van dit proefschrift  richt zich op de verbetering van de diff erentiatie tussen 
indolente en klinisch relevante prostaatkanker. Allereerst werd aangetoond dat tumourvolume 
geen onafh ankelijke prognostische factor is in mannen die behandeld zijn met radicale 
prostatectomie (Hoofdstuk 8), na correctie voor tumourstadium, graad en snijvlakstatus. Naast 
het gebrek aan onafh ankelijke voorspellende waarde is tumourvolume een zeer tijdrovende 
meting en bestaat er grote variatie in gemeten volumes door verschil in laboratoriumtechnieken 
en meetmethodes. Ons advies is daarom om tumourvolume niet standaard op te nemen in het 
pathologieverslag. 
 Het gebrek aan onafh ankelijke voorspellende waarde van tumourvolume is aanleiding 
geweest voor een tweede studie naar tumourvolume. In Hoofdstuk 9 werd de traditionele 
tumourvolume-grenswaarde voor indolente kanker herbepaald in een gescreened cohort 
en de toegevoegde waarde van een tumourvolume-criterium in de defi nitie van indolente 
prostaatkanker geëvalueerd. Een grenswaarde van 0.7 ml werd geobserveerd, echter, 
tumourvolume was geen voorspeller voor biochemische progressie in een cohort patiënten die 
voldeden aan de andere twee criteria voor indolente prostaatkanker: geen extracapsulaire groei 
en geen Gleasonpatroon 4 of 5. Patiënten met een klein tumourvolume hadden evenveel risico 
op progressie als patiënten met een grotere tumour. Deze resultaten trekken de eff ectiviteit van 
een tumourvolumecriterium in de defi nitie van indolente tumouren in twijfel.
 Tenslotte wordt in Hoofdstuk 10 een studie beschreven waarin wordt getracht de identifi catie 
van indolente prostaattumouren te verbeteren op het moment van diagnose, vóór behandeling 
heeft  plaatsgevonden. Hierbij is gebruikt gemaakt van immunohistochemische markers op 
prostaatbiopten met laagrisico prostaatkanker. Vier kleuringen, welke allemaal voorspellende 
waarde hebben voor prognose indien zij gebruikt worden op prostatectomiemateriaal, werden 
getest op biopsiemateriaal: EZH2, p27kip1, BMI-1 and MIB-1. Hoewel MIB-1 en BMI-1 geen 
voorspellende waarde toonden, bleken p27kip1 en EZH2 onafh ankelijke voorspellers te zijn voor 
de aanwezigheid van klinische relevante tumouren in het radicale prostatectomiepreparaat. 
Deze markers zouden de identifi catie van indolente tumouren vóór behandeling kunnen 
verbeteren.
 In het vijfde deel van dit proefschrift  worden de resultaten van de voorgaande hoofdstukken 
samengevat en bediscussieerd. 
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Chapter 7 | Prostate needle-biopsies false-negative for cancer or suspicious lesions during histological 
examination
Figure 1 | False-negative prostate biopsies with adenocarcinoma. A, B: Prostate cancer glands are 
architecturally arranged in a nodule reminiscent of benign tissue. In B two foci (arrowheads) of atypical 
glands are present adjacent to normal pre-existent glands. C, D: At high magnifi cation enlarged nuclei 
and conspicuous nucleoli (arrows) are visible, while cytoplasm is not conspicuous (D). E, F: Basal cells 
are absent (34BE12). In F the second focus of atypical glands also lacked basal cells (not shown); notice 
positive internal control (F). Both lesions were considered adenocarcinoma Gleason score 6 (3+3). Th e 
lesions were derived from two separate patients (A, C, E and B, D, F). Original magnifi cations: A, B H&E 
40x; C, D H&E 200x; E 34BE12 100x; F 34BE12 200x, see page 92. 
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Figure 2 | False-negative prostate biopsies with atypical glands suspicious for adenocarcinoma. A, B: Two 
(A; arrowheads) and one (B) atypical glands were discovered at low magnifi cation by their amphophilic 
cytoplasm and subtle architectural abnormality. C, D: At high magnifi cation, the suspicious glands 
revealed enlarged nuclei and prominent nucleoli (arrows). E, F: Th e atypical glands showed lack of basal 
cells (34BE12). Both lesions were considered highly suspicious for malignancy. Due to a low number 
of atypical glands no defi nitive diagnosis for malignancy was given. Th e lesions were derived from two 
separate patients (A, C, E and B, D, F). Original magnifi cations: A H&E 40x; B H&E 100x; C, D H&E 200x; 
E, F 34BE12 200x, see page 93. 
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Figure 3 | False-negative prostate biopsy with pseudohyperplastic (A, C, E) and foamy gland (B, D) 
prostate adenocarcinoma. A, C: Dilated glands with cytoplasmic amphophilia, enlarged nuclei and 
conspicuous nucleoli characterize pseudohyperplastic cancer. E: Basal cells are absent in 34BE12 staining; 
notice positive staining in pre-existent atrophic glands. Th e lesion might be missed as large-sized glands 
can be interpreted as benign or hyperplastic glands at low magnifi cation. B, D: Foamy gland cancer is 
characterized by architecturally disorganized glands with clear to foamy cytoplasm with some enlarged 
nuclei and sporadic nucleoli (arrow). Th e lesion might be missed as cytoplasmic amphophilia is not 
conspicuous at low magnifi cation and only some of the nuclei are atypical with prominent nucleoli at high 
magnifi cation. No immunohistochemical staining was performed on this lesion. Original magnifi cations: 
A, B H&E 40x; C, D H&E 200x; E 34BE12 200x, see page 94. 
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Chapter 10| Th e value of EZH2, p27kip1, BMI-1 and MIB-1 on biopsy specimens with low risk PC in 
selecting men with signifi cant prostate cancer at prostatectomy
Figure 1 | Various expression levels of the immunomarkers. A: High EZH2 expression, 400x. B: Very 
low EZH2 expression, 200x. C: High MIB-1 expression, 400x. D: Low MIB-1 expression, 400x. E: High 
p27kip1 expression, 400x. F: Low p27kip1 expression, 200x. E: High BMI-1 expression, 400x. F: Low BMI-1 
expression, 200x, see page 138. 
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